Click here for more sample CPC practice exam questions with Full Rationale Answers

Practice Exam

Click here for more sample CPC practice exam questions and answers with full rationale

Practice Exam

CPC Practice Exam and Study Guide Package

Practice Exam

What makes a good CPC Practice Exam? Questions and Answers with Full Rationale

CPC Exam Review Video

Laureen shows you her proprietary “Bubbling and Highlighting Technique”

Download your Free copy of my "Medical Coding From Home Ebook" at the top right corner of this page

Practice Exam

2018 CPC Practice Exam Answer Key 150 Questions With Full Rationale (HCPCS, ICD-9-CM, ICD-10, CPT Codes) Click here for more sample CPC practice exam questions with Full Rationale Answers

Practice Exam

Click here for more sample CPC practice exam questions and answers with full rationale

ONC releases final 2016 interoperability standards

The ONC published the final 2016 Interoperability Standards Advisory (ISA) December 22, 2015. The final version includes structural changes available in the fall 2015 draft version. Each standard and implementation specification is assigned six informative characteristics that describe its maturity and adoptability. These informative characteristics will also allow the measures and standards to be tracked as they progress through updates and version, and the rate at which they are adopted, ONC said in a blog post.

The 2016 ISA has undergone significant changes from the 2015 version. These changes are largely attributed to the two rounds of public comment periods ONC conducted, as well as recommendations from the HIT Standards Committee, according to ONC. The most notable changes and additions are:

  • The inclusion of “interoperability needs,” or desired outcomes for each standard
  • Informative characteristics to describe the status and adoption of each standard and implementation specification
  • Subsections that describe attributes or usage concerns such as limitations or general security recommendations
  • Security standards sources appendix
  • “Projected additions” section
  • Summary public comments that were not incorporated into the 2016 ISA including ONC’s responses
  • Revision history section

Other changes from the draft version include revisions and descriptions for the informative characteristics.

The 2016 ISA will serve as the basis for the 2017 version. The comment period to develop the 2017 version will begin early this year.

HCPro.com – HIM-HIPAA Insider

HIM Briefings, November 2016

MOON requirement delayed in IPPS final rule: What next?

Hospitals got a last-minute reprieve from the Medicare Outpatient Observation Notice (MOON) notification requirement, which was set to go into effect August 6. Citing the need for additional time to revise the standardized notification form that hospitals will need to use to notify patients about the financial implications of being assigned to observation services, CMS moved back the start date for the requirement in the 2017 IPPS final rule to ‘no later than 90 days,’ after the final version of the form is approved (www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/FY2017-IPPS-Final-Rule-Home-Page.html).

CMS released the new draft of the form (www.cms.gov/Regulations-and-Guidance/Legislation/PaperworkReductionActof1995/PRA-Listing-Items/CMS-10611.html?DLPage=1&DLEntries=10&DLFilter=10611&DLSort=1&DLSortDir=descending) August 1 and accepted public comments for 30 days. The MOON notification form is intended to be used to help hospitals comply with the Notice of Observation Treatment and Implication for Care Eligibility (NOTICE) Act. The Act requires hospitals to provide a verbal and written notice of outpatient status to any patient in observation who has been in the hospital for more than 24 hours, stipulating that hospitals must inform patients within 36 hours from the start of the service about their status. However, without a final version of the form ready for use, it would appear that hospitals cannot comply with the NOTICE Act at this time.

‘Hospitals should review the IPPS final rule that contains significant clarification on things like when and how the notice is delivered and finalize their own policies for delivering the notice pending the final version of the MOON being available,’ says Kimberly Anderwood Hoy Baker, JD, CPC, director of Medicare and compliance for HCPro in Middleton, Massachusetts.

CMS stated in the 2017 IPPS final rule:

We expect the final [Paperwork Reduction Act] PRA approval of the MOON around the time the implementing regulations are effective. Therefore, the implementation period for hospitals and CAHs will begin sometime after the effective date of this final rule and will be announced on the CMS Beneficiary Notices Initiative Website at: www.cms.gov/Medicare/Medicare-General-information/Bni/index.html and in an HPMS memorandum to MA plans. During this implementation period, hospitals and CAHs will have time to prepare for implementation, consistent with past implementation practices for beneficiary notices. Hospitals and CAHs will be required to deliver the MOON to applicable patients who begin receiving observation services as outpatients on or after the notice implementation date.

 

‘Hospitals should watch the Beneficiary Notice Initiative page, where CMS said they would announce implementation information, for more information on the finalization of the MOON and implementation time frames,’ says Baker.

Hospitals will likely not be required to provide the MOON notification form to patients until 90 days after PRA approval, which could mean compliance with the MOON and NOTICE Act is at least 120 days out from the final rule release date given that there is also a 30-day comment period on the revised form, according to Baker.

‘When the final version of the notice form is ready for use, hospitals should use the 90-day implementation period to develop a mechanism for the form to be in their EHR with a trigger to print the notice when the patient is registered as or has a status change to observation. This will allow for the form to be delivered by the designated individual to the patient immediately rather than attempting to do it at discharge,’ says Rose T. Dunn, MBA, RHIA, CPA, FACHE, chief operating officer for First Class Solutions, Inc.

The message should be delivered by hospital staff who are well versed in the purpose of the notice and how patient status may financially impact the patient. Dunn recommends that hospitals choose patient access staff, financial counselors, or utilization review/case management staff to deliver the MOON rather than patient care staff.

The role of HIM in MOON compliance

While many facilities plan to task departments outside of HIM with delivering the verbal and written notice to observation patients, that does not mean there isn’t a seat at the table for HIM when it comes to operationalizing this regulation.

At Via Christi Health in Wichita, Kansas, Sam Antonios, MD, FACP, FHM, CCDS, medical director of medical information and ICD-10 physician advisor, and his colleagues are working to ensure they understand the nuances of the MOON.

Antonios’ facility is currently building a daily report to help track patients who have been in observation 24 hours.

The report will help the facility ensure compliance with the NOTICE Act and MOON, but this may be a challenge for facilities that do not have the capability to create such a document in their electronic systems. But even with the right systems and alerts in place, relying on just one report may present challenges. ‘For example, you may have patients who don’t have the right trigger from the initiation of observation services,’ Antonios says. Remember, the MOON must be delivered 24?36 hours after the initiation of observation services, which is not always the time when the patient entered the hospital, especially for those in the emergency department, he says.

In general, HIM should aid in the creation of reports listing any admission for Medicare beneficiaries in observation. Records for patients who have been in observation for more than 24 hours should be flagged when the report is run, which should ideally be done twice daily and be sent to the team tasked with delivering the MOON, Antonios says.

HIM must play a role in deciding what to do with the MOON when it is completed and how to track verbal notification of observation status, Antonios says. Should HIM scan the MOON forms immediately for inclusion in the patient’s medical record, or should scanning be completed at the end of the patient’s hospital stay? Deciding which option is best may depend on the needs of your facility and staffing patterns.

‘HIM professionals should ensure that the form is properly signed and scanned into the appropriate section of the medical record where it can be consistently found during an audit,’ says Edward Hu, MD, CHCQM-PHYADV, system executive director of physician advisor services at UNC Health Care system in Chapel Hill, North Carolina, and president of the American College of Physician Advisors. In addition, HIM will also play a role in ensuring the CMS-approved MOON is given to observation patients, Hu says.

In an era when hospitals are increasingly using electronic methods of documentation and communication, it may be tempting to create an electronic version of the MOON for patients to read and sign. However, Hu notes that if this practice is implemented the patient must still receive a paper copy of the form. ‘Hospitals must provide a signed paper copy of the MOON to the beneficiary, even if he or she reviews and signs on an electronic pad,’ he says. ‘The hospital must provide the MOON on paper for the beneficiary’s review if the beneficiary asks to review a paper version.’

Tracking and delivering the MOON is one hurdle to overcome, but so too is ensuring that patients understand the information presented to them. Language barriers can present a challenge when delivering the MOON. While it may be relatively easy to obtain a copy of the notice for patients who speak more common languages like Spanish, it is a bit more difficult at Antonios’ facility where patients speak a variety of languages that the form is not available in. In turn, staff may have a difficult time verbally notifying patients of observation status during off hours when a translator is unavailable, he says.

Hu notes that HIM can play a role in ensuring the Spanish-language version of the MOON is made available to patients and staff when it is approved by CMS. ‘Hospitals also have an obligation to provide the information on the MOON in a language and manner that the patient understands. Although this does not mean the MOON must be translated into every language, it does mean that the hospital has an obligation to ensure understanding by beneficiaries with limited English proficiency,’ he says.

 

The ups and downs of MOON

Complying with the NOTICE Act and operationalizing MOON has presented a significant challenge for healthcare organizations. Some are unsure of how to deliver the form and little is known about the impact it will have on patient relations and hospital staffing.

The verbal and written notice to observation patients should be given between 24 and 36 hours of the patient being placed in this status, which has many wondering whether they should actually wait 24 hours to deliver the notice since it can be challenging to ensure the notice is given before the 36-hour mark, says Antonios. ‘It leaves you with an open window of only 12 hours of actually being able to deliver before missing the deadline,’ Antonios says. Failure to deliver the notice within the given time frame can result in noncompliance.

While Antonios points out that CMS stated in the 2017 IPPS final rule that facilities can deliver the MOON prior to 24 hours of observation care, this may not always be the best option?especially since CMS noted that it discourages this practice. Delivering it before the 24-hour ma=rk as a proactive measure to ensure observation patients in need of the notice are not overlooked?or even delivering it on time?can present challenges since an observation stay can often become an inpatient stay based on a physician’s finding during the early hours of patient care, Antonios says.

Whether you decide to wait 24 hours or deliver the MOON as soon as observation status is initiated, there will be pros and cons.

Not waiting for the 24-hour mark may mean the verbal and written notice were given but not needed and could result in patients who are confused about their status and the financial implications of it. ‘It’s so early in the process that you may have people switched to inpatient before 24 hours and then you would have wasted the little bit of energy and resources to do a task that you didn’t need to do, because if you switch someone before 24 hours you don’t have to give them anything,’ Antonios says.

Delivering the MOON to all patients when they are first assigned to observation makes it easier to capture these Medicare beneficiaries before the 24?36-hour window passes, he says. It lends a fair amount of standardization and automation to the process of complying with the NOTICE Act and MOON, Antonios says.

However, ensuring that staff who are educated on completing the written notice and verbally explaining observation to patients are available at all times is not an easy task. While emergency departments (ED) are often well staffed during nights and weekends, other areas of hospitals may not have the same coverage, which could result in noncompliance if the MOON delivery window is missed. The ED?be it registration or other staff?may be the ideal setting for delivering the MOON if it is done routinely prior to the 24-hour mark. ‘Staffing on the floor goes down significantly after hours. It goes down significantly during the weekend, but the ED typically still has staff,’ Antonios says. ‘People receive paperwork in the ED anyway. It’s part of the process.’

 

Ready CDI teams for CMS’ proposed expansion of mandatory ortho episode payment models

by Shannon Newell, RHIA, CCS, an AHIMA-approved ICD-10-CM/PCS trainer

If your hospital resides in one of the 67 metropolitan statistical areas (MSA) required to participate in the Comprehensive Joint Replacement Model (CJR), you will also be required to participate in a new orthopedic payment model called ‘SHFFT’ (surgical hip and femur fracture treatment) if an August 2 proposed rule is finalized. The impact? The following assigned MS-DRGs will no longer define hospital reimbursement:

  • Major Joint Replacement or Reattachment of Lower Extremity (MS-DRGs 469, 470)
  • Hip and Femur Procedures Except Major Joint (MS-DRGs 480, 481, 482)

 

MS-DRGs 469 and 470 are included in the CJR, which we have discussed in prior articles. Let’s take a look at the proposed SHFFT episode payment model (EPM), which involves the other three MS-DRGs, and see what role the CDI program can play as reimbursement shifts to episode-based payments.

Model overview

The episode of care defined for the SHFFT EPM begins with an admission to a participating hospital of a fee-for-service Medicare patient assigned MS-DRGs 480?482. This admission is referred to as the anchor hospitalization. The episode continues 90 days post-discharge from the hospital, and payments for all related Part A and Part B services are included in the episode payment bundle. CMS holds the hospital accountable for defined cost and quality outcomes during the episode and links reimbursement?which may consist of payment penalties and/or financial incentives?to outcome performance.

This is a mandatory EPM for hospitals already impacted by the CJR; the SHFFT model will apply to the same 67 geographic MSAs. The EPM is proposed to begin July 1, 2017, and will last for five years, ending in December 2021.

 

Cost outcomes

CMS will initially pay the hospital and all providers who bill for services during the episode using the usual fee-for-service models. Thus, the SHFFT EPM will not impact the revenue cycle at first. However, at the end of each performance period, which typically represents 12 months (January through December), CMS will compare or reconcile the actual costs with a preestablished ‘target price.’

CMS will set target prices using an approach that will phase in a blended rate of hospital to regional costs. In recognition of the higher costs associated with discharges in MS-DRGs with an MCC or CC, CMS has developed an algorithm to adjust the target price for this subset of the patient population.

If the reconciliation process indicates that the costs to deliver services for the episode were higher than the target price, CMS will require repayment from the hospital. If, however, the costs to deliver care for the episode were lower than the target price, CMS will provide additional payments to the hospital for the provided services. To receive additional payments, however, performance for defined quality outcomes must meet or exceed established standards.

Quality-adjusted target price

To receive any earned financial incentives, the hospital must meet or exceed performance standards for established quality outcomes. CMS therefore adjusts the target price based on quality performance, referred to as the quality-adjusted target price.

The SHFFT EPM uses the exact same quality outcomes as those defined for the CJR:

  • Patient experience. This is the HCAHPS measure also used in the Hospital Value-Based Purchasing Program (HVBP). The source of information for this measure is the HCAHPS survey.
  • Patient-reported outcome data. As with the CJR, the hospital can collect and submit patient-reported data elements and at present will earn quality composite points for submitting the data. These data elements are collected both before and after the procedure and will be used by CMS to create a functional status measurement tool.
  • THA/TKA complication rates. This is the Hospital-Level Risk Standardized Complication Rate (RSCR) following the THA/TKA measure. This measure already impacts financial performance under the HVBP. Like the CJR, performance for this measure is weighted the heaviest in the quality composite comprising 50% of the composite score.

 

Hospital (accountable party), collaborators, and Advanced Payment Models

The hospital is held accountable for episode cost and quality outcomes and all associated financial risks/rewards, even though a variety of providers deliver services and impact performance. As with the CJR, the hospital has been designated as the accountable party because CMS believes the hospital is best positioned to influence coordinated, efficient delivery of services from the patient’s initial hospitalization through recovery.

CMS permits the hospital to enter into collaborative arrangements with physicians and other providers to support and redesign care delivery across the episode and to share financial gains and/or losses. The proposed rule expands the list of collaborators defined in the previous CJR final rule to include other hospitals and Medicare Shared Savings Program accountable care organizations.

The proposed rule also provides an Advanced Payment Model (APM) track for the EPMs, an important step that will further incentivize collaborator participation.

 

CDI program opportunities

There are five key ways that clinical documentation and reported codes across the continuum impact SHFFT performance:

  • Identification of patients included in the EPM. The assigned MS-DRG impacts which discharges are included in the cohort. As one example, consider a patient who would fall into the EPM (MS-DRGs 480?482) unless he or she has a bone biopsy. If reported, the bone biopsy would result in assignment of different MS-DRGs (477?479) and the discharge would not be included in the EPM.
  • Establishment of target costs. The capture of the MCC and/or CC impacts establishment of the episode target price.
  • Determination of related costs. The costs for hospital readmissions within the episode are included in episode costs if the readmissions are related. The assigned MS-DRG for the readmission determines whether the readmission is related.

The costs associated with Part B claims are included in episode costs if the services are related. The primary diagnosis for each visit determines whether the visit is related.

  • Reported complications. Assignment of ICD codes for the following conditions are counted as complications when those conditions result in inpatient readmission:
  • Complication risk adjustment. As with other hospital-centric measures such as risk-adjusted readmission and mortality rates, comorbidities reported for the 12 months prior to the anchor hospitalization are used to assess case-mix complexity. The CMS risk adjustment module uses defined comorbidity categories to identify conditions that impacted predicted rates of complications for the THA/TKA cohort.

The capture of at least one condition for each of the 28 comorbid categories over the 12-month period will strengthen risk adjustment and RSCR performance. RSCR performance contributes to 50% of the quality composite score, which, in turn, impacts the quality-adjusted target price.

 

Summary

Together the CJR and SHFFT models cover all surgical treatment options (hip arthroplasty and fixation) for Medicare beneficiaries with hip fractures. These MS-DRGs typically represent one of the largest inpatient surgical volumes for most short-term acute care hospitals.

As hospitals and collaborators assess and refine the management of patients to achieve or exceed the quality-adjusted target price, the data we submit on claims will be used to assess our performance. The CDI program in the inpatient and ambulatory setting must be positioned to promote and support the capture and reporting of impactful documentation.

Additional information on the proposed rule can be located at https://innovation.cms.gov/initiatives/epm.

 

 

Editor’s note

Newell is the director of CDI quality initiatives for Enjoin. Her team provides CDI programs with education, infrastructure design, and audits to successfully and sustainably address the transition to value-based payments. She has extensive operational and consulting expertise in coding and clinical documentation improvement, case management, and health information management. You can reach Newell at 704-931-8537 or [email protected].

 

How coders can build a successful relationship with their physicians

by Sue Egan, CPC, CCD

All coders know that working with physicians is not always a positive experience.

It can be tough providing them education or getting responses from queries. Conversely, providers are busy and typically do not like anything to do with coding. When they hear coding they often take that to mean more work on their part.I have been working with providers for many years and the one thing coders always ask me is, ‘What is your secret for getting along so well with doctors and engaging them to change behavior?’

Building a relationship with your providers can make both of your lives easier. Outlined are a number of ideas that can facilitate building a strong relationship with your physicians.

  • Documentation clarification inquiries for the hospital are likely to support physician billing. Communicate to the physicians that if the hospital is asking for documentation it will better support their billed services as well. Complete and accurate documentation will hold up to increased scrutiny by payers.
  • Demonstrate why. When you ask a physician to change the way he or she documents in the medical record, show them why it matters. Show how accurate and complete documentation enables appropriate risk adjustments for the patients a physician treats. Remind physicians that good documentation can prove that the patients he or she treats really are sicker than others. This approach is more effective than stating the hospital will get a higher paid DRG.
  • Knowing when to step away will help you keep a positive relationship with a provider.
    • Regardless of how important the material is you want to educate the provider on, if he or she has a patient that has just passed away, now is not the time to share?they won’t remember what you tell them. Let the provider know you recognize the situation and will reschedule.
    • If you know a physician is overwhelmed or is having a really bad day, then recognize that now may not be a good time and offer to reschedule.
  • Be available. When approaching a physician for one-on-one education, be flexible in your availability. This could mean coming in early to meet with a doctor before his or her first case. If the physician can meet at lunch, do it. Recognizing the physician’s workload demands and being flexible will yield many benefits to the relationship.
  • Be prepared. Physicians will ask you a question once, maybe twice, where you can say, ‘I don’t know,’ but chances are they won’t ask a third time. Be creative in your response. Instead, try saying, ‘You know, I just read something about that, let me go back and make sure I am giving you the most updated information,’ or ‘I just saw something on this, I am not sure if it was CMS or carrier directed. Let me find it and get back with you.’ Once you lose a physician’s trust, it is very difficult to regain it.
  • Don’t waste their time. One of the biggest complaints I have heard from doctors is related to queries they deem as a waste of time. Make sure the query or question you are asking is
    • Addressed to the right physician/provider
    • Relevant to the patient care being provided
    • The information you are basing your query on is accurate
  • Walk in their shoes for a day. Offer to round with them, where you can provide live audit and education to the provider. See how their days really are. In most cases, you will be amazed at how much they get done.
  • Be a better listener. Some coding and documentation guidelines are not clinical in nature and providers can get frustrated by being asked to document things that aren’t clinically significant (e.g., family history for the 85-year-old patient). Sometimes your provider may just need to vent this frustration and while you may not have a resolution to offer, listening and understanding can go a long way in building rapport.
  • Ask questions. Ask your provider how they translate a patient visit into medical record documentation. Questions that might solicit opportunities for improved documentation may include:
    • What questions are they asking when interviewing the patient?
    • What concerns do they have?
    • What is the patient experiencing? You can utilize this information to point out how the documented note can better demonstrate the patient’s current condition and treatment plan.
  • Share the good as well as the bad. When a physician is doing a really great job documenting timely, accurately, and completely, give them a shout out. Or, when they answer queries timely, let them know. A quick note with a smiley face or even a gold star will be very much appreciated. Positive recognition given to one physician and not another often results in the physician inquiring how he or she can get recognition.
  • Sports and (other interests). While engaging physicians in discussions such as sports is completely unrelated to coding and documentation, it can pay off significantly. Many providers are very loyal to their alma mater’s college football and basketball teams. Relationship building can be accelerated when you engage physicians in areas of personal interest. Gaining an understanding of a physician’s college coach, conference, and team standing, and discussing this information with a physician can go a long way to building a relationship. But sports isn’t the be-all, end-all. If you know a doctor has a particular interest (cooking, piano, horror movies, or painting) learning a little about that interest can go a long way. Expanding your knowledge is a good thing and building your relationship with that provider is a great thing.
  • Empathy. It is important to remember that physicians are busy with competing priorities. Providers often get interrupted while they are dictating and/or documenting their notes, and when they leave something out of their notes, it is not intentional.

 

Recognizing that one of our major responsibilities as coders and documentation specialists is to make the physician’s job easier and their data as accurate as it can be is essential.

Avoid approaches that make them feel like they have done something wrong. Let providers know your job is ‘to make you look as good as you are.’

 

 

Editor’s note

Egan is an associate director with Navigant Consulting and has been working with providers, of all specialties, for more than 25 years. She works with providers to improve documentation as well as provide education and training related to CPT coding. Sue has lived in Charlotte, North Carolina, for the last 23 years, enjoys traveling with friends, and relaxing at home with a good book and her cats. Opinions expressed are that of the author and do not represent HCPro or ACDIS.

 

 

HCPro.com – HIM Briefings

Top 4 Payer Priorities for 2016




Health Leaders Media


Please add this newsletter to your Safe Sender list
View this email as a Web page | Manage Account

  February 17, 2016 Follow us on FacebookFollow us on TwitterJoin us on LinkedInRSS feed

Top 4 Payer Priorities for 2016

Rene Letourneau, Senior Editor for HealthLeaders Media

A new payer survey offers insights for providers as both deal with a common challenge: technology. >>>

 

Editor’s Picks

Value-Based Care Shifts into High Gear

Guideposts for the paths to participating in value-based healthcare models come into focus at a payment innovation summit held in Tennessee. >>>

CMS Finalizes Medicare Overpayment Reporting Rule

An overpayment is considered identified by Medicare when an employee using "reasonable diligence" has, or should have, determined it was received and quantified the amount, according to the final rule. >>>

Incoming Carolinas HealthCare CEO Driven by Community, Mission

The newly named CEO of Carolinas HealthCare System, Eugene A. Woods, talks about his legacy at Christus Health and the challenges that await him when he takes the helm at one of the nation’s largest public health systems. >>>

CMS, AHIP Standardize Quality Measures

Seven measure sets aim to alleviate the burden and cost of measuring clinical quality and will "support multi-payer alignment, for the first time, on core measures primarily for physician quality programs," says CMS. >>>

Dignity Health Announces Urgent Care Partnership

The urgent care centers will be a 50/50 partnership, with Dignity Health Medical Foundation providing the clinicians, GoHealth providing the organizational infrastructure and expertise, and both entities equally sharing the capital investment. >>>

ONC: Time to Get Busy with Value-based Payment Models

"We’re in a little bit of a we-don’t-know-what-we-don’t-know state as an industry. And it’s going to dawn on people really quickly that MACRA is a really big deal," says a co-chair of ONC’s Health IT Standards Committee. >>>

The Healthcare Partnership Midrange

The middle ground of the healthcare partnership continuum is dotted with a variety of relationships that feature varying degrees of shared governance. >>>

Intelligence Report:
The Analytics Challenge—Gaining Critical Insight into Risk-Based Models

As providers undertake contracts with increasing levels of downside risk, their need for advanced analytics to manage decision making and monitor results will only grow. >>>

LIVE Webcast

Webcast: Integrating Behavioral Health: Decreasing Costs and Improving Care

Date: March 15, 2016, 1:00–2:00 p.m. ET
In this expert webcast, hear how Carolinas HealthCare System developed a strategy to optimize resources to create a truly integrated model.
Register Today >>>


News Headlines

Community Health stock slumps after surprise loss, rivals also hit

Fox Business, February 17, 2016

When a brain surgeon becomes a malpractice lawyer

ProPublica, February 17, 2016

High cost of cancer care may take physical and emotional toll on patients

The Wall Street Journal, February 17, 2016

Christ Hospital seals surgery deal with UnitedHealth Group division

Cincinnati Business Courier, February 17, 2016

Aetna gets FL insurance regulator’s approval for Humana deal

CNBC / Reuters, February 16, 2016

Cancer patients snagged in health law’s tangled paperwork

Chicago Tribune, February 16, 2016

Hacking of healthcare records skyrockets

WRCB-TV / NBC News, February 16, 2016

Top hospitals likely are available on a marketplace plan, study finds

Kaiser Health News, February 15, 2016

With end of ‘doc fix’, effort to craft a new payment system underway

The Hill, February 12, 2016

Healthcare battle brewing between governors in KY

ABC News / Associated Press, February 12, 2016

Stay Connected to HealthLeaders

Don’t Miss the News You Want.

Spam filters exist for a reason, but not for the news you need. Make sure you aren’t missing your daily and/or weekly industry coverage. Add our address — [email protected] — to your address book or e-mail whitelist to keep the news you need in your inbox.

Is All of Your Leadership Team In The Know?

Our award-winning Daily News & Analysis e-newsletter can keep your leadership team abreast of relevant breaking news, and with in-depth industry coverage through 10 weekly e-newsletters that hit every pillar of healthcare, we’ve got your whole leadership team covered. Subscribe to any — or all — of our e-newsletters.

Multimedia/Events

HealthLeaders Media LIVE at NCH Healthcare System: Population Health

Date: February 23, 2016 | 11:00–2:00PM ET
In this live e-conference, discover how NCH Healthcare System has expanded its population health program with a multi-layered strategic plan.
Register Today >>>

From HealthLeaders Magazine

Changing Patient Behavior Through Technology

Software and hardware developments are opening new ways to get patients more involved in their own care. >>>

 

Cancer: Aligning Costs and Care

 

The Healthcare Partnership Midrange

Sponsor this Newsletter

For advertising opportunities in this or other HealthLeaders Media email newsletters, please contact [email protected] or call 800.639.7477.

  MAGAZINE | NEWS | TERMS OF SERVICE | PRIVACY POLICY | ADVERTISE Follow us on FacebookFollow us on TwitterJoin us on LinkedInRSS feed

©2016 HealthLeaders Media

If you prefer not to receive this email newsletter, let us know.
HealthLeaders Media Health Plan Insider is a division of Fortis Business Media
HEALTHLEADERS MEDIA
100 Winners Circle, Brentwood, TN 37027
Serving the business information needs of healthcare executives and professionals.

 



HCPro.com – Health Plan Insider

HIM Briefings, October 2016

2016 HIM roles and responsibilities survey

HIM professionals report on their expansive role in the revenue cycle

For approximately 10 years, HIMB has been gathering data about the HIM profession through its annual salary survey. This survey often gives us a glimpse into the responsibilities of HIM professionals, but focuses primarily on the education, experience, and salary of those in the HIM field.

Time and again, the salary survey reveals that HIM directors and managers are wearing many hats and asked to oversee an increasing number of tasks. In an effort to dig a bit deeper into HIM departments, HIMB conducted its first HIM roles and responsibilities survey.

More than half of respondents were HIM directors (26%) or managers (25%), whereas the remaining 49% held other revenue cycle positions. Of the latter group, 50% were coders and 29% were CDI specialists. Responses also came in from transcriptionists, privacy officers, compliance officers, revenue integrity professionals, and consultants.

HIM demographics

The plurality of respondents work in acute care hospitals (55%) and critical access hospitals (17%) or have a corporate position at a multi-system hospital (8%). Other settings represented in the survey include long-term acute care hospitals, psychiatric/behavioral health hospitals, skilled nursing facilities, ambulatory surgery centers, and physician practices.

On average, most respondents appear to be working in a hospital with 100?199 beds, with approximately 20% of respondents selecting this option. Nearly 18% work in hospitals with fewer than 25 beds, and 15% work in hospitals with 500 or more beds.

 

HIM reporting structure

Nearly half of respondents (48%) report that more than 20 staff members report to the HIM director and/or manager at their facility. Nearly one-quarter (22%) of respondents reported that 0?5 staff members report to the HIM director/manager at their facility. The remaining 30% of respondents said the number of employees reporting to HIM is more than five but less than 20.

The majority of HIM departments represented in the survey (78%) report to their facility’s chief financial officer. Others tend to report to the chief executive officer (13%) or chief information officer (9%). Some respondents wrote in to clarify their reporting structure after selecting one of the aforementioned broader options. Write-in responses indicate HIM may also report up to:

  • Vice president of finance
  • Vice president of health data support services
  • Vice president of revenue management
  • Vice president of revenue cycle
  • Vice president of quality management
  • Chief quality officer
  • Chief medical information officer
  • Chief revenue officer

Similarly, HIMB asked respondents which roles report to the HIM director/manager. The top three roles reporting to HIM include release of information staff (90%), coders (89%), and transcriptionists (76%). Less than half of CDI specialists (45%) and privacy officers (42%) report to HIM. And less than one-quarter of information governance (22%), compliance (16%), security (14%), and revenue integrity (12%) staff report to HIM directors/managers. A lesser percentage of risk management (5%) and case management (4%) professionals fall under HIM.

Some respondents wrote in to note that HIM is often responsible for overseeing registration, billing, collections, record management, and patient access.

Respondents indicated that transcription is the most frequently outsourced role in HIM, with 61% indicating their facility outsources this function. "It is very convenient, as transcribers are situated throughout the states and reports are transcribed timely for late night physician dictations," one respondent said.

More than one-third of facilities surveyed (34%) have also opted to outsource release of information (ROI) functions. "We have a one-person department. ROI is outsourced only as it applies to requests from lawyers, courts, and disability agencies. HIM handles requests from hospitals, doctors, and patients," one respondent said.

Other functions frequently outsourced include archives/warehouse storage (33%) and inpatient (28%) and outpatient (24%) coding. (See the figure on p. 3 for more information about outsourcing.) One respondent noted that his or her coding and transcription is only partially outsourced.

"Our outsourced outpatient coding position is for only 20 hours a week. She codes clinical accounts as well as observation and outpatient surgery cases," a survey respondent said.

Respondents seemed to be split on whether outsourcing was the best option. While some respondents noted that outsourcing was helpful in terms of managing costs, others stated that it was expensive. However, for facilities with limited resources and space, it seems to be a viable option.

"Coding is outsourced due to the limited resources we had available at our facility, such as qualified coding candidates in our geographic area as well as competitive compensations with surrounding areas," one respondent said.

While some facilities reported outsourcing functions due to lack of resources, others are simply using it for backfill and vacation coverage or simply to ensure coverage after hours and on weekends for certain functions. "The services outsourced above are mainly outsourced because of the lack of resources to hire qualified personnel who can do the job. In a recent analysis it was also shown that the price we pay for outsourcing coding was low compared to the price it would cost to have it in house," one respondent said.

Notably, one HIM director stated that his or her function is entirely outsourced. This seems like it may present a challenge given that HIM directors and managers are involved in so many projects.

HIM responsibilities

According to survey respondents, HIM directors/managers are actively responsible for the following functions (see the figure on p. 3 for more information):

  • Prepping, scanning, and quality checks for medical records (96%)
  • Record retrieval, assembly, and analysis (93%)
  • Delinquency management (88%)
  • Transcription (79%)
  • Enterprise master person index/master person index (56%)
  • Archives/warehouse management (51%)
  • Patient identity management (46%)

 

When asked to expand upon their roles in HIM, respondents described their responsibilities in various ways, backing up what we have long seen in the HIM director and manager salary survey about HIM playing many roles.

One HIM manager responding to the survey stated that he or she supervises coder education and training, "providing orientation and initial job training for coders, ongoing and new software/processes training for coders and CDI, including all ICD-10-CM and ICD-10-PCS training as job-required."

An HIM director responding to the survey stated that he or she is "responsible for direction and overall performance of all chart assembly, analysis, and coding." This respondent also noted involvement in "ROI functions and all internal and external audit reviews." As if that doesn’t sound like enough to keep one HIM director busy, this particular respondent also noted involvement in the following:

  • Quality improvement
  • Utilization review
  • Chart delinquencies and CMS reporting requirements
  • Working with CDI and physicians on chart requirements and timely documentation

 

See the sidebar on p. 5 for specific information about responsibilities of various titles within the HIM department.

Despite everything HIM directors/managers have on their plates, most respondents chimed in when we asked which committees HIM should play a role in. Respondents wrote in that HIM should participate in committees related to the following:

  • EMR/EHR
  • UR
  • Billing
  • Quality
  • Finance
  • Compliance
  • HIPAA
  • Credentialing
  • Forms creation
  • Population health
  • Patient services
  • CDI
  • Medical executive
  • Nursing
  • Appeals and denials
  • Revenue integrity
  • Information governance

 

If it seems like we just listed off the majority of hospital departments, that’s because we did. Despite an ever-growing list of demands, HIM managers and directors are well suited to take a seat at the table with any of the above departments/committees and are often eager to do so.

"HIM participates in information governance, and quality meetings. I would suggest that our HIM department also participate in medical executive meetings and also ambulatory care meetings," one respondent said.

While some respondents were specific about which committees HIM should be a part of, others simply stated that HIM had earned a seat on any committee that was related to the revenue cycle. "I think HIM should participate in any and all committees needed, as the HIM department touches every piece of PHI that enters the hospital, whether that be on paper or electronic. HIM representation at meetings, I believe, is very important," said an HIM director.

 

Challenges facing HIM today

We asked survey respondents a variety of open-ended questions about the HIM department at their facility. When asked to identify challenges facing HIM, respondents said the following:

  • "HIM professionals are rarely acknowledged for their impact and knowledge they have that benefits the facilities they work at. Most leaders and other departments have no idea what we do and typically will call us ‘glorified paper pushers.’ Because of this, compensation is not where it should be."
  • "Movement to an EMR. Dealing with issues with copy and paste functions within an EMR. Acquiring accurate information on admission with an accurate MPI. Being included in meetings and decision-making that affects the HIM function."
  • "Lack of staffing. Not all facility staff are aware of all the HIM tasks, so they think we only put papers together all day and nothing else."
  • "Building a coding department. Ensuring accurate coding and impact to patient safety indicators. Accurate physician documentation."
  • "Competing salaries with outsource companies for coders and coders wanting remote work only."
  • "It seems that most HIM jobs are outsourced and that we are having to pick a specialty (CDI, Privacy/Security, coding, EHR, etc.) to keep a foothold in our business. It’s not the old HIM department as we knew it!"
  • "Our greatest challenge is the hybrid medical record. Know what is electronic and where it is located in the HIS system and what is still paper. Some physicians still will not electronically sign. Along with EMR is the multiple systems that interfaces must be built for information to be shared which adds to cost."
  • "For us I believe that is trying to get us that last 5% totally electronic. Overall, I would say support of providers to use the electronic system, so that we can get away from pushing around so much paper. We have gone from a department of eight to a department of five in my five years here; we, as well as many other departments, are being asked to do more with less. That is a challenge."

 

Inside the HIM department

Ever wonder what the inside of another facility’s HIM department looks like? Of course you do. To satisfy our curiosity, we asked respondents to describe the makeup and location of the HIM department within their facility:

  • "HIM is on the main level of the hospital. We are located on a separate wing by ourselves away from main traffic of the hospital. It would be beneficial to be more centrally located so that patients can better find us when they need records. The coding department is across the hall from us in a separate office."
  • "Ground floor next to administration, away from the physician lounge. Would be better being closer to the physicians to get records completed. One in-house coder for ancillary coding. All staff in area for ROI, birth certificates, assembly and analysis, scanning, but file room is located across the hall."
  • "HIM at my facility is on the ground level. In fact, I think we are in the perfect location for patient access because we are right inside the door. From the HIM department we only have HIM personnel working alongside each other. Coding works at home and at our affiliate site. Transcription is outsourced. We do share space with another department, not HIM related."
  • "We are located on the first floor of the hospital. Our coding and transcription functions have been regionalized and are managed off-site. The majority of our coders work from home."
  • "Ground level. Coding, scanning, and records review share a large office. Transcription and CDI are in different areas of the hospital."
  • "All of HIM, except for CDI, are all located together in a medical office building on campus. A CDI [specialist] is assigned to a specific floor/unit and works from there."
  • "The HIM department is on the patient floor with coding being done on-site and remotely. Transcription is contracted out and performed remotely and HIM clerical personnel on-site at each building."
  • "HIM located within the core of the patient care area. Four of five HIM staff share the office with the manager."
  • "Basement of hospital for scanning, chart completion, data integrity. Off-site for HIM at rehab, skilled, homecare. Coding is in a separate building off campus."
  • "We have a separate building from the hospital for all non-clinical employees. Most of our coders work from home. All of HIM is in one big area of the second floor."
  •  

Survey respondents weigh in on roles and responsibilities

To understand the intricacies of the HIM role, we asked survey respondents a variety of open-ended questions about the HIM department at their facility. When asked to describe their role and responsibilities as they relate to HIM, respondents said the following (the title that follows each quote was selected by the respondent regardless of the scope of responsibilities described):

  • "My role is inpatient coder and involved in DRG appeals sending out letters of redetermination to insurance companies?HIM department separated from coding/CDI department." ?Coder
  • "I manage the coding and CDI functions within the HIM department. I make sure the coding service is up to date on any facility changes and monitor that they are meeting service agreements." ?HIM manager.
  • "I am a coder and credentialing coordinator by title, however, I perform every single task in HIM department?transcription filing to chart assembly and analysis, denial follow-up cases due to documentation or coding issue, physician delinquent rates, subpoenas and other ROIs, etc." ?Coder.
  • "Only employee?coder, data entry, chart completion, analysis, physician visits, medical staff, release of information." ?Non-director/manager in HIM.
  • "Revenue cycle director, HIM director, privacy officer. I wear several hats to coordinate the areas of admitting, scheduling, switchboard, business office, and medical records." ?HIM director.
  • "My role and responsibilities as the HIM director and privacy officer include education on HIPAA privacy and breach reporting, maintaining the department, conducting and reporting on closed chart reviews, coding quality and quantity, transcription quality and quantity, and other personnel’s productivity. I also play a very active role in educating physicians on using the EHR and completing their records; track delinquency rates; and assist IT in managing information." ?HIM director.
  • "I am an outpatient coder coding some clinical accounts but primarily outpatient surgery and observation accounts. In addition to coding, I check charges on each account to make sure we have a revenue code to link the CPT code to and have charges for any implants/devices that were used. Each account finalized is then sent to billing so the more we code, the faster the billing department can send the bills." ?Coder.
  • "We share/rotate responsibilities in our small department between outpatient ancillary coding, transcription, ROI, prepping charts for scanning our hybrid record, quality controlling scanned documents. I’m in training to take over for my director when she retires in two years. I’m also the module coordinator for our Meditech computer system, working with our IT lady on issues affecting our department." ?Transcriptionist.
  • "I am the HIM coordinator who wears many hats. Coding/privacy officer/quality improvement/core measure reporting/chargemaster/credentialing." ?HIM manager.
  • "Manage coding staff, perform compliance audits, provide education to coders, CDI specialists, and physicians. Support management of budget, supplies, etc. Participate in revenue cycle meetings and work closely to develop and submit appeals/address denials." ?Coding supervisor.

 

2017 IPPS final rule and claims-based measures

by Shannon Newell, RHIA, CCS, AHIMA-approved ICD-10-CM/PCS trainer

The fiscal year (FY) 2017 IPPS final rule was released August 2 and will be published in the Federal Register August 22. The majority of the finalized updates are consistent with those outlined in the proposed rule, but with a few refinements to applicable time periods. The final rule expands and refines the number of claims-based ­outcomes linked to payment under these programs.

Let’s review a few of the key changes to support your CDI program’s strategic focus for the coming year.

 

Risk-standardized readmission rates

Risk-standardized readmission performance for the coronary artery bypass graft (CABG) cohort will be linked to reimbursement in FY 2017. The applicable time period for discharges used to assess performance in FY 2017 has passed, but today’s discharges will impact performance in FY 2018.

This is a great example of why it’s important to focus on new measures adopted in this year’s rule for future program years. CMS utilizes a two- to three-year historical window of data for claims-based measures, so today’s performance impacts us financially two to three years in the future.

 

Risk-adjusted PSI 90 composite

The current Patient Safety Indicator (PSI) 90 measure will continue to be utilized in the Hospital-Acquired Condition Reduction Program (HACRP) and Hospital Value-Based Purchasing Program (HVBP) through FY 2018. At that time:

  • The HACRP will adopt the modified PSI 90 composite in FY 2018
  • The HVBP will discontinue future use of the PSI 90 measure in the FY 2019 rulemaking?CMS notes that the HVBP intends to adopt the modified PSI 90 composite in future rulemaking

 

The modified PSI 90 composite, also called the Patient Safety and Adverse Events Composite, was finalized as proposed. A review of key modifications follows:

  • PSIs in the composite have been revised; one PSI was deleted (PSI 7?CLABSI) and three new PSIs were added, providing a total of 10 PSIs in the modified composite
  • The final rule notes that PSIs 12 and 15 have had specification revisions
  • PSI weighting in the composite has been refined to incorporate the impact of both volume and harm

 

Applicable time periods for the measure were shortened as proposed, although date ranges were revised as noted below in italicized font:

  • HACRP:
    • FY 2018: July 1, 2014?September 30, 2015 (15 months)
    • FY 2019: October 1, 2015?June 30, 2017 (21 months)
  • HVBP:
    • FY 2018: Same as HACRP above (for the performance period; the baseline period will not be revised)

 

Performance scoring for the HACRP will adopt Winsorized z-scores instead of deciles.

  • The z-score method uses a continuous measure score rather than forcing measure results into deciles.
  • Z-scores represent a hospital’s distance from the national mean for a measure in units of standard deviations. A negative z-score reflects values below the national mean, and thus indicates strong performance.
  • To form the total hospital-acquired condition (HAC) score, the z-scores will be used as hospitals’ measure scores. The current scoring approach will then kick in.
    • The domains will be scored as follows:
    • The domain scores will then be multiplied by the domain weight
    • The weighted domain scores will be added together for the total HAC score
    • Hospitals in the top (worst) quartile would be subject to the payment penalty

 

Risk-standardized mortality measures

Risk-adjusted CABG mortality performance will impact financial reimbursement under the HVBP effective with the FY 2022 program. The applicable time periods that will be used to assess performance at that time follow:

  • Baseline period: July 1, 2012?June 30, 2015
  • Performance period: July 1, 2017?June 30, 2020

 

The pneumonia cohort will expand to include patients with a principal diagnosis of aspiration pneumonia and/or patients with a principal diagnosis of sepsis and a secondary present-on-admission diagnosis of pneumonia:

  • This aligns the cohort definition with that for the pneumonia readmission measure adopted with the FY 2021 program year.
  • Applicable timelines will be shortened from the usual three years of data to expedite HVBP adoption. The applicable time period for the cohort follows; italicized font indicates refinements to the dates in the final rule:
    • FY 2021:
    • FY 2022:

 

Cost measures

The previously adopted HVBP payment measure for pneumonia (hospital-level, risk-standardized payment associated with a 30-day episode of care for pneumonia) will expand the pneumonia cohort.

The expanded cohort will be consistent with the cohort definition used for the risk-adjusted readmission measure in the Hospital Readmissions Reduction Program (HRRP) and the risk-adjusted mortality measure used in the HVBP:

  • The expanded cohort is anticipated to shift 9.3% of hospitals from the "average payment" category to the "greater than average payment" category

Two new payment measures will be added to the efficiency and cost reduction domain in the HVBP beginning FY 2021:

  • Hospital-level, risk-standardized payment associated with a 30-day episode of care for acute myocardial infarction
  • Hospital-level, risk-standardized payment associated with a 30-day episode of care for heart failure

 

These payment measures are intended to be paired with the 30-day mortality measures, thereby directly linking payment to quality by the alignment of comparable populations and risk-adjustment methodologies to facilitate the assessment of efficiency and value of care:

  • The applicable time periods for the measures are as follows:
    • Baseline period: July 1, 2012?June 30, 2015
    • Performance period: July 1, 2017?June 30, 2019
  • The risk-adjustment methodologies used for these measures are similar to those used for risk-adjusted mortality

 

Performance for these new measures will be scored using the methodology for the Medicare spending per beneficiary measure.

 

Summary

Effective October 1, 2017, performance for cost and quality measures in the HRRP, HVBP, and HACRP will impact up to 6% of your hospital’s inpatient acute Medicare fee-for-service reimbursement.

So, where to begin? First, become familiar with the measure specifications and risk-adjustment methodologies, in addition to existing CMS provided reports on historical performance, to gain insights into your organization’s clinical documentation and coding vulnerabilities.

Measure specifications can be found at: www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html.

The final rule is available here: www.federalregister.gov/public-inspection.

 

Editor’s note

Newell is the director of CDI quality initiatives for Enjoin. She has extensive operational and consulting expertise in coding and clinical documentation improvement, performance improvement, case management, and health information management. You can reach Newell at [email protected]. Opinions expressed are that of the author and do not represent HCPro or ACDIS.

HCPro.com – HIM Briefings

Briefings on APCs, November 2016

Review your electronic order templates to protect against audits and ensure compliance

by Valerie A. Rinkle, MPA

Orders for services are a vital component of ensuring Medicare coverage. With the advent of computerized provider order entry (CPOE), it is important to review order templates in the electronic medical record (EMR) and the resulting order produced or printed in the formal legal medical record to ensure the templates meet requirements.

Due to increased audit scrutiny, including resumption of inpatient status reviews by Quality Improvement Organizations (QIO) as of late September, it is vital to "audit proof" your organization’s EMR and legal medical record so that the orders substantiate coverage of services. The QIOs are auditing to ensure validity of inpatient orders as well as to ensure cases meet the benchmark for at least two nights of hospital-level care. These determinations are dependent on valid orders.

CMS has published numerous resources on orders for both outpatient services and inpatient admission. Requirements for orders vary based on the type of service, such as inpatient admission, outpatient admission, observation services, diagnostic laboratory services, and other diagnostic tests. A good resource is the CMS article, "Complying With Medical Record Documentation Requirements."

Orders must be signed or otherwise legitimately authenticated. Transmittal 327 contains detailed information concerning physician signature/authentication.

 

Elements of a valid order

To be considered a valid order, several elements must be present. Elements required in statute or regulations by Medicare are bolded:

  • Authentication of the ordering provider (signature or valid electronic signature and credentials)
  • Clinical indication/justification/reason for the test, using medical terminology (e.g., sign, symptom, diagnosis) and/or ICD-10-CM codes
  • Date of the order
  • If a drug is ordered, the drug name, dosage, route of administration, and rate for infusions
  • Name of the ordering provider?this must be a treating provider, meaning he or she has conducted an exam and intends to use the results of that exam in continued treatment of the patient
  • Patient name?best practice also calls for another identifier, such as date of birth
  • Test or service ordered, by name?best practice also calls for the HCPCS/CPT code of the test

 

Format of orders

There is no requirement regarding the format of orders. For providers not linked to a hospital’s EMR, orders may continue to be delivered in writing or via facsimile. Often, the beginning of the workflow for the hospital EMR is to transcribe the order into the EMR for the patient. If this step occurs, it is vitally important that the original order be scanned and linked to the EMR to substantiate the information transcribed.

What if the staff transcribing the order incorrectly enters the information? What if the test is not logical or valid for the indication? The clinical staff providing the service should be able to view the original order and make any corrections, or obtain an updated order, as appropriate. Auditors expect to see the original order. If the order is not entered via CPOE, there will be no documentation in the EMR regarding the origination of the order, which is why scanning and not just transcribing the order is so crucial.

 

Orders missing elements

What does your hospital do if one of the elements is missing from the order? Ideally, if there were elements missing, no test or service would be performed. However, the current emphasis on improving patient experience may lead hospitals to move ahead and perform the service anyway. Recall that the EMR will clearly document the time of the test and the time that the diagnosis or other information is obtained, making it very clear to auditors whether the indications for the test were missing prior to its performance.

Further, because of prior authorization requirements as well as national coverage determinations (NCD) and local coverage determinations (LCD) that establish the medical necessity for outpatient tests, diagnostic indications obtained after test performance will be questioned: Did they actually exist prior to the test being performed?

If the hospital proceeds with testing prior to obtaining all the required elements of the order, it is recommended that the original chart note of the provider ordering the test be obtained, scanned, and linked to the EMR. The original chart note should clearly document that the test is needed along with the indication for the test. Documenting this information will prevent the appearance that the indication has been added after the test solely to justify meeting prior authorization or NCD/LCD requirements. Merely updating the EMR order with a diagnosis, or calling the provider and annotating the addition of a diagnosis on a written or faxed order, will open up the account to scrutiny and allegations of invalid documentation to support services.

 

ED protocols

What about testing initiated via protocol in the ED prior to the patient being seen by the treating provider? Protocols need to be vetted very carefully with the medical staff and with the MAC in your region.

Typically, an order is initiated as a verbal order in the EMR based on the presenting signs and symptoms of the patient. Once the provider sees the patient and uses the test results to treat the patient, the verbal order is authenticated by the treating ED provider in the EMR.

With this workflow, the requirements for orders are met. The concern with this workflow is whether the hospital has controls in place for patients who leave without being seen (LWBS) by the provider and for tests the provider does not agree were needed.

Providers do, at times, disagree with the protocol initiated by the nursing staff. There must be a clear workflow for the provider to do one of the following:

  • Not authenticate the order with which the provider disagrees.
  • Authenticate the order, but annotate the tests the provider disagrees with within the order. In these cases, the disputed tests should be billed and written off as noncovered.

 

Also, if tests are ordered via protocol and the patient is LWBS by a provider, the tests are not usually authenticated by the provider, and they are billed and written off as noncovered.

 

Billing for tests and services

ICD-10-CM codes included on outpatient claims for services typically come from the provider order. For certain imaging, cardiology, and other tests (i.e., nonclinical laboratory tests) where a physician makes a separate report of interpretation, the final impression on the report may be a different diagnosis from that on the order. In this case, the coder should code the final diagnosis from the report of interpretation. This diagnosis should be the diagnosis code billed on the claim. However, a large volume of accounts are billed from the order, and there may not be a process to ensure the diagnosis from the report of interpretation is included on the claim. In the past, some billing and coding departments coded solely from the indication that patient access staff transcribed from the order onto the patient account, meaning the departments did not review the reports of interpretation.

It is critical for compliance that outpatient accounts be coded from the original order if the report of interpretation does not have a more specific diagnosis (i.e., the report states "routine" or "no finding"). Proper coding requires that the staff applying the codes either view the original order in CPOE or via the scanned image.

With today’s gains in automation and productivity, more workflows now pull a code directly from the transcribed information or the data entered into CPOE to the outpatient account for billing. If this is the preferred workflow of the hospital, a sample of accounts should be audited quarterly to ensure that the codes billed match the original order and that the automated workflow is viable for compliance coding and billing and does not bypass reports of interpretation that include more specific diagnoses.

One of the best program memoranda (albeit an older one) that explains CMS policies concerning coding for diagnostic tests is contained in Transmittal PM AB 01-144.

Including ICD-10-CM codes

There is a lot of debate regarding whether the codes themselves (versus terminology) should be included in the order. Coders typically emphasize that they can arrive at the most appropriate code if medical terminology, rather than a less specific ICD-10-CM code, is included on the order. Meanwhile, patient access staff and other employees who must apply NCDs and LCDs and check for prior authorization prefer the actual ICD-10 code to be on the order because it facilitates checking for coverage and authorization in electronic tools designed for that purpose. 

CPOE can improve the specificity of orders if the drop-down menus used by providers are customized to be as specific as possible and avoid more nonspecific codes. Consider also the greater specificity present in ICD-10-CM. If certain order sets for high-volume patients include indications for drugs and other tests at their greatest specificity, documentation can be better captured in more routine workflows to support ICD-10-CM coding, thereby avoiding time-consuming provider queries.

 

Conclusion

EMRs enable workflows that should be scrutinized completely, from the initiation of the order with the treating provider to the order’s appearance in the retained legal medical record.

Other related processes should also be scrutinized, including the workflow used to check orders for medical necessity and prior authorization, as well as the workflow used by staff and/or coders to apply the codes from the orders to the account and the resulting claim. Detailing these workflows and enhancing the processes that go along with them will ensure compliant orders.

 

Editor’s note

Rinkle is a lead regulatory specialist and instructor for HCPro’s Medicare Boot Camp®?Hospital Version, Medicare Boot Camp?Utilization Review Version, and Medicare Boot Camp?Critical Access Hospital Version. She is a former hospital revenue cycle director and has over 30 years in the healthcare industry, including over 12 years of consulting experience in which she has spoken and advised on effective operational solutions for compliance with Medicare coverage, payment, and coding regulations.

 

Updated 2017 ICD-10-CM guidelines come ‘with’ controversial changes

by Shannon E. McCall, RHIA, CCS, CCS-P, CPC, CPC-I, CEMC, CRC, CCDS

 

Just like the lyrics to the popular Gap Band song say, "You dropped a bomb on me… I won’t forget it," there are definitely some changes in the 2017 ICD-10-CM Official Guidelines for Coding and Reporting that some of us may wish the Cooperating Parties will forget were ever mentioned.

Generally, changes to the guidelines are minor and rarely cause the chaos and confusion that will certainly ensue with the most recent release, effective October 1. This release includes some contradictory guidance and downright concerning statements that appear as if no one really thought through the repercussions. These revisions will certainly have an impact not only on code assignment, but also specifically on reimbursement.

With

The guidelines state:

The classification presumes a causal relationship between the two conditions linked by these terms in the Alphabetic Index or Tabular List. These conditions should be coded as related even in the absence of provider documentation explicitly linking them, unless the documentation clearly states the conditions are unrelated. For conditions not specifically linked by these relational terms in the classification, provider documentation must link the conditions in order to code them as related.

 

I consider this paragraph the most controversial addition to the guidelines. We’ll look at the impact the guideline has on previous examples relating to conditions such as diabetes mellitus, hypertensive heart disease, and some other conditions.

The guidance most commonly discussed is that for "diabetes with," which was stated in the AHA’s Coding Clinic for ICD-10-CM/PCS, First Quarter 2016, and reconfirmed in the following quarter. To summarize, the AHA guidance stated:

The classification assumes a cause-and-effect relationship between diabetes and certain diseases of the kidneys, nerves, and circulatory system and ANY condition listed under the term "with" in the Alphabetic Index is intended to be interpreted as a related condition/manifestation.

 

It appears that someone has never looked in the actual ICD-10-CM index file, because all conditions related to diabetes mellitus are indented under the word "with," not just isolated ones as in the ICD-9-CM manual.

Here is the comparison (from the ICD-9-CM index):

Diabetes, diabetic (brittle) (congenital) (familial) (mellitus) (severe) (slight) (without complication) 250.0

Compare to this excerpt from the ICD-10-CM Alphabetic Index:

The most surprising aspect to me in the repeated guidance is the contradiction to not assume a relationship between osteomyelitis and diabetes mellitus, which Coding Clinic originally stated in Fourth Quarter 2013 and reiterated in First Quarter 2016, writing:

ICD-10-CM does not presume a linkage between diabetes and osteomyelitis. The provider will need to document a linkage or relationship between the two conditions before it can be coded as such.

 

Coders understood back in 2013 to not assume relationships between diabetes and other conditions that coexist in a diabetic patient. But this recent guidance creates more questions than answers. This very specific guidance about osteomyelitis leads me to imagine the scenario of a patient who has a relationship created between osteomyelitis and diabetes mellitus by a provider documenting "osteomyelitis due to diabetes mellitus." What codes would be reported?

The correct answer would be to assign the code for other specified complication (e.g., E11.69) since there is no entry specifically for osteomyelitis under diabetes mellitus. It would be classified to the "other" category per the ICD-10-CM conventions. If we examine this a bit closer, E11.69 is listed under the word "with" in the Alphabetic Index.

So, is it assumed or not? The guidance and guidelines directly contradict each other.

Some have argued that the ICD-9-CM index included a specific entry for diabetes with osteomyelitis, and I agree that the word "osteomyelitis" is there in black and white, but take a look at the code title: 250.8 (other specified manifestation of diabetes mellitus). There wasn’t a specific code in ICD-9-CM that said "diabetes with osteomyelitis," just like there isn’t in ICD-10-CM.

Diabetes, diabetic (brittle) (congenital) (familial) (mellitus) (severe) (slight) (without complication) 250.0

I suggest if the Cooperating Parties truly plan on keeping osteomyelitis separate, there should be a separate entry in the Alphabetic Index where it is not at the second indentation level under the word "with," but is under diabetes as a main term with a singular indentation.

The "with" guidance extends much further than I think the Cooperating Parties have considered. For risk-adjusted plans, the assumption of linking diabetes and other related conditions (acute and/or chronic) without necessitating providers document it will have a direct impact on a patient’s overall risk score.

The risk score uses many factors, but chronic conditions like diabetes mellitus are a key component in determining how much CMS should pay an insurance plan for care for Medicare beneficiaries covered under plans like Medicare Advantage (i.e., Part C). Being able to assume a relationship is a major change and will ultimately have a big impact on spending for any risk-adjusted plan, considering diabetes is such a common condition.

The reason this hasn’t really been considered an issue yet is that Medicare Advantage data is compiled based on the previous year’s diagnosis codes to prospectively estimate spending in the upcoming year.

Therefore, CMS is currently using ICD-9-CM data for encounters through September 30, 2015. Hopefully, this new guidance valid for encounters as of January 1, 2016, will be considered a factor, because patients with diabetic complications are certain to increase.

If the word "with" couldn’t get any more controversial, it ventured out of the endocrine system to the very "heart" of every coder’s cardinal rule. We learned, as fledgling coders, to never assume heart disease (like heart failure) is directly related to hypertension unless the provider documents the two conditions as related, like hypertensive heart failure or heart failure due to hypertension.

Well, no more, my friends?this is the dawn of a new age of coding. We can assume away, not only for hypertension and (chronic) kidney involvement, but also for hypertension and heart involvement because they are both indented under the word "with" in the Alphabetic Index.

The revised guideline states (bolding is mine)’:

The classification presumes a causal relationship between hypertension and heart involvement and between hypertension and kidney involvement, as the two conditions are linked by the term "with" in the Alphabetic Index. These conditions should be coded as related even in the absence of provider documentation explicitly linking them, unless the documentation clearly states the conditions are unrelated.

 

Please notice that the past statement does identify that if the provider specifically states another cause, the conditions should be coded as unrelated.

The larger issue I have with assuming anything under "with" is seen in the ICD-10-CM Alphabetic Index and is yet another direct contradiction to the guidelines. If the guidance regarding "with" is truly universal within the Alphabetic Index, then it implies a relationship for diseases extending beyond just diabetes mellitus and hypertensive heart disease. For example, it seems that coders could begin to assume, based on the guidelines, that patients who have sepsis with a coexistence of organ dysfunction have severe sepsis, even though the guidelines specifically state "an acute organ dysfunction must be associated with the sepsis in order to assign the severe sepsis code."

Who knew that a little word like "with" could cause so many issues?

 

Excludes1 notes

The guidelines also include an update on reporting Excludes1 conditions. The updated guidelines state:

An exception to the Excludes1 definition is the circumstance when the two conditions are unrelated to each other. If it is not clear whether the two conditions involving an Excludes1 note are related or not, query the provider.

 

The Excludes1 conventions clarify what was addressed in the interim guidance provided in October 2015 and in the AHA Coding Clinic for ICD-10-CM/PCS, Fourth Quarter 2015, to address situations where Excludes1 notes should be considered Excludes2 or had other exceptions. Category I63 (cerebral infarction) excludes subcategory I69.3- (sequela of cerebral infarction). This guidance directly contradicted the guidelines for Chapter 9, which state: "Codes from category I69 may be assigned on a health care record with codes from I60-I67, if the patient has a current cerebrovascular disease and deficits from an old cerebrovascular disease."

For 2017, subcategory I69.3- has been revised to be included in an Excludes2 note. Exceptions have been added to the guidelines when the exclusion was for a category that may include a number of different conditions, like the "other" category. Some of those inclusive conditions should never be coded with the diagnosis the Excludes1 note appears under, others may be completely unrelated.

This opens the door for a third-party auditor to debate the application of the Excludes1 note if coding the two conditions separately creates a financial impact.

 

Edito’?s note

McCall is the director of HIM and coding for HCPro, a division of BLR, in Middleton, Massachusetts. She oversees all of the Certified Coder Boot Camp programs. McCall works with hospitals, medical practices, and other healthcare providers on a wide range of coding-related custom education sessions. For more information, see www.hcprobootcamps.com.a

 

Making a checklist to prepare for the OPPS final rule

Editor’s note: Jugna Shah, MPH, president and founder of Nimitt Consulting, writes a bimonthly column for Briefings on APCs, commenting on the latest policies and regulations and analyzing their impact on providers.

 

The 2017 OPPS final rule will not be out for a couple of weeks, but that doesn’t mean providers can’t be thinking about what their action plan will be once the rule is released.

With only 60 days between the final rule’s release and the January 1 implementation date, providers will be ahead of the curve by spending time now and thinking about the processes they may need to review, change, or implement based on what CMS finalizes and the sort of financial impact the final rule is likely to have.

While I don’t know with 100% certainty what CMS will finalize, revise, delay, or back away from, I offer providers this list of what they should look at immediately upon the rule’s release.

 

Section 603

With Congress mandating payment changes for all non-grandfathered (those not billing under OPPS prior to November 2, 2015) off-campus, provider-based departments (PBD) starting January 2017, it was no surprise that CMS discussed this issue in the proposed rule. But it was a huge surprise to read CMS’ proposals, which, if finalized, would greatly impact otherwise protected grandfathered locations under Congress’ Section 603.

For example, CMS proposed that if an off-campus PBD moves, changes ownership, or expands its services beyond what it was providing as of November 2, 2015, as defined by APC-based clinical families, then its grandfathered status would be impacted. While this may sound relatively simple, the payment and operational impact would be a nightmare.

There is another aspect of Section 603 and CMS’ proposal to use the Medicare Physician Fee ­Schedule (MPFS) as the "applicable payment system" for ­Medicare Part B services provided at non-grandfathered locations or deemed "non-excepted." Specifically, there are many services for which the MPFS has no facility component for the facility costs associated with performing the procedure because they are only provided in hospital outpatient departments or ambulatory surgery centers. For these services, the industry has to wonder what CMS was thinking, as the agency cannot possibly expect to pay nothing for services that would continue to be rendered in off-campus PBDs.

CMS’ unexpected and hastily configured proposals create such large operational and financial problems that the industry is hoping the agency will simply retreat and delays the implementation of Section 603, or at a minimum revert to paying grandfathered facilities under the OPPS for all of their services, regardless of clinical service expansion, site relocation, or ownership changes. There is precedent for CMS to postpone implementation beyond statutory deadlines. If there were ever a situation where delay is advised, this is one.

Hopefully, providers sent in a surfeit of comments regarding these and other issues and outstanding questions related to the agency’s Section 603 implementation proposals. I hope CMS will acknowledge its proposals have administrative, operational, and financial gaps that are so large, it will be impossible to move forward by January. But even if CMS does choose to put off its proposals until proper payment mechanisms are developed, Congress was clear in its language requiring changes by January 1, 2017, so something is likely going to have to occur.

CMS’ proposals, if finalized, would have drastic long-term implications for all providers, including those who believe that their grandfathered status would protect them; the sad reality is that under CMS’ proposals, there will be massive operational and financial impact, so this is the first topic in the final rule that everyone should review.

 

Packaging proposals

Providers have gotten used to CMS expanding packaging in each OPPS rule, as the agency calls packaging an essential part of a prospective payment system. With CMS’ expansion of lab packaging from date of service to claim level this year, we should not be surprised if the agency finalizes its proposal of expanding the conditional packaging logic of CPT codes assigned to status indicators Q1 and Q2 to the claim level.

Claim-level packaging of these types of ancillary services will have a huge financial impact on providers submitting multiday claims, such as those for chemotherapy and radiation therapy services, despite the fact that multiday claims for these types of services are not required.

Currently, status indicators Q1 and Q2 are packaged into other OPPS services when provided on the same date of service, even when submitted on a claim that spans more than one day. If CMS finalizes its proposal, providers that continue submitting multiday claims when monthly or series claims are not required should not be surprised when they find themselves no longer receiving separate payment for many services.

This is the time for providers to assess whether they submit multiday claims for any services beyond the required repetitive services listed in the Medicare Claims Processing Manual, Chapter 1, section 50.2.2. While it is true the manual states that is is an option to bill nonrepetitive services on multiday claims, it did not have financial implications. At least, until this year, with the claim-based packaging of labs and proposal for claim-based packaging of Q1 and Q2 services. Providers should determine why they are billing multiday claims and what it would take to change their billing processes. If they elect not to move away from multiday claims, then assessing the financial impact that will occur is an important exercise to go through prior to January 1.

The other packaging proposal providers should look for in the final rule involves the use of modifier -L1 for reporting unrelated laboratory tests when they occur on a claim with other OPPS services. CMS proposes to delete the modifier for CY 2017 as it believes that the vast majority of labs should be packaged regardless of whether they are unrelated to other OPPS payable services.

This would have a big impact on providers who provide reference laboratory or nonpatient services, which the agency requires to be reported on the same claim as other OPPS services performed on the same date. Today, the use of the -L1 modifier allows providers to identify these services as separate and unrelated to the other OPPS services so that payment is received from the Clinical Laboratory Fee Schedule.

If CMS finalizes its proposal to eliminate modifier -L1, we can hope the agency will also update its instructions for reporting reference laboratory services so they can be separately paid even when provided on the same date of service or claim as other OPPS services. If CMS does not make a change, then providers can again expect to see a large financial impact. Both of these packaging proposals should be looked at immediately in the final rule.

 

Device-intensive procedures

The final set of proposals providers will want to review relates to the changes proposed for device-intensive procedures. This is a place where we hope to see CMS finalizing changes as proposed.

For example, CMS proposes to use the implantable device cost-to-charge ratio (CCR) to calculate pass-through device payments for hospitals that file cost reports designating that cost center, as this is a more accurate CCR for determining separate pass-through payment. Currently, only about two-thirds of hospitals use the implantable device CCR, which means the remaining one-third need to examine their cost reporting process.

Providers should determine whether they are in the group that reports the implantable cost center; if a provider is not reporting, it should find out why and begin making changes. This will have an impact on facilities’ ability to generate much better pass-through payment going forward, when applicable. It will also ensure future payment rates for device-intensive procedures reflect more accurate payment of the device.

Finally, it will be interesting to see whether CMS finalizes the addition of another 25 comprehensive APCs (C-APC) encompassing 1,844 additional status indicator T services; if it does, a financial impact analysis of these services will also be important, as this will be a large increase in C-APCs for a one-year span.

I plan to discuss these and other final rule changes in my next column, as well as in HCPro’s annual OPPS final rule webcast December 1 (see www.hcmarketplace.com for details), but in the meantime I hope the above checklist will be useful to providers now and in the first weeks of the rule’s release.

 

HCPro.com – Briefings on APCs

CMS adds new comprehensive APCs in 2016 OPPS final rule

The 2016 OPPS final rule includes the first negative payment update for the system, but CMS also listened to commenters on a variety of proposals to make them less onerous either operationally or financially.
 
“CMS’ language is quite firm in parts of the rule when explaining why some proposals were finalized, but the agency also showed its willingness to listen to providers who submitted detailed comments for other proposals,” says Jugna Shah, MPH, president and founder of Nimitt Consulting, based in Washington, D.C., and Spicer, Minnesota.
 
CMS adds 10 C-APCs
CMS did not change the logic for comprehensive APCs (C-APC) or complexity adjustments in the final rule, but did add 10 new C-APCs for 2016 in addition to the 25 established for the first time for 2015. This is up from the nine CMS proposed, due to the addition of a level 5 for musculoskeletal procedures.
 
CMS finalized C-APC 8011 (comprehensive observation services) to replace the existing extended assessment and management (EAM) composite APC 8009. Payment for C-APC 8011 will be made when a claim contains a specific combination of services performed with each other (similar to the existing EAM), instead of only using a primary service CPT® code assigned to status indicator J1 like other C-APCs. CMS will use status indicator J2, newly introduced for 2016, to identify these combinations of services for the observation C-APC.
 
Providers will need to meet all of the following criteria to qualify for C-APC 8011 payment in 2016:
  • Claims do not contain a procedure with status indicator T (significant procedure subject to multiple procedure discounting)
  • Claims do contain eight or more units of services described by HCPCS code G0378 (observation services, per hour)
  • Claims contain G0378 and any one of the following codes on the same date of service or one day prior:
    • HCPCS code G0379 (direct referral of patient for hospital observation care) on the same date of service as HCPCS code G0378
    • CPT codes 99281–99284 (ED visit for the E/M of a patient [Levels 1-4])
    • CPT code 99285 (ED visit for the E/M of a patient [Level 5]) or HCPCS code G0380 (type B ED visit [Level 1])
    • HCPCS code G0381–G0384 (type B ED visit [Levels 2–5])
    • CPT code 99291 (critical care, E/M of the critically ill or critically injured patient; first 30–74 minutes)
    • HCPCS code G0463 (hospital outpatient clinic visit for assessment and management of a patient)
  • Claims do not contain a J1 service
 
CMS originally proposed to only allow high-level ED visits to help generate the observation C-APC, similar to the current EAM composite APC. But this is one of the proposals that CMS agreed with commenters on and determined the observation C-APC should be expanded to include all visit levels, says Shah.
 
The 2016 national payment rate for C-APC 8011 is $ 2,174.14, and while this payment is significantly higher than the EAM composite APC payment received today, providers should keep in mind that no other services are paid separately under the C-APC logic, says Shah, whereas today other services can, and do, generate separate payment.
 
“Any analysis that is done on separately payable observation services must be done carefully,” she says.
CMS finalized C-APC 5881 (ancillary outpatient services when patient dies) to replace composite APC 0375, which has the same description. The single, comprehensive payment would be applied for all services reported on the same date and on the same claim as an inpatient-only procedure with modifier –CA (procedure payable only in the inpatient setting when performed emergently on an outpatient who expires prior to admission).
 
As a result of new C-APCs that are not largely based on previous device-dependent APCs, CMS is expanding the list of add-on codes that are evaluated for a complexity adjustment to include all add-on codes that can be appropriately reported with a base code that describes a primary J1 service.
A list of all packaged CPT add-on codes evaluated for a complexity adjustment is included in Table 8 of the final rule.
 
The other new C-APCs are similar to those established in 2015, assigned to different levels of procedures within similar clinical families.
 
“Providers need let their payment review and denial staff know about the services related to these C-APCs,” says Valerie A. Rinkle, MPA, Medicare regulatory specialist for HCPro, a division of BLR, in Danvers, Massachusetts.
 
With previous bundling that led to certain line items no longer being paid separately, many providers had claims routed to staff as denials, she says. If the billing office is alerted to changes in payment policies, providers can mitigate such delays.

 

Editor’s note: The 2016 OPPS final rule was published in the November 13 issue of the Federal Register. This article was originally published in Briefings on APCs. Email your questions to editor Steven Andrews at [email protected].

 

HCPro.com – JustCoding News: Outpatient

Pay-per-view: Accuracy is paramount for providers when reporting CMS’ new modifiers for 2016

Providers often struggle with modifiers—even those they’ve had available to report for many years—due to the unique scenarios they face at their facilities, staffing changes, and/or unclear or lacking authoritative guidance.
 
Starting January 1, 2016, CMS requires three new modifiers for providers to report. The good news is that it’s pretty clear when they must be reported, but the bad news is that it will take some time to determine the best way for each provider to operationalize them.

 

Continue reading "Accuracy is paramount for providers when reporting CMS’ new modifiers for 2016" on HCPro’s website. Subscribers to Briefings on APCs have free access to this article in the January issue. 

HCPro.com – APCs Insider

Case Management Monthly, November 2016

Accountable care units can help streamline communication and reduce length of stay

Learning objective

At the completion of this educational activity, the learner will be able to:

  • Identify the potential advantages and challenges involved with establishing a hospitalist accountable care unit

 

Opening the lines of communication between clinicians and specialists to make care more efficient can be a sizable challenge.

At many facilities, hospitalists shuttle from floor to floor to see patients, each time trying to track down the nurse and other professionals working on each case. Information is typically transferred through an inefficient system of pages and phone calls?sometimes taking hours at a time to deliver crucial pieces of information.

Enter the accountable care unit?a new way of configuring care systems that can help to uncoil tangled communication wires between clinicians and support staff to provide care that is more efficient and streamlined.

In this model, hospitalists work with patients in a specified geographical area of the hospital in conjunction with interdisciplinary teams.

Having patients in one area helps make care more efficient, and as one hospital system in New Mexico learned, can also reduce length of stay and increase cost-efficiency.

 

A push toward regionalization

Regionalization of hospitalist patients is becoming more common today, because of the benefits it’s been shown to bring, says Stefani Daniels, RN, MSNA, ACM, CMAC, founder and managing partner of Phoenix Medical Management in Pompano Beach, Florida. Those benefits include:

  • Improved teamwork, care coordination, and communication
  • Fewer readmissions
  • Improved resource management to lower cost of care
  • Improvements in patient satisfaction
  • Reduction in inefficiencies

"I’m pushing accountable care units at all my hospital clients," says Daniels. But while the will is there in many cases to make the change, it’s not always an easy conversion.

Sometimes these initiatives face pushback from physicians concerned about personnel or scheduling issues.

Other challenges include:

  • The lack of diagnostic diversity that results from having set teams on a unit
  • The challenge of deciding whether teams should be flexible or static
  • Hammering out logistical issues, such as how patients should be triaged and how beds are managed

 

Despite the challenges these initiatives can face, Presbyterian Medical Group in Albuquerque, New Mexico successfully implemented a unit-based model with multidisciplinary rounds about six years ago, says David J. Yu, MD, MBA, FACP, SFHM, medical director of adult inpatient medicine service for Presbyterian Healthcare Services.

The initiative was prompted by a desire to improve inefficiencies and streamline care. "We basically needed to improve patient flow and communication," says Yu. "But we also realized it was a very large process because it involved almost every department, including case managers, physical therapy, nursing, and ancillary services."

To overcome that daunting multi-departmental challenge, officials enlisted the hospital’s Lean Six Sigma group to help coordinate the project.

Presbyterian sought to trade its outmoded care model for something more efficient; one that would improve communication and eliminate delays related to breakdowns in this area.

The changes began as a unit-based project with multidisciplinary whiteboard rounds, a daily meeting that included the hospitalist, nursing staff, care coordination, physical therapy, and other specialists. They discuss the treatment plan and the goals related to the patient care both for that day and the hospitalization for each patient, he says.

The success of that pilot program led officials to implement the same unit-based model in eight of the medical floors at the hospital.

The payoff for the organization has not only been a huge boost in the efficiency of communication, but reduced length of stay for patients. "We’ve seen significant improvements in the average length of stay. This is not because we’ve reduced therapeutic time, but because we’ve reduced inefficiencies," says Yu. Lag time created by communication gaps has been tightened up, allowing patients to move through the system more quickly and efficiently.

To ensure that these new efficiencies weren’t resulting in quality reductions, Yu says the organization also tracked readmissions, which remained steady, confirming that faster discharges weren’t compromising patient care.

 

Overcoming obstacles

Presbyterian has managed to overcome many hurdles that can make this model a challenge. Although these changes have been successful, they have not necessarily been quick.

"I think in many cases people are just interested in a quick fix," says Yu. This process has been anything but. More than half a decade in, Yu says the program is still a work in progress and the team is continually looking to make improvements.

The initiative took time because it addressed the underlying structure of the organization and didn’t just make surface changes that can’t be sustained.

"I like to use the analogy of painting a wall. The painting is the easiest part. What takes time is all the prep work getting the surface ready," he says.

Most organizations just want the paint on the wall?they aren’t willing to address work needed to fix the underlying structure. "This really is a foundational project that takes months and years to develop and mature," he says.

This project not only solved many communication problems at the organization, but it also helped to ready the facility for the new era in healthcare ahead?one where revenue is driven by quality, not volume.

Organizations that want to thrive in this new model will need to rethink antiquated processes and systems going forward, he says. Those that don’t may not survive in this model.

 

Steps to success

For an initiative like this one to be successful, it has to be well designed and have support?both in commitment and in terms of dollars?from upper management.

"A lack of resources is another reason why a lot of these projects fail," says Yu. "The hospital doesn’t want to fund it. If only one department is very excited about the project, it won’t work."

The model involves a major change that requires support from multiple disciplines. "Without the support of leadership it’s not going to succeed," he says.

You also have to give hospital staff members a reason to support it, which may be the biggest challenge.

"It has to successfully answer the question, ‘What’s in it for me?’ " says Yu.

If the changes are onerous and provide little benefit to the people they affect, there’s little incentive for anyone to support it.

"Understand your worker and your project," he says. And overcoming barriers may involve system and even contract changes, he says.

If you can get that support, you can make changes that will improve communication and consequently care at your organization?and help ready it for the changing healthcare landscape of the future.

 

Commonwealth Fund study shows insurance gaps remain

Learning objective

At the completion of this educational activity, the learner will be able to:

  • Identify potential risk factors and interventions for patients who still don’t have health insurance under the Affordable Care Act

 

While some 26 million Americans have gained insurance since the Affordable Care Act (ACA) became effective in 2010, another 24 million U.S. adults are still living without coverage, according to a new report by the Commonwealth Fund, a private, nonprofit organization that supports health policy research and reform.

This is a concern because not only are uninsured adults likely to skip needed health services due to the cost, but a lack of insurance is also a risk factor for preventable hospitalizations and health declines due to chronic diseases, according to the Henry J. Kaiser Family Foundation (http://ow.ly/Bs3a304bJR7).

So who are these uninsured Americans? According to The Commonwealth Fund survey (http://ow.ly/I8uZ304cB2b), 88% are Latinos under the age of 35 who earn less than $ 16,243 and/or work for a small business. "Half (51%) of the remaining uninsured live in one of the 20 states that had not yet expanded Medicaid at the time of the survey," states a press release issued by the Commonwealth Fund (http://ow.ly/gqsB304bJZk).

Case managers should take note of the survey findings.

"The Commonwealth Fund analysis is beneficial to all case managers, because the uninsured population compromises our most at high-risk groups of patients," says June Stark, RN, BSN, Med, director of care coordination at St. Elizabeth’s Medical Center in Boston. "Most hospitals today seem to be the primary source of healthcare provision to the patients in their communities. Expanding the case manager’s understanding of this population can contribute to the development of successful strategies for managing this group."

 

About the study

The study, called The Commonwealth Fund Affordable Care Act Tracking Survey, consisted of 15-minute telephone interviews. Interviewers conducted the interviews in two languages, either English or Spanish, between February and April 2016. The data was collected by calling a random, nationally representative sample of nearly 5,000 adults ages 19?64.

Since the ACA went into effect, the uninsured population shifted from mostly white adults to Latinos, according to the Commonwealth Fund press release. Results also show that renewed efforts to help uninsured individuals gain coverage might also be in order.

"The ACA held promise for many, especially those with incomes that could bear new market sticker prices, and as can be seen from the study, diverse populations benefitted from targeted reform marketing efforts," says Shawna Grossman Kates, MSW, MBA, LSW, CMA, the director of case management and bed management for RWJBarnabas Health in Toms River, New Jersey. "Yet it is very apparent that while there has been success with some at-risk populations, those with the lowest incomes who do not qualify for Medicaid are still struggling."

This study, she says, shows it may be time for a revival of the initial efforts to enroll Americans in health plans, which have become less prominent over time. There may also be a role for case managers and social workers to help guide uninsured patients they encounter in the hospital to seek coverage.

"The case manager has an active role in helping patients acquire insurance coverage," says Stark. "A mainstay of the traditional case manager role is, during the admission assessment, to determine if the patient has insurance and if so, to validate if it is correct and active. This is accomplished by interviewing the patient, viewing their insurance card, and checking further with the help of the hospital’s financial counselors."

If a patient is uninsured, case managers should refer him or her to financial counselors to determine the patient’s eligibility and to help him or her secure insurance during the hospital stay, she adds.

"The case manager’s efforts to secure insurance is essential, as the specific insurance benefits drive what discharge options are available for the patient, and therefore, helps secure a safe discharge plan," says Stark.

Social workers, too, play a role.

"It is often the social work partner in a case management relationship who provides the under-insured and uninsured the counseling, available tools and resources, and sometimes the hands-on, step-by-step training to explore with patients and families their income/assets/spending and eligibility for entitlement programs or market products," says Kates. "It is a continuous conversation that has been rooted in a long history of patient intervention by social work. Possessing expert knowledge in federal and state eligibility requirements, financial/social access limits, and having strong relationships with county and state providers, the social worker will connect services with patients."

In their role as patient advocates, case managers and social workers can help to break down cultural and social barriers, such as language and access based on geography, she adds.

 

Action points from the Commonwealth Fund

The Commonwealth Fund study authors agree with Kates that enhancing efforts to reach the uninsured and help them enroll in health plans should be a goal based on these findings. Only 62% of people without insurance said they knew about insurance marketplaces.

They also recommend a number of other steps that they say could help more of these uninsured individuals gain coverage. Their recommendations are as follows:

  • Expand state eligibility for Medicare coverage, a move that Commonwealth Fund authors say would "immediately extend health insurance to millions of uninsured people." Twenty states had not yet expanded Medicaid coverage at the time of the survey. If they had, one-third of all adults without insurance would qualify for Medicaid coverage. "This especially affects uninsured young adults, of whom 38% or an estimated 4 million, have incomes that would qualify them for Medicaid but live in non-expansion states," states the press release.
  • Enhance subsidies and lower cost-sharing in marketplace plans to help more people afford insurance. Many people without insurance believe they can’t afford it?even if they might qualify for financial help under the ACA. Some 85% of those without insurance who did shop for a plan said they couldn’t find an affordable option. "A large majority of this group, who were also uninsured, had incomes qualifying them for subsidies or Medicaid, though some may not have been eligible due to their immigration status," states the press release.
  • Promote immigration reform. Changing immigration rules would help more people gain insurance coverage. "A loosening of the law’s restrictions on eligibility for undocumented immigrants would also help," states the Commonwealth Fund press release. While the survey data didn’t definitely prove that this is the case, study authors suspect that many Latinos lack insurance coverage because they may be undocumented and not eligible for coverage under the ACA. Other risk factors that may also be at play: Latinos make up nearly half of adults who are earning less than 138% of the poverty level?$ 16,243 for one person or $ 33,465 for a family of four.

 

Ultimately, using a combination of local and federal interventions can help the U.S. move closer to its goal of helping get coverage for all its citizens.

 

Is the 2-midnight rule going away and when will short-stay audits resume?

Learning objective

At the completion of this educational activity, the learner will be able to:

  • Identify updates to CMS’ 2-midnight rule and best practices for compliance.

 

Every couple months, it seems questions arise about the 2-midnight rule and there are rumors that it may be going away. Below are some questions with answers from our expert Ronald Hirsch, MD, FACP, CHCQM, vice president of the Regulations and Education Group at Accretive Health in Chicago, to clarify where things stand today with regard to the 2-midnight rule.

 

Q: I heard the 2-midnight rule is now gone based on changes to Medicare payment rates under the 2017 inpatient prospective payment system (IPPS) final rule. Is this true, and if not, what changed?

 

A: No, this is not the case. The 2-midnight rule is still alive and kicking. What the FY 2017 IPPS final rule did is finalize two adjustments in addition to updating the annual rate for inpatient hospital payments.

"First, CMS is finalizing the last year of recoupment adjustments required by the American Taxpayer Relief Act of 2012 (ATRA). Section 631 of ATRA requires CMS to recover $ 11 billion by FY 2017 to fully recoup documentation and coding overpayments related to the transition to the MS-DRGs that began in FY 2008," states the CMS Fact Sheet. "For FYs 2014, 2015, and 2016, CMS implemented a series of cumulative -0.8 percent adjustments. For FY 2017, CMS calculates that $ 5.05 billion of the $ 11 billion requirement remains to be addressed. Therefore, CMS is finalizing a -1.5 percent adjustment to complete the statutorily specified recoupment."

And the second part of the change, which seems to be causing the confusion, is CMS took action on a -0.2 percent adjustment it implemented in the FY 2014 IPPS final rule.

This adjustment was initially made to account for an estimated increase in Medicare spending due to the 2-midnight policy. "Specifically, in the FY 2014 IPPS final rule, CMS estimated that this policy would increase expenditures and accordingly made an adjustment of -0.2% to the payment rates," states the fact sheet.

While CMS thought this adjustment was reasonable at the time, a recent review led CMS to permanently remove this adjustment, "and its effects for FYs 2014, 2015, and 2016 by adjusting the 2017 payment rates. This will increase FY 2017 payments by approximately 0.8%," stated CMS.

Hirsch says this move is "purely about money." "They are leaving the 2-midnight rule itself completely intact," he says.

The bottom line: Pay attention to 2-midnight compliance and ensure your organization has good systems in place to support it.

 

Q: When are Beneficiary and Family Centered Care Quality Improvement Organizations (BFCC-QIO) short-stay reviews going to resume?

 

A: Back in May, CMS put a hold on short-stay inpatient audits related to the 2-midnight rule. That hold was lifted effective September 12, 2016, according to a FAQ published by CMS (http://ow.ly/DQxW304bCa6).

According to the FAQ, CMS decided to lift this temporary suspension for five reasons, which are as follows:

  1. BFCC-QIOs were successfully retrained on 2-midnight rule
  2. BFCC-QIOs finished a re-review of claims that were formally denied
  3. CMS "examined and validated the BFCC-QIOs peer review activities related to short-stay reviews"
  4. BFCC-QIOs reached out to providers on claims that were affected by the temporary suspension
  5. BFCC-QIOs started provider outreach and education on the 2-midnight rule

It appears that based on the five points, the temporary audit suspension accomplished its goal of helping BFCC-QIOs sort out the challenges they faced during the initial round of audits.

Prior to the suspension, hospitals complained about inconsistencies in the review process, which triggered the suspension. The BFCC-QIO audits began in October 2015, and hospitals reported a number of surprises including:

  • Auditors requested records as far back as May 2015 when many believed the audits would only look at records from 2015 forward
  • BFCC-QIOs missed deadlines, and provided audit results late
  • Failure by BFCC-QIOs to schedule timely education for providers

 

These problems made it difficult for hospitals to hit filing deadlines, and they were consequently reporting problems because they missed the window to appeal denied claims. Hospitals also didn’t have a chance to get education to understand what they were doing wrong to fix the problem.

There were also rumored problems related to benchmark admissions. Hospitals reported that BFCC-QIOs were routinely and in some cases inappropriately denying inpatient admissions when the patient spent one night as an outpatient in the emergency department or in observation services before he or she was admitted?even when the patient spent a second night in the hospital as an inpatient.

To prevent future problems, CMS said in its FAQ that it will continue to provide oversight for BFCC-QIO efforts by:

  • Reviewing a sample of completed claim reviews each month
  • Monitoring provider education calls
  • Responding to individual provider inquiries and concern. Providers may send questions to the CMS Open Door Forum Mailbox at [email protected].

 

CMS also said that BFCC-QIOs will continue tofollow the guidance called, "Reviewing Short-Stay Hospital Claims for Patient Status." To see a copy ofthe guidance, go to www.cms.gov/research-statistics- data-and-systems/monitoring-programs/medicare-ffs- compliance-programs/medical-review/inpatienthospitalreviews.html.   

The BFCC-QIOs will also be charged with providing provider education going forward. "The BFCC-QIOs were directed to use comprehensive outreach and communication approaches (i.e., website, newsletter, one-on-one training, and town hall type events) to continue to educate providers on when payment under Medicare Part A is appropriate under the 2-midnight policy," states the FAQ. "BFCC-QIOs are required to educate providers using quality improvement core principles that facilitate continuous learning and promote greater provider understanding of the appropriate application of the 2-midnight policy in accordance with the revisions in the CY 2016 OPPS Final Rule (CMS-1633-FC): www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Hospital-Outpatient-Regulations-and-Notices-Items/CMS-1633-FC.html."

Now that audits have resumed, organizations should maintain a focus on 2-midnight compliance. Below are some tips Hirsch has recommended in the past, including:

  • Reviewing every short-stay admission?those between zero and one day?prior to billing.
  • Ensuring that every patient’s status is appropriate up front. Reviewing the chart of every patient that goes upstairs.
  • Using the physician advisor to check compliance on cases that are murky to ensure that they meet one of the exceptions under the 2-midnight rule. Changing cases that don’t meet an exception using condition code 44. If the problem isn’t discovered until after discharge, self-deny and rebill the claim.
  • Ensuring that the case managers and the physicians are up to date about any potential changes to the 2-midnight rule and how to comply.

 

HCPro.com – Case Management Monthly

Credentialing & Peer Review Legal Insider, August 2016

New PSO guidance raises questions over patient safety work product privilege

In May, the U.S. Department of Health and Human Services (HHS) published Guidance Regarding Patient Safety Work Product and Providers’ External Obligations in the hopes of clarifying what documents are considered patient safety work product (PSWP) and thus protected from discovery during litigation. Because the guidance has far-reaching implications for the scope of the privilege and confidentiality protection, providers should consider reexamining their process for collecting information in the pursuit of improving patient safety.

Under the Patient Safety and Quality Improvement Act (PSQIA), providers collect and manage information through a patient safety evaluation system (PSES), which is then sent to a patient safety organization (PSO) for analysis and feedback. To motivate providers to participate in PSOs, PSQIA entitles the submitted information broad privilege and confidentiality protections.

According to Michael R. Callahan, Esq., partner at Katten Muchin Rosenman, LLP, in Chicago, the guidance may impact how discoverability disputes are handled in courts. To understand why, consider the three primary buckets of patient safety information:

  • Bucket one: All mandated reports. For example, some states like New York and Florida require mandated adverse reporting if a wrong site surgery is performed. For these incidents, hospitals are required to prepare and submit a report to the state. Reports that fall within this bucket shouldn’t be treated as PSWP.
  • Bucket two: All reports that hospitals are required to collect and maintain pursuant to state and federal law, such as the Medicare Conditions of Participation (CoP).
  • Bucket three: All other information collected and maintained in a hospital’s PSES to improve quality, safety, and patient outcomes. This information is PSWP.

Disputes will arise from reports that fall into bucket two, Callahan says. HHS’s guidance stated that this type of information isn’t PSWP, but not all state and federal laws have crystal clear language defining what information hospitals need to collect and maintain.

"You will seldom find in the state and federal laws a specific list of documents which identifies the kinds of records and reports a provider is required to maintain and collect and to make available for inspection by a governmental authority. It is not that clear cut and hospitals use different terminology," he says.

For example, Callahan points out that in the case Tibbs v. Bunnell, discussed later in this article, the dispute was over the question of whether an incident report collected and reported to a PSO by a defendant hospital was a bucket two document. "The language under Kentucky law obligated the hospital to maintain and collect ‘incident investigation reports’ but does this refer to the incident report, a resulting root cause analysis report or a peer review investigation report? Is it all or none of the above?"

 

The PSO guidance

The guidance, which was published in the Federal Register in May, clarifies what information can and cannot be called PSWP. Information can be PSWP if:

  • A provider prepares it for reporting to a PSO and follows through in the reporting
  • A PSO develops it for the conduct of patient safety activities
  • A provider places it in a PSES to be reported to a PSO

 

Information that can’t be PSWP includes:

  • Patient medical records, billing and discharge information, or any other original patient or provider information
  • Materials collected and maintained separately from a PSES
  • Records mandated by federal and state law
  • Information prepared to satisfy external obligations

 

One criticism of the guidance is its expansion of the concept of original patient and provider records, Callahan says. PSQIA states these records, such as medical records and billing information, can never be privileged. The guidance further clarified the scope of what these records include:

  • Original records required of a provider to meet any federal, state, or local public health or health oversight requirements regardless of whether they are maintained inside or outside of the PSES
  • Copies of records that reside within a provider’s PSES that were prepared to satisfy a federal, state, or local public health or health oversight record maintenance requirement if the records are maintained only within the PSES and any original records are either not maintained outside of the PSES or were lost or destroyed

Callahan takes issue with HHS’ expansion of the definition of an original patient and provider record to include bucket one and bucket two documents, especially since it was put forth in guidance and not a final rule.

Requirements under the Administrative Procedure Act require a notice and comment period before a final rule is adopted. However, HHS chose to issue the guidance without following this procedure and therefore it should only be viewed as an interpretative rule, Callahan says. The U.S. Supreme Court decision earlier this year in the case of Perez v. Mortgage Bankers Association found that interpretive rules "do not have the force and effect of law."

"The guidance is simply an interpretation provided by HHS. While it certainly expresses the position of HHS, the Office of Civil Rights and the Agency for Healthcare Research and Quality (AHRQ) from a regulatory enforcement standpoint, it is not binding on state or federal courts," he says.

As a result, different interpretations of PSQIA will likely lead to continued challenges to court orders to turn over documents hospitals believe to be PSWP. Some of these discoverability disputes have made their way to state supreme courts.

 

Southern Baptist Hospital of Florida v. Charles

In a case that will go before the Florida Supreme Court later this year, Southern Baptist Hospital of Florida v. Charles, the PSO guidance may play a role in determining whether occurrence reports?reports that hospital collects and maintains for events that are inconsistent with its routine operations or care of patients, or that could result in an injury?are PSWP.

The plaintiff sued Southern Baptist Hospital of Florida, claiming his sister suffered a catastrophic neurological injury due to negligence. During discovery, the plaintiff requested documents related to adverse medical incidents and the conduct of physicians who worked at the hospital. This request was made pursuant to Amendment 7 of the Florida Constitution, which provides patients with the right to access "any records made or received in the course of business by a healthcare facility or provider relating to any adverse medical incident."

Although the hospital produced some of the requested documents, it declined to turn over occurrence reports that were collected within its PSES and reported to its PSO, claiming they were PSWP and therefore privileged and confidential under PSQIA.

The plaintiff argued that PSQIA only protects documents generated exclusively for submission to a PSO, so anything collected to also satisfy a state law is not PSWP. The circuit court agreed, finding that information collected for dual purposes was not PSWP and ordered the hospital to produce the documents.

This order was later reversed by an appellate court, which said the documents were PSWP because they were collected in the hospital’s PSES and reported to a PSO. Further, documents can simultaneously be PSWP and meet a state reporting requirement. The plaintiff appealed to the state supreme court, which will hear the case in October.

Since the documents in question fall into bucket two, the plaintiff will likely cite the guidance to support a position that the reports can’t be treated as PSWP and therefore are discoverable, says Callahan. However, the argument can be made that the guidance is not legally binding on the courts.

 

Tibbs v. Bunnell

The release of the PSO guidance likely contributed to the U.S. Supreme Court’s denial to hear Tibbs v. Bunnell. The case would have provided a nationwide interpretation of the scope of privilege and confidentiality protections under PSQIA for reports submitted to PSO, as well as whether PSQIA preempted state laws.

In Tibbs, a patient’s estate brought a wrongful death and medical malpractice suit against three surgeons employed by University of Kentucky Hospital. The plaintiffs sought to discover a post-incident event report generated by a surgical nurse through the hospital’s PSES and subsequently sent to its PSO.

At trial, the hospital argued that the report was protected under PSQIA and therefore not subject to discovery. However, the trial court ruled that the report was not protected under PSQIA. The hospital appealed.

Although the appellate court found that the privilege provided by the PSQIA did preempt the Kentucky state law, it stipulated that protections afforded by PSQIA only apply to documents that contain "self-examining analysis," meaning those in which the provider analyzes his or her own actions. The court then sent the matter back to the trial court for evaluation of whether the report contained self-examining analysis.

The hospital appealed to the Kentucky Supreme Court, arguing that the appellate court erroneously limited the scope of privilege protections under PSQIA. The Supreme Court reversed the Court of Appeals’ interpretation of PSQIA, finding it too narrow. However, it also ruled that the incident report was not protected under PSQIA because its creation, maintenance, and utilization was required in the regular course of the hospital’s business, as well as under Kentucky state law. Therefore it cannot be collected within the hospital’s PSES and treated as PSWP.

In response, the hospital filed a petition for the U.S. Supreme Court to review the Kentucky Supreme Court’s decision. The petition had the support of more than 50 PSOs, hospitals, and health systems from across the country, as well as the American Hospital Association, AMA, and The Joint Commission. Last October, the court asked the U.S. solicitor general to file a brief on his views of the case and whether the petition should be granted or denied.

Just as the guidance was published, the solicitor general filed his brief to the court. The brief recommended that the court deny the petition in light of the guidance issued by HHS and because hearing the case would be premature until it is seen how the lower courts interpret and apply the guidance.

In June, the U.S. Supreme Court denied the petition without comment and without remanding the case back to the Kentucky Supreme Court to take the guidance into consideration. This leaves the Kentucky Supreme Court’s ruling in place, although the decision is only binding on Kentucky courts.

 

Carron v. Rosenthal

Regardless of the U.S. Supreme Court’s denial to hear Tibbs, discovery disputes are still playing out in other courts. The Rhode Island Supreme Court will be hearing an appeal of an order for a hospital to produce incident reports in Carron v. Rosenthal. In this case, the plaintiff is suing her obstetrician and Newport Hospital for medical malpractice after her newborn baby suffered irreversible brain damage following a failed labor induction and died days later.

Two nurses prepared incident reports known as Medical Event Reporting System (MERS) reports, which were submitted to the hospital’s PSO. The hospital also produced separate state-mandated adverse event reports.

Later during discovery, the nurses were deposed but had difficulty remembering what had happened, so the plaintiffs asked that the hospital produce the MERS reports. The hospital objected, citing PSQIA and the Rhode Island Patient Safety Act.

According to Callahan, much of the plaintiff’s argument was based on the Kentucky Supreme Court’s decision in Tibbs that reports required by state statutes can’t be treated as PSWP. However, Newport Hospital argued that in Tibbs, the University of Kentucky Hospital collected state mandated reports in its PSES. At Newport Hospital, state mandated reports are collected separately. The MERS reports were separate reports distinguishable from the mandated reports and therefore were PSWP, according to the hospital.

Despite this argument, the trial court ruled in favor of the plaintiff and order the hospital to show the MERS reports to the nurses?but not the plaintiff?to refresh their memories before they were to be deposed again. The hospital appealed and, because Rhode Island does not have an appellate court, the state supreme court exercised its discretion to hear the hospital’s appeal. A decision is expected later this year.

 

What can providers do?

With the U.S. Supreme Court declining to hear Tibbs, and ongoing confusion in regards to the guidance, providers that participate in a PSO have a few options for how to proceed.

Providers can choose not to do anything and simply maintain the status quo as they wait for further regulatory or judicial developments, says Callahan. "We have these other cases before state supreme courts and it’s conceivable one of those will be appealed. It doesn’t mean the U.S. Supreme Court is going to accept one of these other ones, but that’s a development that providers may want to wait on."

PSOs will also likely have questions about the guidance and will reach out to AHRQ for additional guidance, so providers will want to wait to see if there is any further clarification, he says.

Providers that choose to comply with the guidance will need to determine if any information they were previously collecting in their PSES for reporting to their PSO is no longer considered PSWP. These providers will need to review state and federal laws, including the Quality Assurance and Performance Improvement standards set forth in the Medicare CoP, to ensure the information doesn’t fall into buckets one or two, Callahan says. Anything that’s determined to fall into those two buckets will require modifications to the provider’s PSES policy.

Since the guidance is an interpretive rule, some providers may choose to fight requests to turn over disputed documents, Callahan says. Providers would choose this path if they believed a court would be more likely to side with their interpretation of PSQIA.

More drastically, providers could simply decide to abandon their PSOs altogether. However, there are several factors to consider before making that move, says Callahan.

The Affordable Care Act requires hospitals with more than 50 beds that want to provide healthcare services to patients enrolled in a state insurance exchange to be enrolled in a PSO. This was modified to allow hospitals to meet the requirement by contracting with a hospital engagement network (HEN) or quality improvement organization (QIO).

However, contracting with a HEN or QIO doesn’t offer providers the same privilege protection received from participating in a PSO. Those providers would still have their state law protections, but those vary and some states may not have any protections at all or limited protections, Callahan says.

Providers considering leaving their PSO will need to evaluate their state protections, including the scope of protected activities and entities.

"Using Illinois as an example, [state law protections] only generally apply to hospitals, surgery centers, and managed-care entities. The statutes do not apply to physicians, physician groups, labs, pharmacies, home health, or other licensed providers. So if you have formed a clinically integrated network with all these different provider boxes, only the hospital?for all practical purposes?will be protected," Callahan says.

Providers should also check to see if it’s possible under state law to inadvertently waive the privilege if protected information is not handled correctly (e.g., information is disclosed improperly). Under PSQIA, the protections afforded to PSWP can never be waived.

Callahan also notes it’s important for providers to know that state privilege protections only apply in state courts or state claims. So, for example, if a physician is terminated but falls under a protected class (race, age, sex, religion, etc.), he or she can file a federal claim. The physician can then request access to protected peer review documents. Although the hospital may try to argue that they are privileged and confidential under the state peer review statute, state privilege statutes cannot be asserted to preempt federal claims. However, if the documents were collected in a PSES and reported to a PSO, they would not be undiscoverable.

"The PSQIA has many advantages to offer. Part of the problem, however, is that there are not many appellate court interpretations of the law and most of those decision have only involved medical malpractice cases" Callahan says. "Unfortunately, because the U.S. Supreme Court denied the petition in Tibbs, these disputes will have to be decided on a state-by-state basis. This is great for the attorneys but not helpful for PSOs and participating providers."

 

Case summary

Texas Supreme Court grants writ of mandamus for peer review committee records

The Supreme Court of Texas (the "Court") recently held that a trial court failed to adequately review allegedly privileged documents?to determine if they were disclosable pursuant to an exception to the state’s peer review statute?before issuing an order compelling Christus Santa Rosa Health System to produce them. As a result, the Court granted a petition for writ of mandamus filed by Christus, ordering the lower court to inspect the documents in question.

The documents concerned a peer review committee convened to review an unsuccessful surgery performed by Gerald Marcus Franklin, MD, in March 2012 to remove the left lobe of a patient’s thyroid gland. Franklin instead removed thymus gland tissue, requiring the patient to undergo a second surgery.

According to Franklin’s deposition, several weeks after the failed surgery he met with a three-member medical peer review committee to provide a verbal report. He said that complications arose due to an abundance of scar tissue, which made it difficult to distinguish between thymus and thyroid tissue. The unavailability of a cryostat machine, a critical piece of equipment that Franklin would have used during the surgery to diagnose the removed tissue, led him to end the surgery. During the meeting, the committee concluded that Franklin’s actions were reasonable and the committee chose not to take action.

As a result of the failed surgery, the patient filed a malpractice lawsuit against Franklin and his medical group in March 2013. Franklin subsequently filed a motion to designate Christus as a responsible third party, alleging that the unavailability of the cryostat machine was responsible for the surgery’s failure. The patient went on to add Christus as a defendant in the suit.

In March 2014, Franklin served Christus with a request to produce documents from its medical peer review file. Christus objected, arguing that the documents were protected from discovery under the medical peer review committee privilege provided by the Texas Occupations Code section 160.007(a), which states, "[E]ach proceeding or record of a medical peer review committee is confidential, and any communication made to a medical peer review committee is privileged."

Following an in camera review, the trial court ordered Christus to produce the documents under a protective order that mandated that they be disclosed only to Franklin and his attorneys.

Christus filed a motion to reconsider, which the trial court denied. Christus then filed a petition for writ of mandamus in the court of appeals, which was also denied, leading to it filing the petition with the state supreme court.

At issue was the interpretation and scope of an exception provided by Texas Occupation Code section 160.007(d), which states, "If a medical peer review committee takes action that could result in censure, suspension, restriction, limitation, revocation, or denial of membership or privileges in a healthcare entity, the affected physician shall be provided a written copy of the recommendation of the medical peer review committee and a copy of the final decision, including a statement of the basis for the decision."

Franklin argued that the documents were subject to disclosure under the exception because, even though the committee opted not to take any action, the medical peer review committee had the opportunity to recommend discipline.

The Court disagreed with Franklin’s interpretation of the privilege: "Looking to the intent of the Legislature, as we must, we conclude that the Legislature intended a medical peer review committee do more than simply convene for review for the exception to apply."

The Court found that applying this interpretation would require disclosure of a medical peer review committee’s documents every time it conducted a review, regardless of its outcome.

"Under this interpretation, it is difficult to conceive of an instance where the physician would not be entitled to the documents and the documents would remain privileged. This would in turn enfeeble confidentiality and prevent physicians from engaging in candid and uninhibited communications, which is essential for improving the standard of medical care in the state," the Court wrote.

The Court also found that the trial court did not review the documents in camera sufficiently to determine if the medical peer review committee took any actions that could result in one of the disciplinary actions listed in the exception to the medical peer review committee privilege, such as censure, suspension, or denial of privileges.

The trial court judge had stated he went through the documents page by page only to ensure that patient’s health information and social security numbers were not disclosed and didn’t look at the documents "closely enough" to determine whether the committee had taken any actions. Christus had argued that an in camera inspection of the documents would clarify if the exception applied.

The Court concluded that the trial court abused its discretion when it ordered Christus to produce the medical peer review committee documents; and ordered the trial court to vacate its order compelling production of the documents and to review the documents further to see if the exception applies.

Source: In re Christus Santa Rosa Health Sys., No. 14-1077 (Tex. May 27, 2016).

 

What does this mean for you?

J. Michael Eisner, Esq., of Eisner & Lugli in New Haven, Connecticut: The Court’s decision stands for the fundamental proposition that a court must comply with the plain meaning of the statutes that it is interpreting. While this may seem to be a "no brainer," too many courts ignore the plain meaning of statutes and act as if they were legislative bodies. Here, the statute required that disclosure only be made if the peer review committee recommended certain actions. According to the Texas Supreme Court, in spite of the clear wording in the statute, the trial court ordered disclosure without making the requisite determination(s). The Supreme Court sent the matter back to the trial court, ordering it to follow the statute.

 

Legal and regulatory news roundup

Find out what’s happening in the world of federal healthcare regulations by reviewing some recent headlines from across the country.

 

Senate Finance Committee aims to reform Stark Law

The Senate Finance Committee hopes to introduce legislation to reform the federal physician self-referral law, commonly referred to as the Stark Law. During a recent hearing, Chairman Orrin Hatch (R-Utah) said the committee would take some action by the end of 2016 but did not elaborate on what that might be.

In June, Hatch released a white paper discussing potential reforms to the Stark Law. Several commenters suggested repealing the law in its entirety. Others suggested changes to the law that would allow providers to implement new payment models.

In a statement released with the white paper, Hatch said the Stark Law is "a real burden for hospitals and doctors trying to find new ways to provide high quality care while reducing costs as they work to implement recent healthcare reforms."

 

Hundreds charged with healthcare fraud in nationwide sweep

More than 300 physicians, nurses, and other medical professionals across the country allegedly involved in healthcare fraud schemes face criminal and civil charges following what the U.S. Department of Justice called the largest coordinated takedown in history. The Medicare Fraud Strike Force in 36 federal districts led the sweep, which also involved 23 state Medicaid Fraud Control Units and 26 U.S. Attorney’s Offices.

The individuals charged are suspected of collectively submitting approximately $ 900 million in fraudulent billing to Medicare and Medicaid. They face multiple healthcare fraud-related charges, including conspiracy to commit healthcare fraud, aggravated identity theft, money laundering, and violations of the anti-kickback laws for schemes in which they submitted claims for medically unnecessary treatments. Often the treatments were never provided. In some cases kickbacks were paid to Medicare beneficiaries, patient recruiters, and other co-conspirators in return for providing beneficiary information to providers to use in submitting fraudulent billing.

Some of the highlights of the sweep include:

  • One-hundred defendants from southern Florida were charged for their alleged involvement in schemes that resulted in $ 220 million in fraudulent billings for home healthcare, mental health services, and pharmacy fraud.
  • Eleven defendants in southern Texas were allegedly responsible for $ 47 million fraudulent billing, including one physician who allowed unlicensed individuals to perform services and then billed Medicare as if he had performed them.
  • Twenty-two defendants in central California allegedly defrauded Medicare of $ 162 million. One physician is believed to be responsible for nearly $ 12 million through fraudulently billing for medically necessary vein ablation procedures.

 

In an announcement of the arrests, Attorney General Loretta E. Lynch said, "The wrongdoers that we pursue in these operations seek to use public funds for private enrichment. They target real people?many of them in need of significant medical care. They promise effective cures and therapies, but they provide none. Above all, they abuse basic bonds of trust?between doctor and patient; between pharmacist and doctor; between taxpayer and government?and pervert them to their own ends."

 

Cardiologist agrees to pay $ 2 million to settle kickback, false billing lawsuit

Asad Qamar, MD, of the Institute of Cardiovascular Excellence (ICE) of Ocala, Florida, has agreed to pay $ 2 million to resolve a lawsuit alleging he paid kickbacks to patients and improperly billed Medicare, Medicaid, and TRICARE?a healthcare program of the U.S. Department of Defense Military Health System. Qamar will also release any claim to $ 5.3 million in suspended Medicare funds and agreed to a three-year exclusion from participating in any federal healthcare program. This will be followed by a three-year integrity agreement with the Department of Health and Human Services Office of the Inspector General.

According to the U.S. Department of Justice, the lawsuit against Qamar claimed that he and ICE billed for peripheral artery interventional services and other related procedures, many of which were medically unnecessary according to the patients’ medical histories or records, or by the severity of their symptoms.

The lawsuit also alleged that Qamar and ICE persuaded patients to agree to the unnecessary procedures by routinely and indiscriminately waiving the 20% Medicare copayment. The copayment is typically used to help patients be smarter healthcare consumers and deter them from unnecessary procedures.

According to The Wall Street Journal, following a legal effort by the paper, CMS made public Medicare payment data which showed that Qamar had collected more than $ 18 million from Medicare in 2012. That ranked him second highest paid among all physicians in the country and four times more than the third highest paid cardiologist.

The settlement resolves two consolidated lawsuits originally filed under the whistleblower provision of the False Claims Act. The two individuals who originally brought the suit will receive about $ 1.3 million for their share of the settlement.

 

Former Warner Chilcott president acquitted on anti-kickback charge

W. Carl Reichel, former president of Warner Chilcott, was found not guilty of conspiring to pay kickbacks to physicians to induce them to prescribe its drugs.

The government’s case against Reichel alleged that he encouraged members of the sales force to provide physicians with payments, meals, and other rewards. According to court documents, Reichel was acquitted on grounds that there wasn’t insufficient evidence to suggest that he had ever given the sales team any such direction.

HCPro.com – Credentialing and Peer Review Legal Insider

List of New ICD 10 Codes Effective from Oct 1st 2016


Chapter 1 Certain infectious and parasitic diseases (A00-B99)


A92.5 Zika virus disease

Chapter 2 Neoplasms (C00-D49)

C49.A0 Gastrointestinal stromal tumor, unspecified site
C49.A1 Gastrointestinal stromal tumor of esophagus
C49.A2 Gastrointestinal stromal tumor of stomach
C49.A3 Gastrointestinal stromal tumor of small intestine
C49.A4 Gastrointestinal stromal tumor of large intestine
C49.A5 Gastrointestinal stromal tumor of rectum
C49.A9 Gastrointestinal stromal tumor of other sites
D47.Z2 Castleman disease
D49.511 Neoplasm of unspecified behavior of right kidney
D49.512 Neoplasm of unspecified behavior of left kidney
D49.519 Neoplasm of unspecified behavior of unspecified kidney
D49.59 Neoplasm of unspecified behavior of other genitourinary organ

Chapter 3 Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (D50-D89)

D78.31 Postprocedural hematoma of the spleen following a procedure on the spleen
D78.32 Postprocedural hematoma of the spleen following other procedure
D78.33 Postprocedural seroma of the spleen following a procedure on the spleen
D78.34 Postprocedural seroma of the spleen following other procedure
D89.40 Mast cell activation, unspecified
D89.41 Monoclonal mast cell activation syndrome
D89.42 Idiopathic mast cell activation syndrome
D89.43 Secondary mast cell activation
D89.49 Other mast cell activation disorder

Chapter 4 Endocrine, nutritional and metabolic diseases (E00-E89)

E08.3211 Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye
E08.3212 Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye
E08.3213 Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E08.3219 Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye
E08.3291 Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye
E08.3292 Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye
E08.3293 Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral
E08.3299 Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye
E08.3311 Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E08.3312 Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E08.3313 Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E08.3319 Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye
E08.3391 Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye
E08.3392 Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye
E08.3393 Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral
E08.3399 Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye
E08.3411 Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye
E08.3412 Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye
E08.3413 Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E08.3419 Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye
E08.3491 Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, right eye
E08.3492 Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left eye
E08.3493 Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, bilateral
E08.3499 Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye
E08.3511 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye
E08.3512 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye
E08.3513 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral
E08.3519 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, unspecified eye
E08.3521 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye
E08.3522 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye
E08.3523 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral
E08.3529 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye
E08.3531 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye
E08.3532 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye
E08.3533 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral
E08.3539 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye
E08.3541 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye
E08.3542 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye
E08.3543 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral
E08.3549 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye
E08.3551 Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right eye
E08.3552 Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left eye
E08.3553 Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, bilateral
E08.3559 Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, unspecified eye
E08.3591 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eye
E08.3592 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left eye
E08.3593 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, bilateral
E08.3599 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, unspecified eye
E08.37X1 Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right eye
E08.37X2 Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, left eye
E08.37X3 Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, bilateral
E08.37X9 Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, unspecified eye
E09.3211 Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E09.3212 Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye
E09.3213 Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E09.3219 Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye
E09.3291 Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye
E09.3292 Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye
E09.3293 Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral
E09.3299 Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye
E09.3311 Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E09.3312 Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E09.3313 Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E09.3319 Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye
E09.3391 Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye
E09.3392 Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye
E09.3393 Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral
E09.3399 Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye
E09.3411 Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye
E09.3412 Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye
E09.3413 Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E09.3419 Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye
E09.3491 Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye
E09.3492 Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye
E09.3493 Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral
E09.3499 Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye
E09.3511 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye
E09.3512 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye
E09.3513 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral
E09.3519 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye
E09.3521 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye
E09.3522 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye
E09.3523 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral
E09.3529 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye
E09.3531 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye
E09.3532 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye
E09.3533 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral
E09.3539 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye
E09.3541 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye
E09.3542 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye
E09.3543 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral
E09.3549 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye
E09.3551 Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, right eye
E09.3552 Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, left eye
E09.3553 Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, bilateral
E09.3559 Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye
E09.3591 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye
E09.3592 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye
E09.3593 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral
E09.3599 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye
E09.37X1 Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, right eye
E09.37X2 Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, left eye
E09.37X3 Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral
E09.37X9 Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye
E10.3211 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E10.3212 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye
E10.3213 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E10.3219 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye
E10.3291 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye
E10.3292 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye
E10.3293 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral
E10.3299 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye
E10.3311 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E10.3312 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E10.3313 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E10.3319 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye
E10.3391 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye
E10.3392 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye
E10.3393 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral
E10.3399 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye
E10.3411 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye
E10.3412 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye
E10.3413 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E10.3419 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye
E10.3491 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye
E10.3492 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye
E10.3493 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral
E10.3499 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye
E10.3511 Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye
E10.3512 Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye
E10.3513 Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral
E10.3519 Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye
E10.3521 Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye
E10.3522 Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye
E10.3523 Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral
E10.3529 Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye
E10.3531 Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye
E10.3532 Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye
E10.3533 Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral
E10.3539 Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye
E10.3541 Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye
E10.3542 Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye
E10.3543 Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral
E10.3549 Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye
E10.3551 Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye
E10.3552 Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye
E10.3553 Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral
E10.3559 Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye
E10.3591 Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye
E10.3592 Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye
E10.3593 Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral
E10.3599 Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye
E10.37X1 Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye
E10.37X2 Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye
E10.37X3 Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral
E10.37X9 Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye
E11.3211 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E11.3212 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye
E11.3213 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E11.3219 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye
E11.3291 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye
E11.3292 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye
E11.3293 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral
E11.3299 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye
E11.3311 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E11.3312 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E11.3313 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E11.3319 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye
E11.3391 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye
E11.3392 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye
E11.3393 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral
E11.3399 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye
E11.3411 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye
E11.3412 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye
E11.3413 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E11.3419 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye
E11.3491 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye
E11.3492 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye
E11.3493 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral
E11.3499 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye
E11.3511 Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye
E11.3512 Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye
E11.3513 Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral
E11.3519 Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye
E11.3521 Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye
E11.3522 Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye
E11.3523 Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral
E11.3529 Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye
E11.3531 Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye
E11.3532 Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye
E11.3533 Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral
E11.3539 Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye
E11.3541 Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye
E11.3542 Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye
E11.3543 Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral
E11.3549 Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye
E11.3551 Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye
E11.3552 Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye
E11.3553 Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral
E11.3559 Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye
E11.3591 Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye
E11.3592 Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye
E11.3593 Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral
E11.3599 Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye
E11.37X1 Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye
E11.37X2 Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye
E11.37X3 Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral
E11.37X9 Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye
E13.3211 Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E13.3212 Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye
E13.3213 Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E13.3219 Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye
E13.3291 Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye
E13.3292 Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye
E13.3293 Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral
E13.3299 Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye
E13.3311 Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E13.3312 Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E13.3313 Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E13.3319 Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye
E13.3391 Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye
E13.3392 Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye
E13.3393 Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral
E13.3399 Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye
E13.3411 Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye
E13.3412 Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye
E13.3413 Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E13.3419 Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye
E13.3491 Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye
E13.3492 Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye
E13.3493 Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral
E13.3499 Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye
E13.3511 Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye
E13.3512 Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye
E13.3513 Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral
E13.3519 Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye
E13.3521 Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye
E13.3522 Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye
E13.3523 Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral
E13.3529 Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye
E13.3531 Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye
E13.3532 Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye
E13.3533 Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral
E13.3539 Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye
E13.3541 Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye
E13.3542 Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye
E13.3543 Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral
E13.3549 Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye
E13.3551 Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye
E13.3552 Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye
E13.3553 Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral
E13.3559 Other specified diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye
E13.3591 Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye
E13.3592 Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye
E13.3593 Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral
E13.3599 Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye
E13.37X1 Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, right eye
E13.37X2 Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, left eye
E13.37X3 Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral
E13.37X9 Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye
E78.00 Pure hypercholesterolemia, unspecified
E78.01 Familial hypercholesterolemia
E89.820 Postprocedural hematoma of an endocrine system organ or structure following an endocrine system procedure
E89.821 Postprocedural hematoma of an endocrine system organ or structure following other procedure
E89.822 Postprocedural seroma of an endocrine system organ or structure following an endocrine system procedure
E89.823 Postprocedural seroma of an endocrine system organ or structure following other procedure

Chapter 5 Mental, Behavioral and Neurodevelopmental disorders (F01-F99)

F32.81 Premenstrual dysphoric disorder
F32.89 Other specified depressive episodes
F34.81 Disruptive mood dysregulation disorder
F34.89 Other specified persistent mood disorders
F42.2 Mixed obsessional thoughts and acts
F42.3 Hoarding disorder
F42.4 Excoriation (skin-picking) disorder
F42.8 Other obsessive-compulsive disorder
F42.9 Obsessive-compulsive disorder, unspecified
F50.81 Binge eating disorder
F50.89 Other specified eating disorder
F64.0 Transsexualism
F80.82 Social pragmatic communication disorder

Chapter 6 Diseases of the nervous system (G00-G99)

G56.03 Carpal tunnel syndrome, bilateral upper limbs
G56.13 Other lesions of median nerve, bilateral upper limbs
G56.23 Lesion of ulnar nerve, bilateral upper limbs
G56.33 Lesion of radial nerve, bilateral upper limbs
G56.43 Causalgia of bilateral upper limbs
G56.83 Other specified mononeuropathies of bilateral upper limbs
G56.93 Unspecified mononeuropathy of bilateral upper limbs
G57.03 Lesion of sciatic nerve, bilateral lower limbs
G57.13 Meralgia paresthetica, bilateral lower limbs
G57.23 Lesion of femoral nerve, bilateral lower limbs
G57.33 Lesion of lateral popliteal nerve, bilateral lower limbs
G57.43 Lesion of medial popliteal nerve, bilateral lower limbs
G57.53 Tarsal tunnel syndrome, bilateral lower limbs
G57.63 Lesion of plantar nerve, bilateral lower limbs
G57.73 Causalgia of bilateral lower limbs
G57.83 Other specified mononeuropathies of bilateral lower limbs
G57.93 Unspecified mononeuropathy of bilateral lower limbs
G61.82 Multifocal motor neuropathy
G97.61 Postprocedural hematoma of a nervous system organ or structure following a nervous system procedure
G97.62 Postprocedural hematoma of a nervous system organ or structure following other procedure
G97.63 Postprocedural seroma of a nervous system organ or structure following a nervous system procedure
G97.64 Postprocedural seroma of a nervous system organ or structure following other procedure

Chapter 7 Diseases of the eye and adnexa (H00-H59)

H34.8110 Central retinal vein occlusion, right eye, with macular edema
H34.8111 Central retinal vein occlusion, right eye, with retinal neovascularization
H34.8112 Central retinal vein occlusion, right eye, stable
H34.8120 Central retinal vein occlusion, left eye, with macular edema
H34.8121 Central retinal vein occlusion, left eye, with retinal neovascularization
H34.8122 Central retinal vein occlusion, left eye, stable
H34.8130 Central retinal vein occlusion, bilateral, with macular edema
H34.8131 Central retinal vein occlusion, bilateral, with retinal neovascularization
H34.8132 Central retinal vein occlusion, bilateral, stable
H34.8190 Central retinal vein occlusion, unspecified eye, with macular edema
H34.8191 Central retinal vein occlusion, unspecified eye, with retinal neovascularization
H34.8192 Central retinal vein occlusion, unspecified eye, stable
H34.8310 Tributary (branch) retinal vein occlusion, right eye, with macular edema
H34.8311 Tributary (branch) retinal vein occlusion, right eye, with retinal neovascularization
H34.8312 Tributary (branch) retinal vein occlusion, right eye, stable
H34.8320 Tributary (branch) retinal vein occlusion, left eye, with macular edema
H34.8321 Tributary (branch) retinal vein occlusion, left eye, with retinal neovascularization
H34.8322 Tributary (branch) retinal vein occlusion, left eye, stable
H34.8330 Tributary (branch) retinal vein occlusion, bilateral, with macular edema
H34.8331 Tributary (branch) retinal vein occlusion, bilateral, with retinal neovascularization
H34.8332 Tributary (branch) retinal vein occlusion, bilateral, stable
H34.8390 Tributary (branch) retinal vein occlusion, unspecified eye, with macular edema
H34.8391 Tributary (branch) retinal vein occlusion, unspecified eye, with retinal neovascularization
H34.8392 Tributary (branch) retinal vein occlusion, unspecified eye, stable
H35.3110 Nonexudative age-related macular degeneration, right eye, stage unspecified
H35.3111 Nonexudative age-related macular degeneration, right eye, early dry stage
H35.3112 Nonexudative age-related macular degeneration, right eye, intermediate dry stage
H35.3113 Nonexudative age-related macular degeneration, right eye, advanced atrophic without subfoveal involvement
H35.3114 Nonexudative age-related macular degeneration, right eye, advanced atrophic with subfoveal involvement
H35.3120 Nonexudative age-related macular degeneration, left eye, stage unspecified
H35.3121 Nonexudative age-related macular degeneration, left eye, early dry stage
H35.3122 Nonexudative age-related macular degeneration, left eye, intermediate dry stage
H35.3123 Nonexudative age-related macular degeneration, left eye, advanced atrophic without subfoveal involvement
H35.3124 Nonexudative age-related macular degeneration, left eye, advanced atrophic with subfoveal involvement
H35.3130 Nonexudative age-related macular degeneration, bilateral, stage unspecified
H35.3131 Nonexudative age-related macular degeneration, bilateral, early dry stage
H35.3132 Nonexudative age-related macular degeneration, bilateral, intermediate dry stage
H35.3133 Nonexudative age-related macular degeneration, bilateral, advanced atrophic without subfoveal involvement
H35.3134 Nonexudative age-related macular degeneration, bilateral, advanced atrophic with subfoveal involvement
H35.3190 Nonexudative age-related macular degeneration, unspecified eye, stage unspecified
H35.3191 Nonexudative age-related macular degeneration, unspecified eye, early dry stage
H35.3192 Nonexudative age-related macular degeneration, unspecified eye, intermediate dry stage
H35.3193 Nonexudative age-related macular degeneration, unspecified eye, advanced atrophic without subfoveal involvement
H35.3194 Nonexudative age-related macular degeneration, unspecified eye, advanced atrophic with subfoveal involvement
H35.3210 Exudative age-related macular degeneration, right eye, stage unspecified
H35.3211 Exudative age-related macular degeneration, right eye, with active choroidal neovascularization
H35.3212 Exudative age-related macular degeneration, right eye, with inactive choroidal neovascularization
H35.3213 Exudative age-related macular degeneration, right eye, with inactive scar
H35.3220 Exudative age-related macular degeneration, left eye, stage unspecified
H35.3221 Exudative age-related macular degeneration, left eye, with active choroidal neovascularization
H35.3222 Exudative age-related macular degeneration, left eye, with inactive choroidal neovascularization
H35.3223 Exudative age-related macular degeneration, left eye, with inactive scar
H35.3230 Exudative age-related macular degeneration, bilateral, stage unspecified
H35.3231 Exudative age-related macular degeneration, bilateral, with active choroidal neovascularization
H35.3232 Exudative age-related macular degeneration, bilateral, with inactive choroidal neovascularization
H35.3233 Exudative age-related macular degeneration, bilateral, with inactive scar
H35.3290 Exudative age-related macular degeneration, unspecified eye, stage unspecified
H35.3291 Exudative age-related macular degeneration, unspecified eye, with active choroidal neovascularization
H35.3292 Exudative age-related macular degeneration, unspecified eye, with inactive choroidal neovascularization
H35.3293 Exudative age-related macular degeneration, unspecified eye, with inactive scar
H40.1110 Primary open-angle glaucoma, right eye, stage unspecified
H40.1111 Primary open-angle glaucoma, right eye, mild stage
H40.1112 Primary open-angle glaucoma, right eye, moderate stage
H40.1113 Primary open-angle glaucoma, right eye, severe stage
H40.1114 Primary open-angle glaucoma, right eye, indeterminate stage
H40.1120 Primary open-angle glaucoma, left eye, stage unspecified
H40.1121 Primary open-angle glaucoma, left eye, mild stage
H40.1122 Primary open-angle glaucoma, left eye, moderate stage
H40.1123 Primary open-angle glaucoma, left eye, severe stage
H40.1124 Primary open-angle glaucoma, left eye, indeterminate stage
H40.1130 Primary open-angle glaucoma, bilateral, stage unspecified
H40.1131 Primary open-angle glaucoma, bilateral, mild stage
H40.1132 Primary open-angle glaucoma, bilateral, moderate stage
H40.1133 Primary open-angle glaucoma, bilateral, severe stage
H40.1134 Primary open-angle glaucoma, bilateral, indeterminate stage
H40.1190 Primary open-angle glaucoma, unspecified eye, stage unspecified
H40.1191 Primary open-angle glaucoma, unspecified eye, mild stage
H40.1192 Primary open-angle glaucoma, unspecified eye, moderate stage
H40.1193 Primary open-angle glaucoma, unspecified eye, severe stage
H40.1194 Primary open-angle glaucoma, unspecified eye, indeterminate stage
H53.041 Amblyopia suspect, right eye
H53.042 Amblyopia suspect, left eye
H53.043 Amblyopia suspect, bilateral
H53.049 Amblyopia suspect, unspecified eye
H59.331 Postprocedural hematoma of right eye and adnexa following an ophthalmic procedure
H59.332 Postprocedural hematoma of left eye and adnexa following an ophthalmic procedure
H59.333 Postprocedural hematoma of eye and adnexa following an ophthalmic procedure, bilateral
H59.339 Postprocedural hematoma of unspecified eye and adnexa following an ophthalmic procedure
H59.341 Postprocedural hematoma of right eye and adnexa following other procedure
H59.342 Postprocedural hematoma of left eye and adnexa following other procedure
H59.343 Postprocedural hematoma of eye and adnexa following other procedure, bilateral
H59.349 Postprocedural hematoma of unspecified eye and adnexa following other procedure
H59.351 Postprocedural seroma of right eye and adnexa following an ophthalmic procedure
H59.352 Postprocedural seroma of left eye and adnexa following an ophthalmic procedure
H59.353 Postprocedural seroma of eye and adnexa following an ophthalmic procedure, bilateral
H59.359 Postprocedural seroma of unspecified eye and adnexa following an ophthalmic procedure
H59.361 Postprocedural seroma of right eye and adnexa following other procedure
H59.362 Postprocedural seroma of left eye and adnexa following other procedure
H59.363 Postprocedural seroma of eye and adnexa following other procedure, bilateral
H59.369 Postprocedural seroma of unspecified eye and adnexa following other procedure

Chapter 8 Diseases of the ear and mastoid process (H60-H95)

H90.A11 Conductive hearing loss, unilateral, right ear with restricted hearing on the contralateral side
H90.A12 Conductive hearing loss, unilateral, left ear with restricted hearing on the contralateral side
H90.A21 Sensorineural hearing loss, unilateral, right ear, with restricted hearing on the contralateral side
H90.A22 Sensorineural hearing loss, unilateral, left ear, with restricted hearing on the contralateral side
H90.A31 Mixed conductive and sensorineural hearing loss, unilateral, right ear with restricted hearing on the contralateral side
H90.A32 Mixed conductive and sensorineural hearing loss, unilateral, left ear with restricted hearing on the contralateral side
H93.A1 Pulsatile tinnitus, right ear
H93.A2 Pulsatile tinnitus, left ear
H93.A3 Pulsatile tinnitus, bilateral
H93.A9 Pulsatile tinnitus, unspecified ear
H95.51 Postprocedural hematoma of ear and mastoid process following a procedure on the ear and mastoid process
H95.52 Postprocedural hematoma of ear and mastoid process following other procedure
H95.53 Postprocedural seroma of ear and mastoid process following a procedure on the ear and mastoid process
H95.54 Postprocedural seroma of ear and mastoid process following other procedure

Chapter 9 Diseases of the circulatory system (I00-I99)

I16.0 Hypertensive urgency
I16.1 Hypertensive emergency
I16.9 Hypertensive crisis, unspecified
I60.2 Nontraumatic subarachnoid hemorrhage from anterior communicating artery
I63.013 Cerebral infarction due to thrombosis of bilateral vertebral arteries
I63.033 Cerebral infarction due to thrombosis of bilateral carotid arteries
I63.113 Cerebral infarction due to embolism of bilateral vertebral arteries
I63.133 Cerebral infarction due to embolism of bilateral carotid arteries
I63.213 Cerebral infarction due to unspecified occlusion or stenosis of bilateral vertebral arteries
I63.233 Cerebral infarction due to unspecified occlusion or stenosis of bilateral carotid arteries
I63.313 Cerebral infarction due to thrombosis of bilateral middle cerebral arteries
I63.323 Cerebral infarction due to thrombosis of bilateral anterior arteries
I63.333 Cerebral infarction to thrombosis of bilateral posterior arteries
I63.343 Cerebral infarction to thrombosis of bilateral cerebellar arteries
I63.413 Cerebral infarction due to embolism of bilateral middle cerebral arteries
I63.423 Cerebral infarction due to embolism of bilateral anterior cerebral arteries
I63.433 Cerebral infarction due to embolism of bilateral posterior cerebral arteries
I63.443 Cerebral infarction due to embolism of bilateral cerebellar arteries
I63.513 Cerebral infarction due to unspecified occlusion or stenosis of bilateral middle arteries
I63.523 Cerebral infarction due to unspecified occlusion or stenosis of bilateral anterior arteries
I63.533 Cerebral infarction due to unspecified occlusion or stenosis of bilateral posterior arteries
I63.543 Cerebral infarction due to unspecified occlusion or stenosis of bilateral cerebellar arteries
I69.010 Attention and concentration deficit following nontraumatic subarachnoid hemorrhage
I69.011 Memory deficit following nontraumatic subarachnoid hemorrhage
I69.012 Visuospatial deficit and spatial neglect following nontraumatic subarachnoid hemorrhage
I69.013 Psychomotor deficit following nontraumatic subarachnoid hemorrhage
I69.014 Frontal lobe and executive function deficit following nontraumatic subarachnoid hemorrhage
I69.015 Cognitive social or emotional deficit following nontraumatic subarachnoid hemorrhage
I69.018 Other symptoms and signs involving cognitive functions following nontraumatic subarachnoid hemorrhage
I69.019 Unspecified symptoms and signs involving cognitive functions following nontraumatic subarachnoid hemorrhage
I69.110 Attention and concentration deficit following nontraumatic intracerebral hemorrhage
I69.111 Memory deficit following nontraumatic intracerebral hemorrhage
I69.112 Visuospatial deficit and spatial neglect following nontraumatic intracerebral hemorrhage
I69.113 Psychomotor deficit following nontraumatic intracerebral hemorrhage
I69.114 Frontal lobe and executive function deficit following nontraumatic intracerebral hemorrhage
I69.115 Cognitive social or emotional deficit following nontraumatic intracerebral hemorrhage
I69.118 Other symptoms and signs involving cognitive functions following nontraumatic intracerebral hemorrhage
I69.119 Unspecified symptoms and signs involving cognitive functions following nontraumatic intracerebral hemorrhage
I69.210 Attention and concentration deficit following other nontraumatic intracranial hemorrhage
I69.211 Memory deficit following other nontraumatic intracranial hemorrhage
I69.212 Visuospatial deficit and spatial neglect following other nontraumatic intracranial hemorrhage
I69.213 Psychomotor deficit following other nontraumatic intracranial hemorrhage
I69.214 Frontal lobe and executive function deficit following other nontraumatic intracranial hemorrhage
I69.215 Cognitive social or emotional deficit following other nontraumatic intracranial hemorrhage
I69.218 Other symptoms and signs involving cognitive functions following other nontraumatic intracranial hemorrhage
I69.219 Unspecified symptoms and signs involving cognitive functions following other nontraumatic intracranial hemorrhage
I69.310 Attention and concentration deficit following cerebral infarction
I69.311 Memory deficit following cerebral infarction
I69.312 Visuospatial deficit and spatial neglect following cerebral infarction
I69.313 Psychomotor deficit following cerebral infarction
I69.314 Frontal lobe and executive function deficit following cerebral infarction
I69.315 Cognitive social or emotional deficit following cerebral infarction
I69.318 Other symptoms and signs involving cognitive functions following cerebral infarction
I69.319 Unspecified symptoms and signs involving cognitive functions following cerebral infarction
I69.810 Attention and concentration deficit following other cerebrovascular disease
I69.811 Memory deficit following other cerebrovascular disease
I69.812 Visuospatial deficit and spatial neglect following other cerebrovascular disease
I69.813 Psychomotor deficit following other cerebrovascular disease
I69.814 Frontal lobe and executive function deficit following other cerebrovascular disease
I69.815 Cognitive social or emotional deficit following other cerebrovascular disease
I69.818 Other symptoms and signs involving cognitive functions following other cerebrovascular disease
I69.819 Unspecified symptoms and signs involving cognitive functions following other cerebrovascular disease
I69.910 Attention and concentration deficit following unspecified cerebrovascular disease
I69.911 Memory deficit following unspecified cerebrovascular disease
I69.912 Visuospatial deficit and spatial neglect following unspecified cerebrovascular disease
I69.913 Psychomotor deficit following unspecified cerebrovascular disease
I69.914 Frontal lobe and executive function deficit following unspecified cerebrovascular disease
I69.915 Cognitive social or emotional deficit following unspecified cerebrovascular disease
I69.918 Other symptoms and signs involving cognitive functions following unspecified cerebrovascular disease
I69.919 Unspecified symptoms and signs involving cognitive functions following unspecified cerebrovascular disease
I72.5 Aneurysm of other precerebral arteries
I72.6 Aneurysm of vertebral artery
I77.70 Dissection of unspecified artery
I77.75 Dissection of other precerebral arteries
I77.76 Dissection of artery of upper extremity
I77.77 Dissection of artery of lower extremity
I97.620 Postprocedural hemorrhage of a circulatory system organ or structure following other procedure
I97.621 Postprocedural hematoma of a circulatory system organ or structure following other procedure
I97.622 Postprocedural seroma of a circulatory system organ or structure following other procedure
I97.630 Postprocedural hematoma of a circulatory system organ or structure following a cardiac catheterization
I97.631 Postprocedural hematoma of a circulatory system organ or structure following cardiac bypass
I97.638 Postprocedural hematoma of a circulatory system organ or structure following other circulatory system procedure
I97.640 Postprocedural seroma of a circulatory system organ or structure following a cardiac catheterization
I97.641 Postprocedural seroma of a circulatory system organ or structure following cardiac bypass
I97.648 Postprocedural seroma of a circulatory system organ or structure following other circulatory system procedure

Chapter 10 Diseases of the respiratory system (J00-J99)

J95.860 Postprocedural hematoma of a respiratory system organ or structure following a respiratory system procedure
J95.861 Postprocedural hematoma of a respiratory system organ or structure following other procedure
J95.862 Postprocedural seroma of a respiratory system organ or structure following a respiratory system procedure
J95.863 Postprocedural seroma of a respiratory system organ or structure following other procedure
J98.51 Mediastinitis
J98.59 Other diseases of mediastinum, not elsewhere classified

Chapter 11 Diseases of the digestive system (K00-K95)

K04.01 Reversible pulpitis
K04.02 Irreversible pulpitis
K05.211 Aggressive periodontitis, localized, slight
K05.212 Aggressive periodontitis, localized, moderate
K05.213 Aggressive periodontitis, localized, severe
K05.219 Aggressive periodontitis, localized, unspecified severity
K05.221 Aggressive periodontitis, generalized, slight
K05.222 Aggressive periodontitis, generalized, moderate
K05.223 Aggressive periodontitis, generalized, severe
K05.229 Aggressive periodontitis, generalized, unspecified severity
K05.311 Chronic periodontitis, localized, slight
K05.312 Chronic periodontitis, localized, moderate
K05.313 Chronic periodontitis, localized, severe
K05.319 Chronic periodontitis, localized, unspecified severity
K05.321 Chronic periodontitis, generalized, slight
K05.322 Chronic periodontitis, generalized, moderate
K05.323 Chronic periodontitis, generalized, severe
K05.329 Chronic periodontitis, generalized, unspecified severity
K06.3 Horizontal alveolar bone loss
K08.81 Primary occlusal trauma
K08.82 Secondary occlusal trauma
K08.89 Other specified disorders of teeth and supporting structures
K52.21 Food protein-induced enterocolitis syndrome
K52.22 Food protein-induced enteropathy
K52.29 Other allergic and dietetic gastroenteritis and colitis
K52.3 Indeterminate colitis
K52.831 Collagenous colitis
K52.832 Lymphocytic colitis
K52.838 Other microscopic colitis
K52.839 Microscopic colitis, unspecified
K55.011 Focal (segmental) acute (reversible) ischemia of small intestine
K55.012 Diffuse acute (reversible) ischemia of small intestine
K55.019 Acute (reversible) ischemia of small intestine, extent unspecified
K55.021 Focal (segmental) acute infarction of small intestine
K55.022 Diffuse acute infarction of small intestine
K55.029 Acute infarction of small intestine, extent unspecified
K55.031 Focal (segmental) acute (reversible) ischemia of large intestine
K55.032 Diffuse acute (reversible) ischemia of large intestine
K55.039 Acute (reversible) ischemia of large intestine, extent unspecified
K55.041 Focal (segmental) acute infarction of large intestine
K55.042 Diffuse acute infarction of large intestine
K55.049 Acute infarction of large intestine, extent unspecified
K55.051 Focal (segmental) acute (reversible) ischemia of intestine, part unspecified
K55.052 Diffuse acute (reversible) ischemia of intestine, part unspecified
K55.059 Acute (reversible) ischemia of intestine, part and extent unspecified
K55.061 Focal (segmental) acute infarction of intestine, part unspecified
K55.062 Diffuse acute infarction of intestine, part unspecified
K55.069 Acute infarction of intestine, part and extent unspecified
K55.30 Necrotizing enterocolitis, unspecified
K55.31 Stage 1 necrotizing enterocolitis
K55.32 Stage 2 necrotizing enterocolitis
K55.33 Stage 3 necrotizing enterocolitis
K58.1 Irritable bowel syndrome with constipation
K58.2 Mixed irritable bowel syndrome
K58.8 Other irritable bowel syndrome
K59.03 Drug induced constipation
K59.04 Chronic idiopathic constipation
K59.31 Toxic megacolon
K59.39 Other megacolon
K85.00 Idiopathic acute pancreatitis without necrosis or infection
K85.01 Idiopathic acute pancreatitis with uninfected necrosis
K85.02 Idiopathic acute pancreatitis with infected necrosis
K85.10 Biliary acute pancreatitis without necrosis or infection
K85.11 Biliary acute pancreatitis with uninfected necrosis
K85.12 Biliary acute pancreatitis with infected necrosis
K85.20 Alcohol induced acute pancreatitis without necrosis or infection
K85.21 Alcohol induced acute pancreatitis with uninfected necrosis
K85.22 Alcohol induced acute pancreatitis with infected necrosis
K85.30 Drug induced acute pancreatitis without necrosis or infection
K85.31 Drug induced acute pancreatitis with uninfected necrosis
K85.32 Drug induced acute pancreatitis with infected necrosis
K85.80 Other acute pancreatitis without necrosis or infection
K85.81 Other acute pancreatitis with uninfected necrosis
K85.82 Other acute pancreatitis with infected necrosis
K85.90 Acute pancreatitis without necrosis or infection, unspecified
K85.91 Acute pancreatitis with uninfected necrosis, unspecified
K85.92 Acute pancreatitis with infected necrosis, unspecified
K86.81 Exocrine pancreatic insufficiency
K86.89 Other specified diseases of pancreas
K90.41 Non-celiac gluten sensitivity
K90.49 Malabsorption due to intolerance, not elsewhere classified
K91.870 Postprocedural hematoma of a digestive system organ or structure following a digestive system procedure
K91.871 Postprocedural hematoma of a digestive system organ or structure following other procedure
K91.872 Postprocedural seroma of a digestive system organ or structure following a digestive system procedure
K91.873 Postprocedural seroma of a digestive system organ or structure following other procedure

Chapter 12 Diseases of the skin and subcutaneous tissue (L00-L99)

L03.213 Periorbital cellulitis
L76.31 Postprocedural hematoma of skin and subcutaneous tissue following a dermatologic procedure
L76.32 Postprocedural hematoma of skin and subcutaneous tissue following other procedure
L76.33 Postprocedural seroma of skin and subcutaneous tissue following a dermatologic procedure
L76.34 Postprocedural seroma of skin and subcutaneous tissue following other procedure
L98.7 Excessive and redundant skin and subcutaneous tissue

Chapter 13 Diseases of the musculoskeletal system and connective tissue (M00-M99)

M04.1 Periodic fever syndromes
M04.2 Cryopyrin-associated periodic syndromes
M04.8 Other autoinflammatory syndromes
M04.9 Autoinflammatory syndrome, unspecified
M21.611 Bunion of right foot
M21.612 Bunion of left foot
M21.619 Bunion of unspecified foot
M21.621 Bunionette of right foot
M21.622 Bunionette of left foot
M21.629 Bunionette of unspecified foot
M25.541 Pain in joints of right hand
M25.542 Pain in joints of left hand
M25.549 Pain in joints of unspecified hand
M26.601 Right temporomandibular joint disorder, unspecified
M26.602 Left temporomandibular joint disorder, unspecified
M26.603 Bilateral temporomandibular joint disorder, unspecified
M26.609 Unspecified temporomandibular joint disorder, unspecified side
M26.611 Adhesions and ankylosis of right temporomandibular joint
M26.612 Adhesions and ankylosis of left temporomandibular joint
M26.613 Adhesions and ankylosis of bilateral temporomandibular joint
M26.619 Adhesions and ankylosis of temporomandibular joint, unspecified side
M26.621 Arthralgia of right temporomandibular joint
M26.622 Arthralgia of left temporomandibular joint
M26.623 Arthralgia of bilateral temporomandibular joint
M26.629 Arthralgia of temporomandibular joint, unspecified side
M26.631 Articular disc disorder of right temporomandibular joint
M26.632 Articular disc disorder of left temporomandibular joint
M26.633 Articular disc disorder of bilateral temporomandibular joint
M26.639 Articular disc disorder of temporomandibular joint, unspecified side
M50.020 Cervical disc disorder with myelopathy, mid-cervical region, unspecified level
M50.021 Cervical disc disorder at C4-C5 level with myelopathy
M50.022 Cervical disc disorder at C5-C6 level with myelopathy
M50.023 Cervical disc disorder at C6-C7 level with myelopathy
M50.120 Mid-cervical disc disorder, unspecified
M50.121 Cervical disc disorder at C4-C5 level with radiculopathy
M50.122 Cervical disc disorder at C5-C6 level with radiculopathy
M50.123 Cervical disc disorder at C6-C7 level with radiculopathy
M50.220 Other cervical disc displacement, mid-cervical region, unspecified level
M50.221 Other cervical disc displacement at C4-C5 level
M50.222 Other cervical disc displacement at C5-C6 level
M50.223 Other cervical disc displacement at C6-C7 level
M50.320 Other cervical disc degeneration, mid-cervical region, unspecified level
M50.321 Other cervical disc degeneration at C4-C5 level
M50.322 Other cervical disc degeneration at C5-C6 level
M50.323 Other cervical disc degeneration at C6-C7 level
M50.820 Other cervical disc disorders, mid-cervical region, unspecified level
M50.821 Other cervical disc disorders at C4-C5 level
M50.822 Other cervical disc disorders at C5-C6 level
M50.823 Other cervical disc disorders at C6-C7 level
M50.920 Unspecified cervical disc disorder, mid-cervical region, unspecified level
M50.921 Unspecified cervical disc disorder at C4-C5 level
M50.922 Unspecified cervical disc disorder at C5-C6 level
M50.923 Unspecified cervical disc disorder at C6-C7 level
M62.84 Sarcopenia
M84.750A Atypical femoral fracture, unspecified, initial encounter for fracture
M84.750D Atypical femoral fracture, unspecified, subsequent encounter for fracture with routine healing
M84.750G Atypical femoral fracture, unspecified, subsequent encounter for fracture with delayed healing
M84.750K Atypical femoral fracture, unspecified, subsequent encounter for fracture with nonunion
M84.750P Atypical femoral fracture, unspecified, subsequent encounter for fracture with malunion
M84.750S Atypical femoral fracture, unspecified, sequela
M84.751A Incomplete atypical femoral fracture, right leg, initial encounter for fracture
M84.751D Incomplete atypical femoral fracture, right leg, subsequent encounter for fracture with routine healing
M84.751G Incomplete atypical femoral fracture, right leg, subsequent encounter for fracture with delayed healing
M84.751K Incomplete atypical femoral fracture, right leg, subsequent encounter for fracture with nonunion
M84.751P Incomplete atypical femoral fracture, right leg, subsequent encounter for fracture with malunion
M84.751S Incomplete atypical femoral fracture, right leg, sequela
M84.752A Incomplete atypical femoral fracture, left leg, initial encounter for fracture
M84.752D Incomplete atypical femoral fracture, left leg, subsequent encounter for fracture with routine healing
M84.752G Incomplete atypical femoral fracture, left leg, subsequent encounter for fracture with delayed healing
M84.752K Incomplete atypical femoral fracture, left leg, subsequent encounter for fracture with nonunion
M84.752P Incomplete atypical femoral fracture, left leg, subsequent encounter for fracture with malunion
M84.752S Incomplete atypical femoral fracture, left leg, sequela
M84.753A Incomplete atypical femoral fracture, unspecified leg, initial encounter for fracture
M84.753D Incomplete atypical femoral fracture, unspecified leg, subsequent encounter for fracture with routine healing
M84.753G Incomplete atypical femoral fracture, unspecified leg, subsequent encounter for fracture with delayed healing
M84.753K Incomplete atypical femoral fracture, unspecified leg, subsequent encounter for fracture with nonunion
M84.753P Incomplete atypical femoral fracture, unspecified leg, subsequent encounter for fracture with malunion
M84.753S Incomplete atypical femoral fracture, unspecified leg, sequela
M84.754A Complete transverse atypical femoral fracture, right leg, initial encounter for fracture
M84.754D Complete transverse atypical femoral fracture, right leg, subsequent encounter for fracture with routine healing
M84.754G Complete transverse atypical femoral fracture, right leg, subsequent encounter for fracture with delayed healing
M84.754K Complete transverse atypical femoral fracture, right leg, subsequent encounter for fracture with nonunion
M84.754P Complete transverse atypical femoral fracture, right leg, subsequent encounter for fracture with malunion
M84.754S Complete transverse atypical femoral fracture, right leg, sequela
M84.755A Complete transverse atypical femoral fracture, left leg, initial encounter for fracture
M84.755D Complete transverse atypical femoral fracture, left leg, subsequent encounter for fracture with routine healing
M84.755G Complete transverse atypical femoral fracture, left leg, subsequent encounter for fracture with delayed healing
M84.755K Complete transverse atypical femoral fracture, left leg, subsequent encounter for fracture with nonunion
M84.755P Complete transverse atypical femoral fracture, left leg, subsequent encounter for fracture with malunion
M84.755S Complete transverse atypical femoral fracture, left leg, sequela
M84.756A Complete transverse atypical femoral fracture, unspecified leg, initial encounter for fracture
M84.756D Complete transverse atypical femoral fracture, unspecified leg, subsequent encounter for fracture with routine healing
M84.756G Complete transverse atypical femoral fracture, unspecified leg, subsequent encounter for fracture with delayed healing
M84.756K Complete transverse atypical femoral fracture, unspecified leg, subsequent encounter for fracture with nonunion
M84.756P Complete transverse atypical femoral fracture, unspecified leg, subsequent encounter for fracture with malunion
M84.756S Complete transverse atypical femoral fracture, unspecified leg, sequela
M84.757A Complete oblique atypical femoral fracture, right leg, initial encounter for fracture
M84.757D Complete oblique atypical femoral fracture, right leg, subsequent encounter for fracture with routine healing
M84.757G Complete oblique atypical femoral fracture, right leg, subsequent encounter for fracture with delayed healing
M84.757K Complete oblique atypical femoral fracture, right leg, subsequent encounter for fracture with nonunion
M84.757P Complete oblique atypical femoral fracture, right leg, subsequent encounter for fracture with malunion
M84.757S Complete oblique atypical femoral fracture, right leg, sequela
M84.758A Complete oblique atypical femoral fracture, left leg, initial encounter for fracture
M84.758D Complete oblique atypical femoral fracture, left leg, subsequent encounter for fracture with routine healing
M84.758G Complete oblique atypical femoral fracture, left leg, subsequent encounter for fracture with delayed healing
M84.758K Complete oblique atypical femoral fracture, left leg, subsequent encounter for fracture with nonunion
M84.758P Complete oblique atypical femoral fracture, left leg, subsequent encounter for fracture with malunion
M84.758S Complete oblique atypical femoral fracture, left leg, sequela
M84.759A Complete oblique atypical femoral fracture, unspecified leg, initial encounter for fracture
M84.759D Complete oblique atypical femoral fracture, unspecified leg, subsequent encounter for fracture with routine healing
M84.759G Complete oblique atypical femoral fracture, unspecified leg, subsequent encounter for fracture with delayed healing
M84.759K Complete oblique atypical femoral fracture, unspecified leg, subsequent encounter for fracture with nonunion
M84.759P Complete oblique atypical femoral fracture, unspecified leg, subsequent encounter for fracture with malunion
M84.759S Complete oblique atypical femoral fracture, unspecified leg, sequela
M96.840 Postprocedural hematoma of a musculoskeletal structure following a musculoskeletal system procedure
M96.841 Postprocedural hematoma of a musculoskeletal structure following other procedure
M96.842 Postprocedural seroma of a musculoskeletal structure following a musculoskeletal system procedure
M96.843 Postprocedural seroma of a musculoskeletal structure following other procedure
M97.01XA Periprosthetic fracture around internal prosthetic right hip joint, initial encounter
M97.01XD Periprosthetic fracture around internal prosthetic right hip joint, subsequent encounter
M97.01XS Periprosthetic fracture around internal prosthetic right hip joint, sequela
M97.02XA Periprosthetic fracture around internal prosthetic left hip joint, initial encounter
M97.02XD Periprosthetic fracture around internal prosthetic left hip joint, subsequent encounter
M97.02XS Periprosthetic fracture around internal prosthetic left hip joint, sequela
M97.11XA Periprosthetic fracture around internal prosthetic right knee joint, initial encounter
M97.11XD Periprosthetic fracture around internal prosthetic right knee joint, subsequent encounter
M97.11XS Periprosthetic fracture around internal prosthetic right knee joint, sequela
M97.12XA Periprosthetic fracture around internal prosthetic left knee joint, initial encounter
M97.12XD Periprosthetic fracture around internal prosthetic left knee joint, subsequent encounter
M97.12XS Periprosthetic fracture around internal prosthetic left knee joint, sequela
M97.21XA Periprosthetic fracture around internal prosthetic right ankle joint, initial encounter
M97.21XD Periprosthetic fracture around internal prosthetic right ankle joint, subsequent encounter
M97.21XS Periprosthetic fracture around internal prosthetic right ankle joint, sequela
M97.22XA Periprosthetic fracture around internal prosthetic left ankle joint, initial encounter
M97.22XD Periprosthetic fracture around internal prosthetic left ankle joint, subsequent encounter
M97.22XS Periprosthetic fracture around internal prosthetic left ankle joint, sequela
M97.31XA Periprosthetic fracture around internal prosthetic right shoulder joint, initial encounter
M97.31XD Periprosthetic fracture around internal prosthetic right shoulder joint, subsequent encounter
M97.31XS Periprosthetic fracture around internal prosthetic right shoulder joint, sequela
M97.32XA Periprosthetic fracture around internal prosthetic left shoulder joint, initial encounter
M97.32XD Periprosthetic fracture around internal prosthetic left shoulder joint, subsequent encounter
M97.32XS Periprosthetic fracture around internal prosthetic left shoulder joint, sequela
M97.41XA Periprosthetic fracture around internal prosthetic right elbow joint, initial encounter
M97.41XD Periprosthetic fracture around internal prosthetic right elbow joint, subsequent encounter
M97.41XS Periprosthetic fracture around internal prosthetic right elbow joint, sequela
M97.42XA Periprosthetic fracture around internal prosthetic left elbow joint, initial encounter
M97.42XD Periprosthetic fracture around internal prosthetic left elbow joint, subsequent encounter
M97.42XS Periprosthetic fracture around internal prosthetic left elbow joint, sequela
M97.8XXA Periprosthetic fracture around other internal prosthetic joint, initial encounter
M97.8XXD Periprosthetic fracture around other internal prosthetic joint, subsequent encounter
M97.8XXS Periprosthetic fracture around other internal prosthetic joint, sequela
M97.9XXA Periprosthetic fracture around unspecified internal prosthetic joint, initial encounter
M97.9XXD Periprosthetic fracture around unspecified internal prosthetic joint, subsequent encounter
M97.9XXS Periprosthetic fracture around unspecified internal prosthetic joint, sequela

Chapter 14 Diseases of the genitourinary system (N00-N99)

N13.0 Hydronephrosis with ureteropelvic junction obstruction
N39.491 Coital incontinence
N39.492 Postural (urinary) incontinence
N42.30 Unspecified dysplasia of prostate
N42.31 Prostatic intraepithelial neoplasia
N42.32 Atypical small acinar proliferation of prostate
N42.39 Other dysplasia of prostate
N50.811 Right testicular pain
N50.812 Left testicular pain
N50.819 Testicular pain, unspecified
N50.82 Scrotal pain
N50.89 Other specified disorders of the male genital organs
N52.35 Erectile dysfunction following radiation therapy
N52.36 Erectile dysfunction following interstitial seed therapy
N52.37 Erectile dysfunction following prostate ablative therapy
N61.0 Mastitis without abscess
N61.1 Abscess of the breast and nipple
N83.00 Follicular cyst of ovary, unspecified side
N83.01 Follicular cyst of right ovary
N83.02 Follicular cyst of left ovary
N83.10 Corpus luteum cyst of ovary, unspecified side
N83.11 Corpus luteum cyst of right ovary
N83.12 Corpus luteum cyst of left ovary
N83.201 Unspecified ovarian cyst, right side
N83.202 Unspecified ovarian cyst, left side
N83.209 Unspecified ovarian cyst, unspecified side
N83.291 Other ovarian cyst, right side
N83.292 Other ovarian cyst, left side
N83.299 Other ovarian cyst, unspecified side
N83.311 Acquired atrophy of right ovary
N83.312 Acquired atrophy of left ovary
N83.319 Acquired atrophy of ovary, unspecified side
N83.321 Acquired atrophy of right fallopian tube
N83.322 Acquired atrophy of left fallopian tube
N83.329 Acquired atrophy of fallopian tube, unspecified side
N83.331 Acquired atrophy of right ovary and fallopian tube
N83.332 Acquired atrophy of left ovary and fallopian tube
N83.339 Acquired atrophy of ovary and fallopian tube, unspecified side
N83.40 Prolapse and hernia of ovary and fallopian tube, unspecified side
N83.41 Prolapse and hernia of right ovary and fallopian tube
N83.42 Prolapse and hernia of left ovary and fallopian tube
N83.511 Torsion of right ovary and ovarian pedicle
N83.512 Torsion of left ovary and ovarian pedicle
N83.519 Torsion of ovary and ovarian pedicle, unspecified side
N83.521 Torsion of right fallopian tube
N83.522 Torsion of left fallopian tube
N83.529 Torsion of fallopian tube, unspecified side
N90.60 Unspecified hypertrophy of vulva
N90.61 Childhood asymmetric labium majus enlargement
N90.69 Other specified hypertrophy of vulva
N93.1 Pre-pubertal vaginal bleeding
N94.10 Unspecified dyspareunia
N94.11 Superficial (introital) dyspareunia
N94.12 Deep dyspareunia
N94.19 Other specified dyspareunia
N99.115 Postprocedural fossa navicularis urethral stricture
N99.523 Herniation of incontinent stoma of urinary tract
N99.524 Stenosis of incontinent stoma of urinary tract
N99.533 Herniation of continent stoma of urinary tract
N99.534 Stenosis of continent stoma of urinary tract
N99.840 Postprocedural hematoma of a genitourinary system organ or structure following a genitourinary system procedure
N99.841 Postprocedural hematoma of a genitourinary system organ or structure following other procedure
N99.842 Postprocedural seroma of a genitourinary system organ or structure following a genitourinary system procedure
N99.843 Postprocedural seroma of a genitourinary system organ or structure following other procedure

Chapter 15 Pregnancy, childbirth and the puerperium (O00-O9A)

O00.00 Abdominal pregnancy without intrauterine pregnancy
O00.01 Abdominal pregnancy with intrauterine pregnancy
O00.10 Tubal pregnancy without intrauterine pregnancy
O00.11 Tubal pregnancy with intrauterine pregnancy
O00.20 Ovarian pregnancy without intrauterine pregnancy
O00.21 Ovarian pregnancy with intrauterine pregnancy
O00.80 Other ectopic pregnancy without intrauterine pregnancy
O00.81 Other ectopic pregnancy with intrauterine pregnancy
O00.90 Unspecified ectopic pregnancy without intrauterine pregnancy
O00.91 Unspecified ectopic pregnancy with intrauterine pregnancy
O09.A0 Supervision of pregnancy with history of molar pregnancy, unspecified trimester
O09.A1 Supervision of pregnancy with history of molar pregnancy, first trimester
O09.A2 Supervision of pregnancy with history of molar pregnancy, second trimester
O09.A3 Supervision of pregnancy with history of molar pregnancy, third trimester
O11.4 Pre-existing hypertension with pre-eclampsia, complicating childbirth
O11.5 Pre-existing hypertension with pre-eclampsia, complicating the puerperium
O12.04 Gestational edema, complicating childbirth
O12.05 Gestational edema, complicating the puerperium
O12.14 Gestational proteinuria, complicating childbirth
O12.15 Gestational proteinuria, complicating the puerperium
O12.24 Gestational edema with proteinuria, complicating childbirth
O12.25 Gestational edema with proteinuria, complicating the puerperium
O13.4 Gestational [pregnancy-induced] hypertension without significant proteinuria, complicating childbirth
O13.5 Gestational [pregnancy-induced] hypertension without significant proteinuria, complicating the puerperium
O14.04 Mild to moderate pre-eclampsia, complicating childbirth
O14.05 Mild to moderate pre-eclampsia, complicating the puerperium
O14.14 Severe pre-eclampsia complicating childbirth
O14.15 Severe pre-eclampsia, complicating the puerperium
O14.24 HELLP syndrome, complicating childbirth
O14.25 HELLP syndrome, complicating the puerperium
O14.94 Unspecified pre-eclampsia, complicating childbirth
O14.95 Unspecified pre-eclampsia, complicating the puerperium
O16.4 Unspecified maternal hypertension, complicating childbirth
O16.5 Unspecified maternal hypertension, complicating the puerperium
O24.415 Gestational diabetes mellitus in pregnancy, controlled by oral hypoglycemic drugs
O24.425 Gestational diabetes mellitus in childbirth, controlled by oral hypoglycemic drugs
O24.435 Gestational diabetes mellitus in puerperium, controlled by oral hypoglycemic drugs
O33.7XX0 Maternal care for disproportion due to other fetal deformities, not applicable or unspecified
O33.7XX1 Maternal care for disproportion due to other fetal deformities, fetus 1
O33.7XX2 Maternal care for disproportion due to other fetal deformities, fetus 2
O33.7XX3 Maternal care for disproportion due to other fetal deformities, fetus 3
O33.7XX4 Maternal care for disproportion due to other fetal deformities, fetus 4
O33.7XX5 Maternal care for disproportion due to other fetal deformities, fetus 5
O33.7XX9 Maternal care for disproportion due to other fetal deformities, other fetus
O34.211 Maternal care for low transverse scar from previous cesarean delivery
O34.212 Maternal care for vertical scar from previous cesarean delivery
O34.219 Maternal care for unspecified type scar from previous cesarean delivery
O44.20 Partial placenta previa NOS or without hemorrhage, unspecified trimester
O44.21 Partial placenta previa NOS or without hemorrhage, first trimester
O44.22 Partial placenta previa NOS or without hemorrhage, second trimester
O44.23 Partial placenta previa NOS or without hemorrhage, third trimester
O44.30 Partial placenta previa with hemorrhage, unspecified trimester
O44.31 Partial placenta previa with hemorrhage, first trimester
O44.32 Partial placenta previa with hemorrhage, second trimester
O44.33 Partial placenta previa with hemorrhage, third trimester
O44.40 Low lying placenta NOS or without hemorrhage, unspecified trimester
O44.41 Low lying placenta NOS or without hemorrhage, first trimester
O44.42 Low lying placenta NOS or without hemorrhage, second trimester
O44.43 Low lying placenta NOS or without hemorrhage, third trimester
O44.50 Low lying placenta with hemorrhage, unspecified trimester
O44.51 Low lying placenta with hemorrhage, first trimester
O44.52 Low lying placenta with hemorrhage, second trimester
O44.53 Low lying placenta with hemorrhage, third trimester
O70.20 Third degree perineal laceration during delivery, unspecified
O70.21 Third degree perineal laceration during delivery, IIIa
O70.22 Third degree perineal laceration during delivery, IIIb
O70.23 Third degree perineal laceration during delivery, IIIc

Chapter 16 Certain conditions originating in the perinatal period (P00-P96)

P05.09 Newborn light for gestational age, 2500 grams and over
P05.19 Newborn small for gestational age, other

Chapter 17 Congenital malformations, deformations and chromosomal abnormalities (Q00-Q99)

Q25.21 Interruption of aortic arch
Q25.29 Other atresia of aorta
Q25.40 Congenital malformation of aorta unspecified
Q25.41 Absence and aplasia of aorta
Q25.42 Hypoplasia of aorta
Q25.43 Congenital aneurysm of aorta
Q25.44 Congenital dilation of aorta
Q25.45 Double aortic arch
Q25.46 Tortuous aortic arch
Q25.47 Right aortic arch
Q25.48 Anomalous origin of subclavian artery
Q25.49 Other congenital malformations of aorta
Q52.120 Longitudinal vaginal septum, nonobstructing
Q52.121 Longitudinal vaginal septum, obstructing, right side
Q52.122 Longitudinal vaginal septum, obstructing, left side
Q52.123 Longitudinal vaginal septum, microperforate, right side
Q52.124 Longitudinal vaginal septum, microperforate, left side
Q52.129 Other and unspecified longitudinal vaginal septum
Q66.21 Congenital metatarsus primus varus
Q66.22 Congenital metatarsus adductus
Q82.6 Congenital sacral dimple
Q87.82 Arterial tortuosity syndrome

Chapter 18 Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified (R00-R99)

R29.700 NIHSS score 0
R29.701 NIHSS score 1
R29.702 NIHSS score 2
R29.703 NIHSS score 3
R29.704 NIHSS score 4
R29.705 NIHSS score 5
R29.706 NIHSS score 6
R29.707 NIHSS score 7
R29.708 NIHSS score 8
R29.709 NIHSS score 9
R29.710 NIHSS score 10
R29.711 NIHSS score 11
R29.712 NIHSS score 12
R29.713 NIHSS score 13
R29.714 NIHSS score 14
R29.715 NIHSS score 15
R29.716 NIHSS score 16
R29.717 NIHSS score 17
R29.718 NIHSS score 18
R29.719 NIHSS score 19
R29.720 NIHSS score 20
R29.721 NIHSS score 21
R29.722 NIHSS score 22
R29.723 NIHSS score 23
R29.724 NIHSS score 24
R29.725 NIHSS score 25
R29.726 NIHSS score 26
R29.727 NIHSS score 27
R29.728 NIHSS score 28
R29.729 NIHSS score 29
R29.730 NIHSS score 30
R29.731 NIHSS score 31
R29.732 NIHSS score 32
R29.733 NIHSS score 33
R29.734 NIHSS score 34
R29.735 NIHSS score 35
R29.736 NIHSS score 36
R29.737 NIHSS score 37
R29.738 NIHSS score 38
R29.739 NIHSS score 39
R29.740 NIHSS score 40
R29.741 NIHSS score 41
R29.742 NIHSS score 42
R31.21 Asymptomatic microscopic hematuria
R31.29 Other microscopic hematuria
R39.191 Need to immediately re-void
R39.192 Position dependent micturition
R39.198 Other difficulties with micturition
R39.82 Chronic bladder pain
R40.2410 Glasgow coma scale score 13-15, unspecified time
R40.2411 Glasgow coma scale score 13-15, in the field [EMT or ambulance]
R40.2412 Glasgow coma scale score 13-15, at arrival to emergency department
R40.2413 Glasgow coma scale score 13-15, at hospital admission
R40.2414 Glasgow coma scale score 13-15, 24 hours or more after hospital admission
R40.2420 Glasgow coma scale score 9-12, unspecified time
R40.2421 Glasgow coma scale score 9-12, in the field [EMT or ambulance]
R40.2422 Glasgow coma scale score 9-12, at arrival to emergency department
R40.2423 Glasgow coma scale score 9-12, at hospital admission
R40.2424 Glasgow coma scale score 9-12, 24 hours or more after hospital admission
R40.2430 Glasgow coma scale score 3-8, unspecified time
R40.2431 Glasgow coma scale score 3-8, in the field [EMT or ambulance]
R40.2432 Glasgow coma scale score 3-8, at arrival to emergency department
R40.2433 Glasgow coma scale score 3-8, at hospital admission
R40.2434 Glasgow coma scale score 3-8, 24 hours or more after hospital admission
R40.2440 Other coma, without documented Glasgow coma scale score, or with partial score reported, unspecified time
R40.2441 Other coma, without documented Glasgow coma scale score, or with partial score reported, in the field [EMT or ambulance]
R40.2442 Other coma, without documented Glasgow coma scale score, or with partial score reported, at arrival to emergency department
R40.2443 Other coma, without documented Glasgow coma scale score, or with partial score reported, at hospital admission
R40.2444 Other coma, without documented Glasgow coma scale score, or with partial score reported, 24 hours or more after hospital admission
R73.03 Prediabetes
R82.71 Bacteriuria
R82.79 Other abnormal findings on microbiological examination of urine
R93.41 Abnormal radiologic findings on diagnostic imaging of renal pelvis, ureter, or bladder
R93.421 Abnormal radiologic findings on diagnostic imaging of right kidney
R93.422 Abnormal radiologic findings on diagnostic imaging of left kidney
R93.429 Abnormal radiologic findings on diagnostic imaging of unspecified kidney
R93.49 Abnormal radiologic findings on diagnostic imaging of other urinary organs
R97.20 Elevated prostate specific antigen [PSA]
R97.21 Rising PSA following treatment for malignant neoplasm of prostate

Chapter 19 Injury, poisoning and certain other consequences of external causes (S00-T88)

S02.101A Fracture of base of skull, right side, initial encounter for closed fracture
S02.101B Fracture of base of skull, right side, initial encounter for open fracture
S02.101D Fracture of base of skull, right side, subsequent encounter for fracture with routine healing
S02.101G Fracture of base of skull, right side, subsequent encounter for fracture with delayed healing
S02.101K Fracture of base of skull, right side, subsequent encounter for fracture with nonunion
S02.101S Fracture of base of skull, right side, sequela
S02.102A Fracture of base of skull, left side, initial encounter for closed fracture
S02.102B Fracture of base of skull, left side, initial encounter for open fracture
S02.102D Fracture of base of skull, left side, subsequent encounter for fracture with routine healing
S02.102G Fracture of base of skull, left side, subsequent encounter for fracture with delayed healing
S02.102K Fracture of base of skull, left side, subsequent encounter for fracture with nonunion
S02.102S Fracture of base of skull, left side, sequela
S02.109A Fracture of base of skull, unspecified side, initial encounter for closed fracture
S02.109B Fracture of base of skull, unspecified side, initial encounter for open fracture
S02.109D Fracture of base of skull, unspecified side, subsequent encounter for fracture with routine healing
S02.109G Fracture of base of skull, unspecified side, subsequent encounter for fracture with delayed healing
S02.109K Fracture of base of skull, unspecified side, subsequent encounter for fracture with nonunion
S02.109S Fracture of base of skull, unspecified side, sequela
S02.11AA Type I occipital condyle fracture, right side, initial encounter for closed fracture
S02.11AB Type I occipital condyle fracture, right side, initial encounter for open fracture
S02.11AD Type I occipital condyle fracture, right side, subsequent encounter for fracture with routine healing
S02.11AG Type I occipital condyle fracture, right side, subsequent encounter for fracture with delayed healing
S02.11AK Type I occipital condyle fracture, right side, subsequent encounter for fracture with nonunion
S02.11AS Type I occipital condyle fracture, right side, sequela
S02.11BA Type I occipital condyle fracture, left side, initial encounter for closed fracture
S02.11BB Type I occipital condyle fracture, left side, initial encounter for open fracture
S02.11BD Type I occipital condyle fracture, left side, subsequent encounter for fracture with routine healing
S02.11BG Type I occipital condyle fracture, left side, subsequent encounter for fracture with delayed healing
S02.11BK Type I occipital condyle fracture, left side, subsequent encounter for fracture with nonunion
S02.11BS Type I occipital condyle fracture, left side, sequela
S02.11CA Type II occipital condyle fracture, right side, initial encounter for closed fracture
S02.11CB Type II occipital condyle fracture, right side, initial encounter for open fracture
S02.11CD Type II occipital condyle fracture, right side, subsequent encounter for fracture with routine healing
S02.11CG Type II occipital condyle fracture, right side, subsequent encounter for fracture with delayed healing
S02.11CK Type II occipital condyle fracture, right side, subsequent encounter for fracture with nonunion
S02.11CS Type II occipital condyle fracture, right side, sequela
S02.11DA Type II occipital condyle fracture, left side, initial encounter for closed fracture
S02.11DB Type II occipital condyle fracture, left side, initial encounter for open fracture
S02.11DD Type II occipital condyle fracture, left side, subsequent encounter for fracture with routine healing
S02.11DG Type II occipital condyle fracture, left side, subsequent encounter for fracture with delayed healing
S02.11DK Type II occipital condyle fracture, left side, subsequent encounter for fracture with nonunion
S02.11DS Type II occipital condyle fracture, left side, sequela
S02.11EA Type III occipital condyle fracture, right side, initial encounter for closed fracture
S02.11EB Type III occipital condyle fracture, right side, initial encounter for open fracture
S02.11ED Type III occipital condyle fracture, right side, subsequent encounter for fracture with routine healing
S02.11EG Type III occipital condyle fracture, right side, subsequent encounter for fracture with delayed healing
S02.11EK Type III occipital condyle fracture, right side, subsequent encounter for fracture with nonunion
S02.11ES Type III occipital condyle fracture, right side, sequela
S02.11FA Type III occipital condyle fracture, left side, initial encounter for closed fracture
S02.11FB Type III occipital condyle fracture, left side, initial encounter for open fracture
S02.11FD Type III occipital condyle fracture, left side, subsequent encounter for fracture with routine healing
S02.11FG Type III occipital condyle fracture, left side, subsequent encounter for fracture with delayed healing
S02.11FK Type III occipital condyle fracture, left side, subsequent encounter for fracture with nonunion
S02.11FS Type III occipital condyle fracture, left side, sequela
S02.11GA Other fracture of occiput, right side, initial encounter for closed fracture
S02.11GB Other fracture of occiput, right side, initial encounter for open fracture
S02.11GD Other fracture of occiput, right side, subsequent encounter for fracture with routine healing
S02.11GG Other fracture of occiput, right side, subsequent encounter for fracture with delayed healing
S02.11GK Other fracture of occiput, right side, subsequent encounter for fracture with nonunion
S02.11GS Other fracture of occiput, right side, sequela
S02.11HA Other fracture of occiput, left side, initial encounter for closed fracture
S02.11HB Other fracture of occiput, left side, initial encounter for open fracture
S02.11HD Other fracture of occiput, left side, subsequent encounter for fracture with routine healing
S02.11HG Other fracture of occiput, left side, subsequent encounter for fracture with delayed healing
S02.11HK Other fracture of occiput, left side, subsequent encounter for fracture with nonunion
S02.11HS Other fracture of occiput, left side, sequela
S02.30XA Fracture of orbital floor, unspecified side, initial encounter for closed fracture
S02.30XB Fracture of orbital floor, unspecified side, initial encounter for open fracture
S02.30XD Fracture of orbital floor, unspecified side, subsequent encounter for fracture with routine healing
S02.30XG Fracture of orbital floor, unspecified side, subsequent encounter for fracture with delayed healing
S02.30XK Fracture of orbital floor, unspecified side, subsequent encounter for fracture with nonunion
S02.30XS Fracture of orbital floor, unspecified side, sequela
S02.31XA Fracture of orbital floor, right side, initial encounter for closed fracture
S02.31XB Fracture of orbital floor, right side, initial encounter for open fracture
S02.31XD Fracture of orbital floor, right side, subsequent encounter for fracture with routine healing
S02.31XG Fracture of orbital floor, right side, subsequent encounter for fracture with delayed healing
S02.31XK Fracture of orbital floor, right side, subsequent encounter for fracture with nonunion
S02.31XS Fracture of orbital floor, right side, sequela
S02.32XA Fracture of orbital floor, left side, initial encounter for closed fracture
S02.32XB Fracture of orbital floor, left side, initial encounter for open fracture
S02.32XD Fracture of orbital floor, left side, subsequent encounter for fracture with routine healing
S02.32XG Fracture of orbital floor, left side, subsequent encounter for fracture with delayed healing
S02.32XK Fracture of orbital floor, left side, subsequent encounter for fracture with nonunion
S02.32XS Fracture of orbital floor, left side, sequela
S02.40AA Malar fracture, right side, initial encounter for closed fracture
S02.40AB Malar fracture, right side, initial encounter for open fracture
S02.40AD Malar fracture, right side, subsequent encounter for fracture with routine healing
S02.40AG Malar fracture, right side, subsequent encounter for fracture with delayed healing
S02.40AK Malar fracture, right side, subsequent encounter for fracture with nonunion
S02.40AS Malar fracture, right side, sequela
S02.40BA Malar fracture, left side, initial encounter for closed fracture
S02.40BB Malar fracture, left side, initial encounter for open fracture
S02.40BD Malar fracture, left side, subsequent encounter for fracture with routine healing
S02.40BG Malar fracture, left side, subsequent encounter for fracture with delayed healing
S02.40BK Malar fracture, left side, subsequent encounter for fracture with nonunion
S02.40BS Malar fracture, left side, sequela
S02.40CA Maxillary fracture, right side, initial encounter for closed fracture
S02.40CB Maxillary fracture, right side, initial encounter for open fracture
S02.40CD Maxillary fracture, right side, subsequent encounter for fracture with routine healing
S02.40CG Maxillary fracture, right side, subsequent encounter for fracture with delayed healing
S02.40CK Maxillary fracture, right side, subsequent encounter for fracture with nonunion
S02.40CS Maxillary fracture, right side, sequela
S02.40DA Maxillary fracture, left side, initial encounter for closed fracture
S02.40DB Maxillary fracture, left side, initial encounter for open fracture
S02.40DD Maxillary fracture, left side, subsequent encounter for fracture with routine healing
S02.40DG Maxillary fracture, left side, subsequent encounter for fracture with delayed healing
S02.40DK Maxillary fracture, left side, subsequent encounter for fracture with nonunion
S02.40DS Maxillary fracture, left side, sequela
S02.40EA Zygomatic fracture, right side, initial encounter for closed fracture
S02.40EB Zygomatic fracture, right side, initial encounter for open fracture
S02.40ED Zygomatic fracture, right side, subsequent encounter for fracture with routine healing
S02.40EG Zygomatic fracture, right side, subsequent encounter for fracture with delayed healing
S02.40EK Zygomatic fracture, right side, subsequent encounter for fracture with nonunion
S02.40ES Zygomatic fracture, right side, sequela
S02.40FA Zygomatic fracture, left side, initial encounter for closed fracture
S02.40FB Zygomatic fracture, left side, initial encounter for open fracture
S02.40FD Zygomatic fracture, left side, subsequent encounter for fracture with routine healing
S02.40FG Zygomatic fracture, left side, subsequent encounter for fracture with delayed healing
S02.40FK Zygomatic fracture, left side, subsequent encounter for fracture with nonunion
S02.40FS Zygomatic fracture, left side, sequela
S02.601A Fracture of unspecified part of body of right mandible, initial encounter for closed fracture
S02.601B Fracture of unspecified part of body of right mandible, initial encounter for open fracture
S02.601D Fracture of unspecified part of body of right mandible, subsequent encounter for fracture with routine healing
S02.601G Fracture of unspecified part of body of right mandible, subsequent encounter for fracture with delayed healing
S02.601K Fracture of unspecified part of body of right mandible, subsequent encounter for fracture with nonunion
S02.601S Fracture of unspecified part of body of right mandible, sequela
S02.602A Fracture of unspecified part of body of left mandible, initial encounter for closed fracture
S02.602B Fracture of unspecified part of body of left mandible, initial encounter for open fracture
S02.602D Fracture of unspecified part of body of left mandible, subsequent encounter for fracture with routine healing
S02.602G Fracture of unspecified part of body of left mandible, subsequent encounter for fracture with delayed healing
S02.602K Fracture of unspecified part of body of left mandible, subsequent encounter for fracture with nonunion
S02.602S Fracture of unspecified part of body of left mandible, sequela
S02.610A Fracture of condylar process of mandible, unspecified side, initial encounter for closed fracture
S02.610B Fracture of condylar process of mandible, unspecified side, initial encounter for open fracture
S02.610D Fracture of condylar process of mandible, unspecified side, subsequent encounter for fracture with routine healing
S02.610G Fracture of condylar process of mandible, unspecified side, subsequent encounter for fracture with delayed healing
S02.610K Fracture of condylar process of mandible, unspecified side, subsequent encounter for fracture with nonunion
S02.610S Fracture of condylar process of mandible, unspecified side, sequela
S02.611A Fracture of condylar process of right mandible, initial encounter for closed fracture
S02.611B Fracture of condylar process of right mandible, initial encounter for open fracture
S02.611D Fracture of condylar process of right mandible, subsequent encounter for fracture with routine healing
S02.611G Fracture of condylar process of right mandible, subsequent encounter for fracture with delayed healing
S02.611K Fracture of condylar process of right mandible, subsequent encounter for fracture with nonunion
S02.611S Fracture of condylar process of right mandible, sequela
S02.612A Fracture of condylar process of left mandible, initial encounter for closed fracture
S02.612B Fracture of condylar process of left mandible, initial encounter for open fracture
S02.612D Fracture of condylar process of left mandible, subsequent encounter for fracture with routine healing
S02.612G Fracture of condylar process of left mandible, subsequent encounter for fracture with delayed healing
S02.612K Fracture of condylar process of left mandible, subsequent encounter for fracture with nonunion
S02.612S Fracture of condylar process of left mandible, sequela
S02.620A Fracture of subcondylar process of mandible, unspecified side, initial encounter for closed fracture
S02.620B Fracture of subcondylar process of mandible, unspecified side, initial encounter for open fracture
S02.620D Fracture of subcondylar process of mandible, unspecified side, subsequent encounter for fracture with routine healing
S02.620G Fracture of subcondylar process of mandible, unspecified side, subsequent encounter for fracture with delayed healing
S02.620K Fracture of subcondylar process of mandible, unspecified side, subsequent encounter for fracture with nonunion
S02.620S Fracture of subcondylar process of mandible, unspecified side, sequela
S02.621A Fracture of subcondylar process of right mandible, initial encounter for closed fracture
S02.621B Fracture of subcondylar process of right mandible, initial encounter for open fracture
S02.621D Fracture of subcondylar process of right mandible, subsequent encounter for fracture with routine healing
S02.621G Fracture of subcondylar process of right mandible, subsequent encounter for fracture with delayed healing
S02.621K Fracture of subcondylar process of right mandible, subsequent encounter for fracture with nonunion
S02.621S Fracture of subcondylar process of right mandible, sequela
S02.622A Fracture of subcondylar process of left mandible, initial encounter for closed fracture
S02.622B Fracture of subcondylar process of left mandible, initial encounter for open fracture
S02.622D Fracture of subcondylar process of left mandible, subsequent encounter for fracture with routine healing
S02.622G Fracture of subcondylar process of left mandible, subsequent encounter for fracture with delayed healing
S02.622K Fracture of subcondylar process of left mandible, subsequent encounter for fracture with nonunion
S02.622S Fracture of subcondylar process of left mandible, sequela
S02.630A Fracture of coronoid process of mandible, unspecified side, initial encounter for closed fracture
S02.630B Fracture of coronoid process of mandible, unspecified side, initial encounter for open fracture
S02.630D Fracture of coronoid process of mandible, unspecified side, subsequent encounter for fracture with routine healing
S02.630G Fracture of coronoid process of mandible, unspecified side, subsequent encounter for fracture with delayed healing
S02.630K Fracture of coronoid process of mandible, unspecified side, subsequent encounter for fracture with nonunion
S02.630S Fracture of coronoid process of mandible, unspecified side, sequela
S02.631A Fracture of coronoid process of right mandible, initial encounter for closed fracture
S02.631B Fracture of coronoid process of right mandible, initial encounter for open fracture
S02.631D Fracture of coronoid process of right mandible, subsequent encounter for fracture with routine healing
S02.631G Fracture of coronoid process of right mandible, subsequent encounter for fracture with delayed healing
S02.631K Fracture of coronoid process of right mandible, subsequent encounter for fracture with nonunion
S02.631S Fracture of coronoid process of right mandible, sequela
S02.632A Fracture of coronoid process of left mandible, initial encounter for closed fracture
S02.632B Fracture of coronoid process of left mandible, initial encounter for open fracture
S02.632D Fracture of coronoid process of left mandible, subsequent encounter for fracture with routine healing
S02.632G Fracture of coronoid process of left mandible, subsequent encounter for fracture with delayed healing
S02.632K Fracture of coronoid process of left mandible, subsequent encounter for fracture with nonunion
S02.632S Fracture of coronoid process of left mandible, sequela
S02.640A Fracture of ramus of mandible, unspecified side, initial encounter for closed fracture
S02.640B Fracture of ramus of mandible, unspecified side, initial encounter for open fracture
S02.640D Fracture of ramus of mandible, unspecified side, subsequent encounter for fracture with routine healing
S02.640G Fracture of ramus of mandible, unspecified side, subsequent encounter for fracture with delayed healing
S02.640K Fracture of ramus of mandible, unspecified side, subsequent encounter for fracture with nonunion
S02.640S Fracture of ramus of mandible, unspecified side, sequela
S02.641A Fracture of ramus of right mandible, initial encounter for closed fracture
S02.641B Fracture of ramus of right mandible, initial encounter for open fracture
S02.641D Fracture of ramus of right mandible, subsequent encounter for fracture with routine healing
S02.641G Fracture of ramus of right mandible, subsequent encounter for fracture with delayed healing
S02.641K Fracture of ramus of right mandible, subsequent encounter for fracture with nonunion
S02.641S Fracture of ramus of right mandible, sequela
S02.642A Fracture of ramus of left mandible, initial encounter for closed fracture
S02.642B Fracture of ramus of left mandible, initial encounter for open fracture
S02.642D Fracture of ramus of left mandible, subsequent encounter for fracture with routine healing
S02.642G Fracture of ramus of left mandible, subsequent encounter for fracture with delayed healing
S02.642K Fracture of ramus of left mandible, subsequent encounter for fracture with nonunion
S02.642S Fracture of ramus of left mandible, sequela
S02.650A Fracture of angle of mandible, unspecified side, initial encounter for closed fracture
S02.650B Fracture of angle of mandible, unspecified side, initial encounter for open fracture
S02.650D Fracture of angle of mandible, unspecified side, subsequent encounter for fracture with routine healing
S02.650G Fracture of angle of mandible, unspecified side, subsequent encounter for fracture with delayed healing
S02.650K Fracture of angle of mandible, unspecified side, subsequent encounter for fracture with nonunion
S02.650S Fracture of angle of mandible, unspecified side, sequela
S02.651A Fracture of angle of right mandible, initial encounter for closed fracture
S02.651B Fracture of angle of right mandible, initial encounter for open fracture
S02.651D Fracture of angle of right mandible, subsequent encounter for fracture with routine healing
S02.651G Fracture of angle of right mandible, subsequent encounter for fracture with delayed healing
S02.651K Fracture of angle of right mandible, subsequent encounter for fracture with nonunion
S02.651S Fracture of angle of right mandible, sequela
S02.652A Fracture of angle of left mandible, initial encounter for closed fracture
S02.652B Fracture of angle of left mandible, initial encounter for open fracture
S02.652D Fracture of angle of left mandible, subsequent encounter for fracture with routine healing
S02.652G Fracture of angle of left mandible, subsequent encounter for fracture with delayed healing
S02.652K Fracture of angle of left mandible, subsequent encounter for fracture with nonunion
S02.652S Fracture of angle of left mandible, sequela
S02.670A Fracture of alveolus of mandible, unspecified side, initial encounter for closed fracture
S02.670B Fracture of alveolus of mandible, unspecified side, initial encounter for open fracture
S02.670D Fracture of alveolus of mandible, unspecified side, subsequent encounter for fracture with routine healing
S02.670G Fracture of alveolus of mandible, unspecified side, subsequent encounter for fracture with delayed healing
S02.670K Fracture of alveolus of mandible, unspecified side, subsequent encounter for fracture with nonunion
S02.670S Fracture of alveolus of mandible, unspecified side, sequela
S02.671A Fracture of alveolus of right mandible, initial encounter for closed fracture
S02.671B Fracture of alveolus of right mandible, initial encounter for open fracture
S02.671D Fracture of alveolus of right mandible, subsequent encounter for fracture with routine healing
S02.671G Fracture of alveolus of right mandible, subsequent encounter for fracture with delayed healing
S02.671K Fracture of alveolus of right mandible, subsequent encounter for fracture with nonunion
S02.671S Fracture of alveolus of right mandible, sequela
S02.672A Fracture of alveolus of left mandible, initial encounter for closed fracture
S02.672B Fracture of alveolus of left mandible, initial encounter for open fracture
S02.672D Fracture of alveolus of left mandible, subsequent encounter for fracture with routine healing
S02.672G Fracture of alveolus of left mandible, subsequent encounter for fracture with delayed healing
S02.672K Fracture of alveolus of left mandible, subsequent encounter for fracture with nonunion
S02.672S Fracture of alveolus of left mandible, sequela
S02.80XA Fracture of other specified skull and facial bones, unspecified side, initial encounter for closed fracture
S02.80XB Fracture of other specified skull and facial bones, unspecified side, initial encounter for open fracture
S02.80XD Fracture of other specified skull and facial bones, unspecified side, subsequent encounter for fracture with routine healing
S02.80XG Fracture of other specified skull and facial bones, unspecified side, subsequent encounter for fracture with delayed healing
S02.80XK Fracture of other specified skull and facial bones, unspecified side, subsequent encounter for fracture with nonunion
S02.80XS Fracture of other specified skull and facial bones, unspecified side, sequela
S02.81XA Fracture of other specified skull and facial bones, right side, initial encounter for closed fracture
S02.81XB Fracture of other specified skull and facial bones, right side, initial encounter for open fracture
S02.81XD Fracture of other specified skull and facial bones, right side, subsequent encounter for fracture with routine healing
S02.81XG Fracture of other specified skull and facial bones, right side, subsequent encounter for fracture with delayed healing
S02.81XK Fracture of other specified skull and facial bones, right side, subsequent encounter for fracture with nonunion
S02.81XS Fracture of other specified skull and facial bones, right side, sequela
S02.82XA Fracture of other specified skull and facial bones, left side, initial encounter for closed fracture
S02.82XB Fracture of other specified skull and facial bones, left side, initial encounter for open fracture
S02.82XD Fracture of other specified skull and facial bones, left side, subsequent encounter for fracture with routine healing
S02.82XG Fracture of other specified skull and facial bones, left side, subsequent encounter for fracture with delayed healing
S02.82XK Fracture of other specified skull and facial bones, left side, subsequent encounter for fracture with nonunion
S02.82XS Fracture of other specified skull and facial bones, left side, sequela
S03.00XA Dislocation of jaw, unspecified side, initial encounter
S03.00XD Dislocation of jaw, unspecified side, subsequent encounter
S03.00XS Dislocation of jaw, unspecified side, sequela
S03.01XA Dislocation of jaw, right side, initial encounter
S03.01XD Dislocation of jaw, right side, subsequent encounter
S03.01XS Dislocation of jaw, right side, sequela
S03.02XA Dislocation of jaw, left side, initial encounter
S03.02XD Dislocation of jaw, left side, subsequent encounter
S03.02XS Dislocation of jaw, left side, sequela
S03.03XA Dislocation of jaw, bilateral, initial encounter
S03.03XD Dislocation of jaw, bilateral, subsequent encounter
S03.03XS Dislocation of jaw, bilateral, sequela
S03.40XA Sprain of jaw, unspecified side, initial encounter
S03.40XD Sprain of jaw, unspecified side, subsequent encounter
S03.40XS Sprain of jaw, unspecified side, sequela
S03.41XA Sprain of jaw, right side, initial encounter
S03.41XD Sprain of jaw, right side, subsequent encounter
S03.41XS Sprain of jaw, right side, sequela
S03.42XA Sprain of jaw, left side, initial encounter
S03.42XD Sprain of jaw, left side, subsequent encounter
S03.42XS Sprain of jaw, left side, sequela
S03.43XA Sprain of jaw, bilateral, initial encounter
S03.43XD Sprain of jaw, bilateral, subsequent encounter
S03.43XS Sprain of jaw, bilateral, sequela
S92.811A Other fracture of right foot, initial encounter for closed fracture
S92.811B Other fracture of right foot, initial encounter for open fracture
S92.811D Other fracture of right foot, subsequent encounter for fracture with routine healing
S92.811G Other fracture of right foot, subsequent encounter for fracture with delayed healing
S92.811K Other fracture of right foot, subsequent encounter for fracture with nonunion
S92.811P Other fracture of right foot, subsequent encounter for fracture with malunion
S92.811S Other fracture of right foot, sequela
S92.812A Other fracture of left foot, initial encounter for closed fracture
S92.812B Other fracture of left foot, initial encounter for open fracture
S92.812D Other fracture of left foot, subsequent encounter for fracture with routine healing
S92.812G Other fracture of left foot, subsequent encounter for fracture with delayed healing
S92.812K Other fracture of left foot, subsequent encounter for fracture with nonunion
S92.812P Other fracture of left foot, subsequent encounter for fracture with malunion
S92.812S Other fracture of left foot, sequela
S92.819A Other fracture of unspecified foot, initial encounter for closed fracture
S92.819B Other fracture of unspecified foot, initial encounter for open fracture
S92.819D Other fracture of unspecified foot, subsequent encounter for fracture with routine healing
S92.819G Other fracture of unspecified foot, subsequent encounter for fracture with delayed healing
S92.819K Other fracture of unspecified foot, subsequent encounter for fracture with nonunion
S92.819P Other fracture of unspecified foot, subsequent encounter for fracture with malunion
S92.819S Other fracture of unspecified foot, sequela
S99.001A Unspecified physeal fracture of right calcaneus, initial encounter for closed fracture
S99.001B Unspecified physeal fracture of right calcaneus, initial encounter for open fracture
S99.001D Unspecified physeal fracture of right calcaneus, subsequent encounter for fracture with routine healing
S99.001G Unspecified physeal fracture of right calcaneus, subsequent encounter for fracture with delayed healing
S99.001K Unspecified physeal fracture of right calcaneus, subsequent encounter for fracture with nonunion
S99.001P Unspecified physeal fracture of right calcaneus, subsequent encounter for fracture with malunion
S99.001S Unspecified physeal fracture of right calcaneus, sequela
S99.002A Unspecified physeal fracture of left calcaneus, initial encounter for closed fracture
S99.002B Unspecified physeal fracture of left calcaneus, initial encounter for open fracture
S99.002D Unspecified physeal fracture of left calcaneus, subsequent encounter for fracture with routine healing
S99.002G Unspecified physeal fracture of left calcaneus, subsequent encounter for fracture with delayed healing
S99.002K Unspecified physeal fracture of left calcaneus, subsequent encounter for fracture with nonunion
S99.002P Unspecified physeal fracture of left calcaneus, subsequent encounter for fracture with malunion
S99.002S Unspecified physeal fracture of left calcaneus, sequela
S99.009A Unspecified physeal fracture of unspecified calcaneus, initial encounter for closed fracture
S99.009B Unspecified physeal fracture of unspecified calcaneus, initial encounter for open fracture
S99.009D Unspecified physeal fracture of unspecified calcaneus, subsequent encounter for fracture with routine healing
S99.009G Unspecified physeal fracture of unspecified calcaneus, subsequent encounter for fracture with delayed healing
S99.009K Unspecified physeal fracture of unspecified calcaneus, subsequent encounter for fracture with nonunion
S99.009P Unspecified physeal fracture of unspecified calcaneus, subsequent encounter for fracture with malunion
S99.009S Unspecified physeal fracture of unspecified calcaneus, sequela
S99.011A Salter-Harris Type I physeal fracture of right calcaneus, initial encounter for closed fracture
S99.011B Salter-Harris Type I physeal fracture of right calcaneus, initial encounter for open fracture
S99.011D Salter-Harris Type I physeal fracture of right calcaneus, subsequent encounter for fracture with routine healing
S99.011G Salter-Harris Type I physeal fracture of right calcaneus, subsequent encounter for fracture with delayed healing
S99.011K Salter-Harris Type I physeal fracture of right calcaneus, subsequent encounter for fracture with nonunion
S99.011P Salter-Harris Type I physeal fracture of right calcaneus, subsequent encounter for fracture with malunion
S99.011S Salter-Harris Type I physeal fracture of right calcaneus, sequela
S99.012A Salter-Harris Type I physeal fracture of left calcaneus, initial encounter for closed fracture
S99.012B Salter-Harris Type I physeal fracture of left calcaneus, initial encounter for open fracture
S99.012D Salter-Harris Type I physeal fracture of left calcaneus, subsequent encounter for fracture with routine healing
S99.012G Salter-Harris Type I physeal fracture of left calcaneus, subsequent encounter for fracture with delayed healing
S99.012K Salter-Harris Type I physeal fracture of left calcaneus, subsequent encounter for fracture with nonunion
S99.012P Salter-Harris Type I physeal fracture of left calcaneus, subsequent encounter for fracture with malunion
S99.012S Salter-Harris Type I physeal fracture of left calcaneus, sequela
S99.019A Salter-Harris Type I physeal fracture of unspecified calcaneus, initial encounter for closed fracture
S99.019B Salter-Harris Type I physeal fracture of unspecified calcaneus, initial encounter for open fracture
S99.019D Salter-Harris Type I physeal fracture of unspecified calcaneus, subsequent encounter for fracture with routine healing
S99.019G Salter-Harris Type I physeal fracture of unspecified calcaneus, subsequent encounter for fracture with delayed healing
S99.019K Salter-Harris Type I physeal fracture of unspecified calcaneus, subsequent encounter for fracture with nonunion
S99.019P Salter-Harris Type I physeal fracture of unspecified calcaneus, subsequent encounter for fracture with malunion
S99.019S Salter-Harris Type I physeal fracture of unspecified calcaneus, sequela
S99.021A Salter-Harris Type II physeal fracture of right calcaneus, initial encounter for closed fracture
S99.021B Salter-Harris Type II physeal fracture of right calcaneus, initial encounter for open fracture
S99.021D Salter-Harris Type II physeal fracture of right calcaneus, subsequent encounter for fracture with routine healing
S99.021G Salter-Harris Type II physeal fracture of right calcaneus, subsequent encounter for fracture with delayed healing
S99.021K Salter-Harris Type II physeal fracture of right calcaneus, subsequent encounter for fracture with nonunion
S99.021P Salter-Harris Type II physeal fracture of right calcaneus, subsequent encounter for fracture with malunion
S99.021S Salter-Harris Type II physeal fracture of right calcaneus, sequela
S99.022A Salter-Harris Type II physeal fracture of left calcaneus, initial encounter for closed fracture
S99.022B Salter-Harris Type II physeal fracture of left calcaneus, initial encounter for open fracture
S99.022D Salter-Harris Type II physeal fracture of left calcaneus, subsequent encounter for fracture with routine healing
S99.022G Salter-Harris Type II physeal fracture of left calcaneus, subsequent encounter for fracture with delayed healing
S99.022K Salter-Harris Type II physeal fracture of left calcaneus, subsequent encounter for fracture with nonunion
S99.022P Salter-Harris Type II physeal fracture of left calcaneus, subsequent encounter for fracture with malunion
S99.022S Salter-Harris Type II physeal fracture of left calcaneus, sequela
S99.029A Salter-Harris Type II physeal fracture of unspecified calcaneus, initial encounter for closed fracture
S99.029B Salter-Harris Type II physeal fracture of unspecified calcaneus, initial encounter for open fracture
S99.029D Salter-Harris Type II physeal fracture of unspecified calcaneus, subsequent encounter for fracture with routine healing
S99.029G Salter-Harris Type II physeal fracture of unspecified calcaneus, subsequent encounter for fracture with delayed healing
S99.029K Salter-Harris Type II physeal fracture of unspecified calcaneus, subsequent encounter for fracture with nonunion
S99.029P Salter-Harris Type II physeal fracture of unspecified calcaneus, subsequent encounter for fracture with malunion
S99.029S Salter-Harris Type II physeal fracture of unspecified calcaneus, sequela
S99.031A Salter-Harris Type III physeal fracture of right calcaneus, initial encounter for closed fracture
S99.031B Salter-Harris Type III physeal fracture of right calcaneus, initial encounter for open fracture
S99.031D Salter-Harris Type III physeal fracture of right calcaneus, subsequent encounter for fracture with routine healing
S99.031G Salter-Harris Type III physeal fracture of right calcaneus, subsequent encounter for fracture with delayed healing
S99.031K Salter-Harris Type III physeal fracture of right calcaneus, subsequent encounter for fracture with nonunion
S99.031P Salter-Harris Type III physeal fracture of right calcaneus, subsequent encounter for fracture with malunion
S99.031S Salter-Harris Type III physeal fracture of right calcaneus, sequela
S99.032A Salter-Harris Type III physeal fracture of left calcaneus, initial encounter for closed fracture
S99.032B Salter-Harris Type III physeal fracture of left calcaneus, initial encounter for open fracture
S99.032D Salter-Harris Type III physeal fracture of left calcaneus, subsequent encounter for fracture with routine healing
S99.032G Salter-Harris Type III physeal fracture of left calcaneus, subsequent encounter for fracture with delayed healing
S99.032K Salter-Harris Type III physeal fracture of left calcaneus, subsequent encounter for fracture with nonunion
S99.032P Salter-Harris Type III physeal fracture of left calcaneus, subsequent encounter for fracture with malunion
S99.032S Salter-Harris Type III physeal fracture of left calcaneus, sequela
S99.039A Salter-Harris Type III physeal fracture of unspecified calcaneus, initial encounter for closed fracture
S99.039B Salter-Harris Type III physeal fracture of unspecified calcaneus, initial encounter for open fracture
S99.039D Salter-Harris Type III physeal fracture of unspecified calcaneus, subsequent encounter for fracture with routine healing
S99.039G Salter-Harris Type III physeal fracture of unspecified calcaneus, subsequent encounter for fracture with delayed healing
S99.039K Salter-Harris Type III physeal fracture of unspecified calcaneus, subsequent encounter for fracture with nonunion
S99.039P Salter-Harris Type III physeal fracture of unspecified calcaneus, subsequent encounter for fracture with malunion
S99.039S Salter-Harris Type III physeal fracture of unspecified calcaneus, sequela
S99.041A Salter-Harris Type IV physeal fracture of right calcaneus, initial encounter for closed fracture
S99.041B Salter-Harris Type IV physeal fracture of right calcaneus, initial encounter for open fracture
S99.041D Salter-Harris Type IV physeal fracture of right calcaneus, subsequent encounter for fracture with routine healing
S99.041G Salter-Harris Type IV physeal fracture of right calcaneus, subsequent encounter for fracture with delayed healing
S99.041K Salter-Harris Type IV physeal fracture of right calcaneus, subsequent encounter for fracture with nonunion
S99.041P Salter-Harris Type IV physeal fracture of right calcaneus, subsequent encounter for fracture with malunion
S99.041S Salter-Harris Type IV physeal fracture of right calcaneus, sequela
S99.042A Salter-Harris Type IV physeal fracture of left calcaneus, initial encounter for closed fracture
S99.042B Salter-Harris Type IV physeal fracture of left calcaneus, initial encounter for open fracture
S99.042D Salter-Harris Type IV physeal fracture of left calcaneus, subsequent encounter for fracture with routine healing
S99.042G Salter-Harris Type IV physeal fracture of left calcaneus, subsequent encounter for fracture with delayed healing
S99.042K Salter-Harris Type IV physeal fracture of left calcaneus, subsequent encounter for fracture with nonunion
S99.042P Salter-Harris Type IV physeal fracture of left calcaneus, subsequent encounter for fracture with malunion
S99.042S Salter-Harris Type IV physeal fracture of left calcaneus, sequela
S99.049A Salter-Harris Type IV physeal fracture of unspecified calcaneus, initial encounter for closed fracture
S99.049B Salter-Harris Type IV physeal fracture of unspecified calcaneus, initial encounter for open fracture
S99.049D Salter-Harris Type IV physeal fracture of unspecified calcaneus, subsequent encounter for fracture with routine healing
S99.049G Salter-Harris Type IV physeal fracture of unspecified calcaneus, subsequent encounter for fracture with delayed healing
S99.049K Salter-Harris Type IV physeal fracture of unspecified calcaneus, subsequent encounter for fracture with nonunion
S99.049P Salter-Harris Type IV physeal fracture of unspecified calcaneus, subsequent encounter for fracture with malunion
S99.049S Salter-Harris Type IV physeal fracture of unspecified calcaneus, sequela
S99.091A Other physeal fracture of right calcaneus, initial encounter for closed fracture
S99.091B Other physeal fracture of right calcaneus, initial encounter for open fracture
S99.091D Other physeal fracture of right calcaneus, subsequent encounter for fracture with routine healing
S99.091G Other physeal fracture of right calcaneus, subsequent encounter for fracture with delayed healing
S99.091K Other physeal fracture of right calcaneus, subsequent encounter for fracture with nonunion
S99.091P Other physeal fracture of right calcaneus, subsequent encounter for fracture with malunion
S99.091S Other physeal fracture of right calcaneus, sequela
S99.092A Other physeal fracture of left calcaneus, initial encounter for closed fracture
S99.092B Other physeal fracture of left calcaneus, initial encounter for open fracture
S99.092D Other physeal fracture of left calcaneus, subsequent encounter for fracture with routine healing
S99.092G Other physeal fracture of left calcaneus, subsequent encounter for fracture with delayed healing
S99.092K Other physeal fracture of left calcaneus, subsequent encounter for fracture with nonunion
S99.092P Other physeal fracture of left calcaneus, subsequent encounter for fracture with malunion
S99.092S Other physeal fracture of left calcaneus, sequela
S99.099A Other physeal fracture of unspecified calcaneus, initial encounter for closed fracture
S99.099B Other physeal fracture of unspecified calcaneus, initial encounter for open fracture
S99.099D Other physeal fracture of unspecified calcaneus, subsequent encounter for fracture with routine healing
S99.099G Other physeal fracture of unspecified calcaneus, subsequent encounter for fracture with delayed healing
S99.099K Other physeal fracture of unspecified calcaneus, subsequent encounter for fracture with nonunion
S99.099P Other physeal fracture of unspecified calcaneus, subsequent encounter for fracture with malunion
S99.099S Other physeal fracture of unspecified calcaneus, sequela
S99.101A Unspecified physeal fracture of right metatarsal, initial encounter for closed fracture
S99.101B Unspecified physeal fracture of right metatarsal, initial encounter for open fracture
S99.101D Unspecified physeal fracture of right metatarsal, subsequent encounter for fracture with routine healing
S99.101G Unspecified physeal fracture of right metatarsal, subsequent encounter for fracture with delayed healing
S99.101K Unspecified physeal fracture of right metatarsal, subsequent encounter for fracture with nonunion
S99.101P Unspecified physeal fracture of right metatarsal, subsequent encounter for fracture with malunion
S99.101S Unspecified physeal fracture of right metatarsal, sequela
S99.102A Unspecified physeal fracture of left metatarsal, initial encounter for closed fracture
S99.102B Unspecified physeal fracture of left metatarsal, initial encounter for open fracture
S99.102D Unspecified physeal fracture of left metatarsal, subsequent encounter for fracture with routine healing
S99.102G Unspecified physeal fracture of left metatarsal, subsequent encounter for fracture with delayed healing
S99.102K Unspecified physeal fracture of left metatarsal, subsequent encounter for fracture with nonunion
S99.102P Unspecified physeal fracture of left metatarsal, subsequent encounter for fracture with malunion
S99.102S Unspecified physeal fracture of left metatarsal, sequela
S99.109A Unspecified physeal fracture of unspecified metatarsal, initial encounter for closed fracture
S99.109B Unspecified physeal fracture of unspecified metatarsal, initial encounter for open fracture
S99.109D Unspecified physeal fracture of unspecified metatarsal, subsequent encounter for fracture with routine healing
S99.109G Unspecified physeal fracture of unspecified metatarsal, subsequent encounter for fracture with delayed healing
S99.109K Unspecified physeal fracture of unspecified metatarsal, subsequent encounter for fracture with nonunion
S99.109P Unspecified physeal fracture of unspecified metatarsal, subsequent encounter for fracture with malunion
S99.109S Unspecified physeal fracture of unspecified metatarsal, sequela
S99.111A Salter-Harris Type I physeal fracture of right metatarsal, initial encounter for closed fracture
S99.111B Salter-Harris Type I physeal fracture of right metatarsal, initial encounter for open fracture
S99.111D Salter-Harris Type I physeal fracture of right metatarsal, subsequent encounter for fracture with routine healing
S99.111G Salter-Harris Type I physeal fracture of right metatarsal, subsequent encounter for fracture with delayed healing
S99.111K Salter-Harris Type I physeal fracture of right metatarsal, subsequent encounter for fracture with nonunion
S99.111P Salter-Harris Type I physeal fracture of right metatarsal, subsequent encounter for fracture with malunion
S99.111S Salter-Harris Type I physeal fracture of right metatarsal, sequela
S99.112A Salter-Harris Type I physeal fracture of left metatarsal, initial encounter for closed fracture
S99.112B Salter-Harris Type I physeal fracture of left metatarsal, initial encounter for open fracture
S99.112D Salter-Harris Type I physeal fracture of left metatarsal, subsequent encounter for fracture with routine healing
S99.112G Salter-Harris Type I physeal fracture of left metatarsal, subsequent encounter for fracture with delayed healing
S99.112K Salter-Harris Type I physeal fracture of left metatarsal, subsequent encounter for fracture with nonunion
S99.112P Salter-Harris Type I physeal fracture of left metatarsal, subsequent encounter for fracture with malunion
S99.112S Salter-Harris Type I physeal fracture of left metatarsal, sequela
S99.119A Salter-Harris Type I physeal fracture of unspecified metatarsal, initial encounter for closed fracture
S99.119B Salter-Harris Type I physeal fracture of unspecified metatarsal, initial encounter for open fracture
S99.119D Salter-Harris Type I physeal fracture of unspecified metatarsal, subsequent encounter for fracture with routine healing
S99.119G Salter-Harris Type I physeal fracture of unspecified metatarsal, subsequent encounter for fracture with delayed healing
S99.119K Salter-Harris Type I physeal fracture of unspecified metatarsal, subsequent encounter for fracture with nonunion
S99.119P Salter-Harris Type I physeal fracture of unspecified metatarsal, subsequent encounter for fracture with malunion
S99.119S Salter-Harris Type I physeal fracture of unspecified metatarsal, sequela
S99.121A Salter-Harris Type II physeal fracture of right metatarsal, initial encounter for closed fracture
S99.121B Salter-Harris Type II physeal fracture of right metatarsal, initial encounter for open fracture
S99.121D Salter-Harris Type II physeal fracture of right metatarsal, subsequent encounter for fracture with routine healing
S99.121G Salter-Harris Type II physeal fracture of right metatarsal, subsequent encounter for fracture with delayed healing
S99.121K Salter-Harris Type II physeal fracture of right metatarsal, subsequent encounter for fracture with nonunion
S99.121P Salter-Harris Type II physeal fracture of right metatarsal, subsequent encounter for fracture with malunion
S99.121S Salter-Harris Type II physeal fracture of right metatarsal, sequela
S99.122A Salter-Harris Type II physeal fracture of left metatarsal, initial encounter for closed fracture
S99.122B Salter-Harris Type II physeal fracture of left metatarsal, initial encounter for open fracture
S99.122D Salter-Harris Type II physeal fracture of left metatarsal, subsequent encounter for fracture with routine healing
S99.122G Salter-Harris Type II physeal fracture of left metatarsal, subsequent encounter for fracture with delayed healing
S99.122K Salter-Harris Type II physeal fracture of left metatarsal, subsequent encounter for fracture with nonunion
S99.122P Salter-Harris Type II physeal fracture of left metatarsal, subsequent encounter for fracture with malunion
S99.122S Salter-Harris Type II physeal fracture of left metatarsal, sequela
S99.129A Salter-Harris Type II physeal fracture of unspecified metatarsal, initial encounter for closed fracture
S99.129B Salter-Harris Type II physeal fracture of unspecified metatarsal, initial encounter for open fracture
S99.129D Salter-Harris Type II physeal fracture of unspecified metatarsal, subsequent encounter for fracture with routine healing
S99.129G Salter-Harris Type II physeal fracture of unspecified metatarsal, subsequent encounter for fracture with delayed healing
S99.129K Salter-Harris Type II physeal fracture of unspecified metatarsal, subsequent encounter for fracture with nonunion
S99.129P Salter-Harris Type II physeal fracture of unspecified metatarsal, subsequent encounter for fracture with malunion
S99.129S Salter-Harris Type II physeal fracture of unspecified metatarsal, sequela
S99.131A Salter-Harris Type III physeal fracture of right metatarsal, initial encounter for closed fracture
S99.131B Salter-Harris Type III physeal fracture of right metatarsal, initial encounter for open fracture
S99.131D Salter-Harris Type III physeal fracture of right metatarsal, subsequent encounter for fracture with routine healing
S99.131G Salter-Harris Type III physeal fracture of right metatarsal, subsequent encounter for fracture with delayed healing
S99.131K Salter-Harris Type III physeal fracture of right metatarsal, subsequent encounter for fracture with nonunion
S99.131P Salter-Harris Type III physeal fracture of right metatarsal, subsequent encounter for fracture with malunion
S99.131S Salter-Harris Type III physeal fracture of right metatarsal, sequela
S99.132A Salter-Harris Type III physeal fracture of left metatarsal, initial encounter for closed fracture
S99.132B Salter-Harris Type III physeal fracture of left metatarsal, initial encounter for open fracture
S99.132D Salter-Harris Type III physeal fracture of left metatarsal, subsequent encounter for fracture with routine healing
S99.132G Salter-Harris Type III physeal fracture of left metatarsal, subsequent encounter for fracture with delayed healing
S99.132K Salter-Harris Type III physeal fracture of left metatarsal, subsequent encounter for fracture with nonunion
S99.132P Salter-Harris Type III physeal fracture of left metatarsal, subsequent encounter for fracture with malunion
S99.132S Salter-Harris Type III physeal fracture of left metatarsal, sequela
S99.139A Salter-Harris Type III physeal fracture of unspecified metatarsal, initial encounter for closed fracture
S99.139B Salter-Harris Type III physeal fracture of unspecified metatarsal, initial encounter for open fracture
S99.139D Salter-Harris Type III physeal fracture of unspecified metatarsal, subsequent encounter for fracture with routine healing
S99.139G Salter-Harris Type III physeal fracture of unspecified metatarsal, subsequent encounter for fracture with delayed healing
S99.139K Salter-Harris Type III physeal fracture of unspecified metatarsal, subsequent encounter for fracture with nonunion
S99.139P Salter-Harris Type III physeal fracture of unspecified metatarsal, subsequent encounter for fracture with malunion
S99.139S Salter-Harris Type III physeal fracture of unspecified metatarsal, sequela
S99.141A Salter-Harris Type IV physeal fracture of right metatarsal, initial encounter for closed fracture
S99.141B Salter-Harris Type IV physeal fracture of right metatarsal, initial encounter for open fracture
S99.141D Salter-Harris Type IV physeal fracture of right metatarsal, subsequent encounter for fracture with routine healing
S99.141G Salter-Harris Type IV physeal fracture of right metatarsal, subsequent encounter for fracture with delayed healing
S99.141K Salter-Harris Type IV physeal fracture of right metatarsal, subsequent encounter for fracture with nonunion
S99.141P Salter-Harris Type IV physeal fracture of right metatarsal, subsequent encounter for fracture with malunion
S99.141S Salter-Harris Type IV physeal fracture of right metatarsal, sequela
S99.142A Salter-Harris Type IV physeal fracture of left metatarsal, initial encounter for closed fracture
S99.142B Salter-Harris Type IV physeal fracture of left metatarsal, initial encounter for open fracture
S99.142D Salter-Harris Type IV physeal fracture of left metatarsal, subsequent encounter for fracture with routine healing
S99.142G Salter-Harris Type IV physeal fracture of left metatarsal, subsequent encounter for fracture with delayed healing
S99.142K Salter-Harris Type IV physeal fracture of left metatarsal, subsequent encounter for fracture with nonunion
S99.142P Salter-Harris Type IV physeal fracture of left metatarsal, subsequent encounter for fracture with malunion
S99.142S Salter-Harris Type IV physeal fracture of left metatarsal, sequela
S99.149A Salter-Harris Type IV physeal fracture of unspecified metatarsal, initial encounter for closed fracture
S99.149B Salter-Harris Type IV physeal fracture of unspecified metatarsal, initial encounter for open fracture
S99.149D Salter-Harris Type IV physeal fracture of unspecified metatarsal, subsequent encounter for fracture with routine healing
S99.149G Salter-Harris Type IV physeal fracture of unspecified metatarsal, subsequent encounter for fracture with delayed healing
S99.149K Salter-Harris Type IV physeal fracture of unspecified metatarsal, subsequent encounter for fracture with nonunion
S99.149P Salter-Harris Type IV physeal fracture of unspecified metatarsal, subsequent encounter for fracture with malunion
S99.149S Salter-Harris Type IV physeal fracture of unspecified metatarsal, sequela
S99.191A Other physeal fracture of right metatarsal, initial encounter for closed fracture
S99.191B Other physeal fracture of right metatarsal, initial encounter for open fracture
S99.191D Other physeal fracture of right metatarsal, subsequent encounter for fracture with routine healing
S99.191G Other physeal fracture of right metatarsal, subsequent encounter for fracture with delayed healing
S99.191K Other physeal fracture of right metatarsal, subsequent encounter for fracture with nonunion
S99.191P Other physeal fracture of right metatarsal, subsequent encounter for fracture with malunion
S99.191S Other physeal fracture of right metatarsal, sequela
S99.192A Other physeal fracture of left metatarsal, initial encounter for closed fracture
S99.192B Other physeal fracture of left metatarsal, initial encounter for open fracture
S99.192D Other physeal fracture of left metatarsal, subsequent encounter for fracture with routine healing
S99.192G Other physeal fracture of left metatarsal, subsequent encounter for fracture with delayed healing
S99.192K Other physeal fracture of left metatarsal, subsequent encounter for fracture with nonunion
S99.192P Other physeal fracture of left metatarsal, subsequent encounter for fracture with malunion
S99.192S Other physeal fracture of left metatarsal, sequela
S99.199A Other physeal fracture of unspecified metatarsal, initial encounter for closed fracture
S99.199B Other physeal fracture of unspecified metatarsal, initial encounter for open fracture
S99.199D Other physeal fracture of unspecified metatarsal, subsequent encounter for fracture with routine healing
S99.199G Other physeal fracture of unspecified metatarsal, subsequent encounter for fracture with delayed healing
S99.199K Other physeal fracture of unspecified metatarsal, subsequent encounter for fracture with nonunion
S99.199P Other physeal fracture of unspecified metatarsal, subsequent encounter for fracture with malunion
S99.199S Other physeal fracture of unspecified metatarsal, sequela
S99.201A Unspecified physeal fracture of phalanx of right toe, initial encounter for closed fracture
S99.201B Unspecified physeal fracture of phalanx of right toe, initial encounter for open fracture
S99.201D Unspecified physeal fracture of phalanx of right toe, subsequent encounter for fracture with routine healing
S99.201G Unspecified physeal fracture of phalanx of right toe, subsequent encounter for fracture with delayed healing
S99.201K Unspecified physeal fracture of phalanx of right toe, subsequent encounter for fracture with nonunion
S99.201P Unspecified physeal fracture of phalanx of right toe, subsequent encounter for fracture with malunion
S99.201S Unspecified physeal fracture of phalanx of right toe, sequela
S99.202A Unspecified physeal fracture of phalanx of left toe, initial encounter for closed fracture
S99.202B Unspecified physeal fracture of phalanx of left toe, initial encounter for open fracture
S99.202D Unspecified physeal fracture of phalanx of left toe, subsequent encounter for fracture with routine healing
S99.202G Unspecified physeal fracture of phalanx of left toe, subsequent encounter for fracture with delayed healing
S99.202K Unspecified physeal fracture of phalanx of left toe, subsequent encounter for fracture with nonunion
S99.202P Unspecified physeal fracture of phalanx of left toe, subsequent encounter for fracture with malunion
S99.202S Unspecified physeal fracture of phalanx of left toe, sequela
S99.209A Unspecified physeal fracture of phalanx of unspecified toe, initial encounter for closed fracture
S99.209B Unspecified physeal fracture of phalanx of unspecified toe, initial encounter for open fracture
S99.209D Unspecified physeal fracture of phalanx of unspecified toe, subsequent encounter for fracture with routine healing
S99.209G Unspecified physeal fracture of phalanx of unspecified toe, subsequent encounter for fracture with delayed healing
S99.209K Unspecified physeal fracture of phalanx of unspecified toe, subsequent encounter for fracture with nonunion
S99.209P Unspecified physeal fracture of phalanx of unspecified toe, subsequent encounter for fracture with malunion
S99.209S Unspecified physeal fracture of phalanx of unspecified toe, sequela
S99.211A Salter-Harris Type I physeal fracture of phalanx of right toe, initial encounter for closed fracture
S99.211B Salter-Harris Type I physeal fracture of phalanx of right toe, initial encounter for open fracture
S99.211D Salter-Harris Type I physeal fracture of phalanx of right toe, subsequent encounter for fracture with routine healing
S99.211G Salter-Harris Type I physeal fracture of phalanx of right toe, subsequent encounter for fracture with delayed healing
S99.211K Salter-Harris Type I physeal fracture of phalanx of right toe, subsequent encounter for fracture with nonunion
S99.211P Salter-Harris Type I physeal fracture of phalanx of right toe, subsequent encounter for fracture with malunion
S99.211S Salter-Harris Type I physeal fracture of phalanx of right toe, sequela
S99.212A Salter-Harris Type I physeal fracture of phalanx of left toe, initial encounter for closed fracture
S99.212B Salter-Harris Type I physeal fracture of phalanx of left toe, initial encounter for open fracture
S99.212D Salter-Harris Type I physeal fracture of phalanx of left toe, subsequent encounter for fracture with routine healing
S99.212G Salter-Harris Type I physeal fracture of phalanx of left toe, subsequent encounter for fracture with delayed healing
S99.212K Salter-Harris Type I physeal fracture of phalanx of left toe, subsequent encounter for fracture with nonunion
S99.212P Salter-Harris Type I physeal fracture of phalanx of left toe, subsequent encounter for fracture with malunion
S99.212S Salter-Harris Type I physeal fracture of phalanx of left toe, sequela
S99.219A Salter-Harris Type I physeal fracture of phalanx of unspecified toe, initial encounter for closed fracture
S99.219B Salter-Harris Type I physeal fracture of phalanx of unspecified toe, initial encounter for open fracture
S99.219D Salter-Harris Type I physeal fracture of phalanx of unspecified toe, subsequent encounter for fracture with routine healing
S99.219G Salter-Harris Type I physeal fracture of phalanx of unspecified toe, subsequent encounter for fracture with delayed healing
S99.219K Salter-Harris Type I physeal fracture of phalanx of unspecified toe, subsequent encounter for fracture with nonunion
S99.219P Salter-Harris Type I physeal fracture of phalanx of unspecified toe, subsequent encounter for fracture with malunion
S99.219S Salter-Harris Type I physeal fracture of phalanx of unspecified toe, sequela
S99.221A Salter-Harris Type II physeal fracture of phalanx of right toe, initial encounter for closed fracture
S99.221B Salter-Harris Type II physeal fracture of phalanx of right toe, initial encounter for open fracture
S99.221D Salter-Harris Type II physeal fracture of phalanx of right toe, subsequent encounter for fracture with routine healing
S99.221G Salter-Harris Type II physeal fracture of phalanx of right toe, subsequent encounter for fracture with delayed healing
S99.221K Salter-Harris Type II physeal fracture of phalanx of right toe, subsequent encounter for fracture with nonunion
S99.221P Salter-Harris Type II physeal fracture of phalanx of right toe, subsequent encounter for fracture with malunion
S99.221S Salter-Harris Type II physeal fracture of phalanx of right toe, sequela
S99.222A Salter-Harris Type II physeal fracture of phalanx of left toe, initial encounter for closed fracture
S99.222B Salter-Harris Type II physeal fracture of phalanx of left toe, initial encounter for open fracture
S99.222D Salter-Harris Type II physeal fracture of phalanx of left toe, subsequent encounter for fracture with routine healing
S99.222G Salter-Harris Type II physeal fracture of phalanx of left toe, subsequent encounter for fracture with delayed healing
S99.222K Salter-Harris Type II physeal fracture of phalanx of left toe, subsequent encounter for fracture with nonunion
S99.222P Salter-Harris Type II physeal fracture of phalanx of left toe, subsequent encounter for fracture with malunion
S99.222S Salter-Harris Type II physeal fracture of phalanx of left toe, sequela
S99.229A Salter-Harris Type II physeal fracture of phalanx of unspecified toe, initial encounter for closed fracture
S99.229B Salter-Harris Type II physeal fracture of phalanx of unspecified toe, initial encounter for open fracture
S99.229D Salter-Harris Type II physeal fracture of phalanx of unspecified toe, subsequent encounter for fracture with routine healing
S99.229G Salter-Harris Type II physeal fracture of phalanx of unspecified toe, subsequent encounter for fracture with delayed healing
S99.229K Salter-Harris Type II physeal fracture of phalanx of unspecified toe, subsequent encounter for fracture with nonunion
S99.229P Salter-Harris Type II physeal fracture of phalanx of unspecified toe, subsequent encounter for fracture with malunion
S99.229S Salter-Harris Type II physeal fracture of phalanx of unspecified toe, sequela
S99.231A Salter-Harris Type III physeal fracture of phalanx of right toe, initial encounter for closed fracture
S99.231B Salter-Harris Type III physeal fracture of phalanx of right toe, initial encounter for open fracture
S99.231D Salter-Harris Type III physeal fracture of phalanx of right toe, subsequent encounter for fracture with routine healing
S99.231G Salter-Harris Type III physeal fracture of phalanx of right toe, subsequent encounter for fracture with delayed healing
S99.231K Salter-Harris Type III physeal fracture of phalanx of right toe, subsequent encounter for fracture with nonunion
S99.231P Salter-Harris Type III physeal fracture of phalanx of right toe, subsequent encounter for fracture with malunion
S99.231S Salter-Harris Type III physeal fracture of phalanx of right toe, sequela
S99.232A Salter-Harris Type III physeal fracture of phalanx of left toe, initial encounter for closed fracture
S99.232B Salter-Harris Type III physeal fracture of phalanx of left toe, initial encounter for open fracture
S99.232D Salter-Harris Type III physeal fracture of phalanx of left toe, subsequent encounter for fracture with routine healing
S99.232G Salter-Harris Type III physeal fracture of phalanx of left toe, subsequent encounter for fracture with delayed healing
S99.232K Salter-Harris Type III physeal fracture of phalanx of left toe, subsequent encounter for fracture with nonunion
S99.232P Salter-Harris Type III physeal fracture of phalanx of left toe, subsequent encounter for fracture with malunion
S99.232S Salter-Harris Type III physeal fracture of phalanx of left toe, sequela
S99.239A Salter-Harris Type III physeal fracture of phalanx of unspecified toe, initial encounter for closed fracture
S99.239B Salter-Harris Type III physeal fracture of phalanx of unspecified toe, initial encounter for open fracture
S99.239D Salter-Harris Type III physeal fracture of phalanx of unspecified toe, subsequent encounter for fracture with routine healing
S99.239G Salter-Harris Type III physeal fracture of phalanx of unspecified toe, subsequent encounter for fracture with delayed healing
S99.239K Salter-Harris Type III physeal fracture of phalanx of unspecified toe, subsequent encounter for fracture with nonunion
S99.239P Salter-Harris Type III physeal fracture of phalanx of unspecified toe, subsequent encounter for fracture with malunion
S99.239S Salter-Harris Type III physeal fracture of phalanx of unspecified toe, sequela
S99.241A Salter-Harris Type IV physeal fracture of phalanx of right toe, initial encounter for closed fracture
S99.241B Salter-Harris Type IV physeal fracture of phalanx of right toe, initial encounter for open fracture
S99.241D Salter-Harris Type IV physeal fracture of phalanx of right toe, subsequent encounter for fracture with routine healing
S99.241G Salter-Harris Type IV physeal fracture of phalanx of right toe, subsequent encounter for fracture with delayed healing
S99.241K Salter-Harris Type IV physeal fracture of phalanx of right toe, subsequent encounter for fracture with nonunion
S99.241P Salter-Harris Type IV physeal fracture of phalanx of right toe, subsequent encounter for fracture with malunion
S99.241S Salter-Harris Type IV physeal fracture of phalanx of right toe, sequela
S99.242A Salter-Harris Type IV physeal fracture of phalanx of left toe, initial encounter for closed fracture
S99.242B Salter-Harris Type IV physeal fracture of phalanx of left toe, initial encounter for open fracture
S99.242D Salter-Harris Type IV physeal fracture of phalanx of left toe, subsequent encounter for fracture with routine healing
S99.242G Salter-Harris Type IV physeal fracture of phalanx of left toe, subsequent encounter for fracture with delayed healing
S99.242K Salter-Harris Type IV physeal fracture of phalanx of left toe, subsequent encounter for fracture with nonunion
S99.242P Salter-Harris Type IV physeal fracture of phalanx of left toe, subsequent encounter for fracture with malunion
S99.242S Salter-Harris Type IV physeal fracture of phalanx of left toe, sequela
S99.249A Salter-Harris Type IV physeal fracture of phalanx of unspecified toe, initial encounter for closed fracture
S99.249B Salter-Harris Type IV physeal fracture of phalanx of unspecified toe, initial encounter for open fracture
S99.249D Salter-Harris Type IV physeal fracture of phalanx of unspecified toe, subsequent encounter for fracture with routine healing
S99.249G Salter-Harris Type IV physeal fracture of phalanx of unspecified toe, subsequent encounter for fracture with delayed healing
S99.249K Salter-Harris Type IV physeal fracture of phalanx of unspecified toe, subsequent encounter for fracture with nonunion
S99.249P Salter-Harris Type IV physeal fracture of phalanx of unspecified toe, subsequent encounter for fracture with malunion
S99.249S Salter-Harris Type IV physeal fracture of phalanx of unspecified toe, sequela
S99.291A Other physeal fracture of phalanx of right toe, initial encounter for closed fracture
S99.291B Other physeal fracture of phalanx of right toe, initial encounter for open fracture
S99.291D Other physeal fracture of phalanx of right toe, subsequent encounter for fracture with routine healing
S99.291G Other physeal fracture of phalanx of right toe, subsequent encounter for fracture with delayed healing
S99.291K Other physeal fracture of phalanx of right toe, subsequent encounter for fracture with nonunion
S99.291P Other physeal fracture of phalanx of right toe, subsequent encounter for fracture with malunion
S99.291S Other physeal fracture of phalanx of right toe, sequela
S99.292A Other physeal fracture of phalanx of left toe, initial encounter for closed fracture
S99.292B Other physeal fracture of phalanx of left toe, initial encounter for open fracture
S99.292D Other physeal fracture of phalanx of left toe, subsequent encounter for fracture with routine healing
S99.292G Other physeal fracture of phalanx of left toe, subsequent encounter for fracture with delayed healing
S99.292K Other physeal fracture of phalanx of left toe, subsequent encounter for fracture with nonunion
S99.292P Other physeal fracture of phalanx of left toe, subsequent encounter for fracture with malunion
S99.292S Other physeal fracture of phalanx of left toe, sequela
S99.299A Other physeal fracture of phalanx of unspecified toe, initial encounter for closed fracture
S99.299B Other physeal fracture of phalanx of unspecified toe, initial encounter for open fracture
S99.299D Other physeal fracture of phalanx of unspecified toe, subsequent encounter for fracture with routine healing
S99.299G Other physeal fracture of phalanx of unspecified toe, subsequent encounter for fracture with delayed healing
S99.299K Other physeal fracture of phalanx of unspecified toe, subsequent encounter for fracture with nonunion
S99.299P Other physeal fracture of phalanx of unspecified toe, subsequent encounter for fracture with malunion
S99.299S Other physeal fracture of phalanx of unspecified toe, sequela
T82.855A Stenosis of coronary artery stent, initial encounter
T82.855D Stenosis of coronary artery stent, subsequent encounter
T82.855S Stenosis of coronary artery stent, sequela
T82.856A Stenosis of peripheral vascular stent, initial encounter
T82.856D Stenosis of peripheral vascular stent, subsequent encounter
T82.856S Stenosis of peripheral vascular stent, sequela
T83.011A Breakdown (mechanical) of indwelling urethral catheter, initial encounter
T83.011D Breakdown (mechanical) of indwelling urethral catheter, subsequent encounter
T83.011S Breakdown (mechanical) of indwelling urethral catheter, sequela
T83.012A Breakdown (mechanical) of nephrostomy catheter, initial encounter
T83.012D Breakdown (mechanical) of nephrostomy catheter, subsequent encounter
T83.012S Breakdown (mechanical) of nephrostomy catheter, sequela
T83.021A Displacement of indwelling urethral catheter, initial encounter
T83.021D Displacement of indwelling urethral catheter, subsequent encounter
T83.021S Displacement of indwelling urethral catheter, sequela
T83.022A Displacement of nephrostomy catheter, initial encounter
T83.022D Displacement of nephrostomy catheter, subsequent encounter
T83.022S Displacement of nephrostomy catheter, sequela
T83.031A Leakage of indwelling urethral catheter, initial encounter
T83.031D Leakage of indwelling urethral catheter, subsequent encounter
T83.031S Leakage of indwelling urethral catheter, sequela
T83.032A Leakage of nephrostomy catheter, initial encounter
T83.032D Leakage of nephrostomy catheter, subsequent encounter
T83.032S Leakage of nephrostomy catheter, sequela
T83.091A Other mechanical complication of indwelling urethral catheter, initial encounter
T83.091D Other mechanical complication of indwelling urethral catheter, subsequent encounter
T83.091S Other mechanical complication of indwelling urethral catheter, sequela
T83.092A Other mechanical complication of nephrostomy catheter, initial encounter
T83.092D Other mechanical complication of nephrostomy catheter, subsequent encounter
T83.092S Other mechanical complication of nephrostomy catheter, sequela
T83.113A Breakdown (mechanical) of other urinary stents, initial encounter
T83.113D Breakdown (mechanical) of other urinary stents, subsequent encounter
T83.113S Breakdown (mechanical) of other urinary stents, sequela
T83.123A Displacement of other urinary stents, initial encounter
T83.123D Displacement of other urinary stents, subsequent encounter
T83.123S Displacement of other urinary stents, sequela
T83.193A Other mechanical complication of other urinary stent, initial encounter
T83.193D Other mechanical complication of other urinary stent, subsequent encounter
T83.193S Other mechanical complication of other urinary stent, sequela
T83.24XA Erosion of graft of urinary organ, initial encounter
T83.24XD Erosion of graft of urinary organ, subsequent encounter
T83.24XS Erosion of graft of urinary organ, sequela
T83.25XA Exposure of graft of urinary organ, initial encounter
T83.25XD Exposure of graft of urinary organ, subsequent encounter
T83.25XS Exposure of graft of urinary organ, sequela
T83.411A Breakdown (mechanical) of implanted testicular prosthesis, initial encounter
T83.411D Breakdown (mechanical) of implanted testicular prosthesis, subsequent encounter
T83.411S Breakdown (mechanical) of implanted testicular prosthesis, sequela
T83.421A Displacement of implanted testicular prosthesis, initial encounter
T83.421D Displacement of implanted testicular prosthesis, subsequent encounter
T83.421S Displacement of implanted testicular prosthesis, sequela
T83.491A Other mechanical complication of implanted testicular prosthesis, initial encounter
T83.491D Other mechanical complication of implanted testicular prosthesis, subsequent encounter
T83.491S Other mechanical complication of implanted testicular prosthesis, sequela
T83.510A Infection and inflammatory reaction due to cystostomy catheter, initial encounter
T83.510D Infection and inflammatory reaction due to cystostomy catheter, subsequent encounter
T83.510S Infection and inflammatory reaction due to cystostomy catheter, sequela
T83.511A Infection and inflammatory reaction due to indwelling urethral catheter, initial encounter
T83.511D Infection and inflammatory reaction due to indwelling urethral catheter, subsequent encounter
T83.511S Infection and inflammatory reaction due to indwelling urethral catheter, sequela
T83.512A Infection and inflammatory reaction due to nephrostomy catheter, initial encounter
T83.512D Infection and inflammatory reaction due to nephrostomy catheter, subsequent encounter
T83.512S Infection and inflammatory reaction due to nephrostomy catheter, sequela
T83.518A Infection and inflammatory reaction due to other urinary catheter, initial encounter
T83.518D Infection and inflammatory reaction due to other urinary catheter, subsequent encounter
T83.518S Infection and inflammatory reaction due to other urinary catheter, sequela
T83.590A Infection and inflammatory reaction due to implanted urinary neurostimulation device, initial encounter
T83.590D Infection and inflammatory reaction due to implanted urinary neurostimulation device, subsequent encounter
T83.590S Infection and inflammatory reaction due to implanted urinary neurostimulation device, sequela
T83.591A Infection and inflammatory reaction due to implanted urinary sphincter, initial encounter
T83.591D Infection and inflammatory reaction due to implanted urinary sphincter, subsequent encounter
T83.591S Infection and inflammatory reaction due to implanted urinary sphincter, sequela
T83.592A Infection and inflammatory reaction due to indwelling ureteral stent, initial encounter
T83.592D Infection and inflammatory reaction due to indwelling ureteral stent, subsequent encounter
T83.592S Infection and inflammatory reaction due to indwelling ureteral stent, sequela
T83.593A Infection and inflammatory reaction due to other urinary stents, initial encounter
T83.593D Infection and inflammatory reaction due to other urinary stents, subsequent encounter
T83.593S Infection and inflammatory reaction due to other urinary stents, sequela
T83.598A Infection and inflammatory reaction due to other prosthetic device, implant and graft in urinary system, initial encounter
T83.598D Infection and inflammatory reaction due to other prosthetic device, implant and graft in urinary system, subsequent encounter
T83.598S Infection and inflammatory reaction due to other prosthetic device, implant and graft in urinary system, sequela
T83.61XA Infection and inflammatory reaction due to implanted penile prosthesis, initial encounter
T83.61XD Infection and inflammatory reaction due to implanted penile prosthesis, subsequent encounter
T83.61XS Infection and inflammatory reaction due to implanted penile prosthesis, sequela
T83.62XA Infection and inflammatory reaction due to implanted testicular prosthesis, initial encounter
T83.62XD Infection and inflammatory reaction due to implanted testicular prosthesis, subsequent encounter
T83.62XS Infection and inflammatory reaction due to implanted testicular prosthesis, sequela
T83.69XA Infection and inflammatory reaction due to other prosthetic device, implant and graft in genital tract, initial encounter
T83.69XD Infection and inflammatory reaction due to other prosthetic device, implant and graft in genital tract, subsequent encounter
T83.69XS Infection and inflammatory reaction due to other prosthetic device, implant and graft in genital tract, sequela
T83.712A Erosion of implanted urethral mesh to surrounding organ or tissue, initial encounter
T83.712D Erosion of implanted urethral mesh to surrounding organ or tissue, subsequent encounter
T83.712S Erosion of implanted urethral mesh to surrounding organ or tissue, sequela
T83.713A Erosion of implanted urethral bulking agent to surrounding organ or tissue, initial encounter
T83.713D Erosion of implanted urethral bulking agent to surrounding organ or tissue, subsequent encounter
T83.713S Erosion of implanted urethral bulking agent to surrounding organ or tissue, sequela
T83.714A Erosion of implanted ureteral bulking agent to surrounding organ or tissue, initial encounter
T83.714D Erosion of implanted ureteral bulking agent to surrounding organ or tissue, subsequent encounter
T83.714S Erosion of implanted ureteral bulking agent to surrounding organ or tissue, sequela
T83.719A Erosion of other prosthetic materials to surrounding organ or tissue, initial encounter
T83.719D Erosion of other prosthetic materials to surrounding organ or tissue, subsequent encounter
T83.719S Erosion of other prosthetic materials to surrounding organ or tissue, sequela
T83.722A Exposure of implanted urethral mesh into urethra, initial encounter
T83.722D Exposure of implanted urethral mesh into urethra, subsequent encounter
T83.722S Exposure of implanted urethral mesh into urethra, sequela
T83.723A Exposure of implanted urethral bulking agent into urethra, initial encounter
T83.723D Exposure of implanted urethral bulking agent into urethra, subsequent encounter
T83.723S Exposure of implanted urethral bulking agent into urethra, sequela
T83.724A Exposure of implanted ureteral bulking agent into ureter, initial encounter
T83.724D Exposure of implanted ureteral bulking agent into ureter, subsequent encounter
T83.724S Exposure of implanted ureteral bulking agent into ureter, sequela
T83.729A Exposure of other prosthetic materials into organ or tissue, initial encounter
T83.729D Exposure of other prosthetic materials into organ or tissue, subsequent encounter
T83.729S Exposure of other prosthetic materials into organ or tissue, sequela
T83.79XA Other specified complications due to other genitourinary prosthetic materials, initial encounter
T83.79XD Other specified complications due to other genitourinary prosthetic materials, subsequent encounter
T83.79XS Other specified complications due to other genitourinary prosthetic materials, sequela
T85.113A Breakdown (mechanical) of implanted electronic neurostimulator, generator, initial encounter
T85.113D Breakdown (mechanical) of implanted electronic neurostimulator, generator, subsequent encounter
T85.113S Breakdown (mechanical) of implanted electronic neurostimulator, generator, sequela
T85.123A Displacement of implanted electronic neurostimulator, generator, initial encounter
T85.123D Displacement of implanted electronic neurostimulator, generator, subsequent encounter
T85.123S Displacement of implanted electronic neurostimulator, generator, sequela
T85.193A Other mechanical complication of implanted electronic neurostimulator, generator, initial encounter
T85.193D Other mechanical complication of implanted electronic neurostimulator, generator, subsequent encounter
T85.193S Other mechanical complication of implanted electronic neurostimulator, generator, sequela
T85.615A Breakdown (mechanical) of other nervous system device, implant or graft, initial encounter
T85.615D Breakdown (mechanical) of other nervous system device, implant or graft, subsequent encounter
T85.615S Breakdown (mechanical) of other nervous system device, implant or graft, sequela
T85.625A Displacement of other nervous system device, implant or graft, initial encounter
T85.625D Displacement of other nervous system device, implant or graft, subsequent encounter
T85.625S Displacement of other nervous system device, implant or graft, sequela
T85.635A Leakage of other nervous system device, implant or graft, initial encounter
T85.635D Leakage of other nervous system device, implant or graft, subsequent encounter
T85.635S Leakage of other nervous system device, implant or graft, sequela
T85.695A Other mechanical complication of other nervous system device, implant or graft, initial encounter
T85.695D Other mechanical complication of other nervous system device, implant or graft, subsequent encounter
T85.695S Other mechanical complication of other nervous system device, implant or graft, sequela
T85.730A Infection and inflammatory reaction due to ventricular intracranial (communicating) shunt, initial encounter
T85.730D Infection and inflammatory reaction due to ventricular intracranial (communicating) shunt, subsequent encounter
T85.730S Infection and inflammatory reaction due to ventricular intracranial (communicating) shunt, sequela
T85.731A Infection and inflammatory reaction due to implanted electronic neurostimulator of brain, electrode (lead), initial encounter
T85.731D Infection and inflammatory reaction due to implanted electronic neurostimulator of brain, electrode (lead), subsequent encounter
T85.731S Infection and inflammatory reaction due to implanted electronic neurostimulator of brain, electrode (lead), sequela
T85.732A Infection and inflammatory reaction due to implanted electronic neurostimulator of peripheral nerve, electrode (lead), initial encounter
T85.732D Infection and inflammatory reaction due to implanted electronic neurostimulator of peripheral nerve, electrode (lead), subsequent encounter
T85.732S Infection and inflammatory reaction due to implanted electronic neurostimulator of peripheral nerve, electrode (lead), sequela
T85.733A Infection and inflammatory reaction due to implanted electronic neurostimulator of spinal cord, electrode (lead), initial encounter
T85.733D Infection and inflammatory reaction due to implanted electronic neurostimulator of spinal cord, electrode (lead), subsequent encounter
T85.733S Infection and inflammatory reaction due to implanted electronic neurostimulator of spinal cord, electrode (lead), sequela
T85.734A Infection and inflammatory reaction due to implanted electronic neurostimulator, generator, initial encounter
T85.734D Infection and inflammatory reaction due to implanted electronic neurostimulator, generator, subsequent encounter
T85.734S Infection and inflammatory reaction due to implanted electronic neurostimulator, generator, sequela
T85.735A Infection and inflammatory reaction due to cranial or spinal infusion catheter, initial encounter
T85.735D Infection and inflammatory reaction due to cranial or spinal infusion catheter, subsequent encounter
T85.735S Infection and inflammatory reaction due to cranial or spinal infusion catheter, sequela
T85.738A Infection and inflammatory reaction due to other nervous system device, implant or graft, initial encounter
T85.738D Infection and inflammatory reaction due to other nervous system device, implant or graft, subsequent encounter
T85.738S Infection and inflammatory reaction due to other nervous system device, implant or graft, sequela
T85.810A Embolism due to nervous system prosthetic devices, implants and grafts, initial encounter
T85.810D Embolism due to nervous system prosthetic devices, implants and grafts, subsequent encounter
T85.810S Embolism due to nervous system prosthetic devices, implants and grafts, sequela
T85.818A Embolism due to other internal prosthetic devices, implants and grafts, initial encounter
T85.818D Embolism due to other internal prosthetic devices, implants and grafts, subsequent encounter
T85.818S Embolism due to other internal prosthetic devices, implants and grafts, sequela
T85.820A Fibrosis due to nervous system prosthetic devices, implants and grafts, initial encounter
T85.820D Fibrosis due to nervous system prosthetic devices, implants and grafts, subsequent encounter
T85.820S Fibrosis due to nervous system prosthetic devices, implants and grafts, sequela
T85.828A Fibrosis due to other internal prosthetic devices, implants and grafts, initial encounter
T85.828D Fibrosis due to other internal prosthetic devices, implants and grafts, subsequent encounter
T85.828S Fibrosis due to other internal prosthetic devices, implants and grafts, sequela
T85.830A Hemorrhage due to nervous system prosthetic devices, implants and grafts, initial encounter
T85.830D Hemorrhage due to nervous system prosthetic devices, implants and grafts, subsequent encounter
T85.830S Hemorrhage due to nervous system prosthetic devices, implants and grafts, sequela
T85.838A Hemorrhage due to other internal prosthetic devices, implants and grafts, initial encounter
T85.838D Hemorrhage due to other internal prosthetic devices, implants and grafts, subsequent encounter
T85.838S Hemorrhage due to other internal prosthetic devices, implants and grafts, sequela
T85.840A Pain due to nervous system prosthetic devices, implants and grafts, initial encounter
T85.840D Pain due to nervous system prosthetic devices, implants and grafts, subsequent encounter
T85.840S Pain due to nervous system prosthetic devices, implants and grafts, sequela
T85.848A Pain due to other internal prosthetic devices, implants and grafts, initial encounter
T85.848D Pain due to other internal prosthetic devices, implants and grafts, subsequent encounter
T85.848S Pain due to other internal prosthetic devices, implants and grafts, sequela
T85.850A Stenosis due to nervous system prosthetic devices, implants and grafts, initial encounter
T85.850D Stenosis due to nervous system prosthetic devices, implants and grafts, subsequent encounter
T85.850S Stenosis due to nervous system prosthetic devices, implants and grafts, sequela
T85.858A Stenosis due to other internal prosthetic devices, implants and grafts, initial encounter
T85.858D Stenosis due to other internal prosthetic devices, implants and grafts, subsequent encounter
T85.858S Stenosis due to other internal prosthetic devices, implants and grafts, sequela
T85.860A Thrombosis due to nervous system prosthetic devices, implants and grafts, initial encounter
T85.860D Thrombosis due to nervous system prosthetic devices, implants and grafts, subsequent encounter
T85.860S Thrombosis due to nervous system prosthetic devices, implants and grafts, sequela
T85.868A Thrombosis due to other internal prosthetic devices, implants and grafts, initial encounter
T85.868D Thrombosis due to other internal prosthetic devices, implants and grafts, subsequent encounter
T85.868S Thrombosis due to other internal prosthetic devices, implants and grafts, sequela
T85.890A Other specified complication of nervous system prosthetic devices, implants and grafts, initial encounter
T85.890D Other specified complication of nervous system prosthetic devices, implants and grafts, subsequent encounter
T85.890S Other specified complication of nervous system prosthetic devices, implants and grafts, sequela
T85.898A Other specified complication of other internal prosthetic devices, implants and grafts, initial encounter
T85.898D Other specified complication of other internal prosthetic devices, implants and grafts, subsequent encounter
T85.898S Other specified complication of other internal prosthetic devices, implants and grafts, sequela
T88.53XA Unintended awareness under general anesthesia during procedure, initial encounter
T88.53XD Unintended awareness under general anesthesia during procedure, subsequent encounter
T88.53XS Unintended awareness under general anesthesia during procedure, sequela

Chapter 20 External causes of morbidity (V00-Y99)

V47.0XXA Car driver injured in collision with fixed or stationary object in nontraffic accident, initial encounter
V47.0XXD Car driver injured in collision with fixed or stationary object in nontraffic accident, subsequent encounter
V47.0XXS Car driver injured in collision with fixed or stationary object in nontraffic accident, sequela
V47.1XXA Car passenger injured in collision with fixed or stationary object in nontraffic accident, initial encounter
V47.1XXD Car passenger injured in collision with fixed or stationary object in nontraffic accident, subsequent encounter
V47.1XXS Car passenger injured in collision with fixed or stationary object in nontraffic accident, sequela
V47.3XXA Unspecified car occupant injured in collision with fixed or stationary object in nontraffic accident, initial encounter
V47.3XXD Unspecified car occupant injured in collision with fixed or stationary object in nontraffic accident, subsequent encounter
V47.3XXS Unspecified car occupant injured in collision with fixed or stationary object in nontraffic accident, sequela
V47.5XXA Car driver injured in collision with fixed or stationary object in traffic accident, initial encounter
V47.5XXD Car driver injured in collision with fixed or stationary object in traffic accident, subsequent encounter
V47.5XXS Car driver injured in collision with fixed or stationary object in traffic accident, sequela
V47.6XXA Car passenger injured in collision with fixed or stationary object in traffic accident, initial encounter
V47.6XXD Car passenger injured in collision with fixed or stationary object in traffic accident, subsequent encounter
V47.6XXS Car passenger injured in collision with fixed or stationary object in traffic accident, sequela
V47.9XXA Unspecified car occupant injured in collision with fixed or stationary object in traffic accident, initial encounter
V47.9XXD Unspecified car occupant injured in collision with fixed or stationary object in traffic accident, subsequent encounter
V47.9XXS Unspecified car occupant injured in collision with fixed or stationary object in traffic accident, sequela
W26.2XXA Contact with edge of stiff paper, initial encounter
W26.2XXD Contact with edge of stiff paper, subsequent encounter
W26.2XXS Contact with edge of stiff paper, sequela
W26.8XXA Contact with other sharp object(s), not elsewhere classified, initial encounter
W26.8XXD Contact with other sharp object(s), not elsewhere classified, subsequent encounter
W26.8XXS Contact with other sharp object(s), not elsewhere classified, sequela
W26.9XXA Contact with unspecified sharp object(s), initial encounter
W26.9XXD Contact with unspecified sharp object(s), subsequent encounter
W26.9XXS Contact with unspecified sharp object(s), sequela
X50.0XXA Overexertion from strenuous movement or load, initial encounter
X50.0XXD Overexertion from strenuous movement or load, subsequent encounter
X50.0XXS Overexertion from strenuous movement or load, sequela
X50.1XXA Overexertion from prolonged static or awkward postures, initial encounter
X50.1XXD Overexertion from prolonged static or awkward postures, subsequent encounter
X50.1XXS Overexertion from prolonged static or awkward postures, sequela
X50.3XXA Overexertion from repetitive movements, initial encounter
X50.3XXD Overexertion from repetitive movements, subsequent encounter
X50.3XXS Overexertion from repetitive movements, sequela
X50.9XXA Other and unspecified overexertion or strenuous movements or postures, initial encounter
X50.9XXD Other and unspecified overexertion or strenuous movements or postures, subsequent encounter
X50.9XXS Other and unspecified overexertion or strenuous movements or postures, sequela
Y93.85 Activity, choking game

Chapter 21 Factors influencing health status and contact with health services (Z00-Z99)

Z05.0 Observation and evaluation of newborn for suspected cardiac condition ruled out
Z05.1 Observation and evaluation of newborn for suspected infectious condition ruled out
Z05.2 Observation and evaluation of newborn for suspected neurological condition ruled out
Z05.3 Observation and evaluation of newborn for suspected respiratory condition ruled out
Z05.41 Observation and evaluation of newborn for suspected genetic condition ruled out
Z05.42 Observation and evaluation of newborn for suspected metabolic condition ruled out
Z05.43 Observation and evaluation of newborn for suspected immunologic condition ruled out
Z05.5 Observation and evaluation of newborn for suspected gastrointestinal condition ruled out
Z05.6 Observation and evaluation of newborn for suspected genitourinary condition ruled out
Z05.71 Observation and evaluation of newborn for suspected skin and subcutaneous tissue condition ruled out
Z05.72 Observation and evaluation of newborn for suspected musculoskeletal condition ruled out
Z05.73 Observation and evaluation of newborn for suspected connective tissue condition ruled out
Z05.8 Observation and evaluation of newborn for other specified suspected condition ruled out
Z05.9 Observation and evaluation of newborn for unspecified suspected condition ruled out
Z19.1 Hormone sensitive malignancy status
Z19.2 Hormone resistant malignancy status
Z29.11 Encounter for prophylactic immunotherapy for respiratory syncytial virus (RSV)
Z29.12 Encounter for prophylactic antivenin
Z29.13 Encounter for prophylactic Rho(D) immune globulin
Z29.14 Encounter for prophylactic rabies immune globin
Z29.3 Encounter for prophylactic fluoride administration
Z29.8 Encounter for other specified prophylactic measures
Z29.9 Encounter for prophylactic measures, unspecified
Z30.015 Encounter for initial prescription of vaginal ring hormonal contraceptive
Z30.016 Encounter for initial prescription of transdermal patch hormonal contraceptive device
Z30.017 Encounter for initial prescription of implantable subdermal contraceptive
Z30.44 Encounter for surveillance of vaginal ring hormonal contraceptive device
Z30.45 Encounter for surveillance of transdermal patch hormonal contraceptive device
Z30.46 Encounter for surveillance of implantable subdermal contraceptive
Z31.7 Encounter for procreative management and counseling for gestational carrier
Z33.3 Pregnant state, gestational carrier
Z51.6 Encounter for desensitization to allergens
Z53.31 Laparoscopic surgical procedure converted to open procedure
Z53.32 Thoracoscopic surgical procedure converted to open procedure
Z53.33 Arthroscopic surgical procedure converted to open procedure
Z53.39 Other specified procedure converted to open procedure
Z79.84 Long term (current) use of oral hypoglycemic drugs
Z83.42 Family history of familial hypercholesterolemia
Z84.82 Family history of sudden infant death syndrome
Z92.84 Personal history of unintended awareness under general anesthesia
Z98.890 Other specified postprocedural states
Z98.891 History of uterine scar from previous surgery

See Also Deleted ICD 10 codes list


Coding Ahead